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Abstract 
 
Apoptosis represents a finely orchestrated and highly conserved natural form of cell death. It 
exhibits unique morphological and biochemical characteristics which culminate in the controlled 
dismantling of a cell from within followed by its discreet removal by phagocytic cells. Apoptosis is 
vital for the preservation of cell and tissue homeostasis but also performs several defensive and 
protective functions. Owing to its importance, apoptosis is highly regulated and a large number of 
proteins have been shown to mediate and safeguard the process. Furthermore, deregulated or 
altered levels of apoptosis can have severe pathological consequences; indeed, apoptosis has 
been shown to play a central role in several diseases, including neurological and autoimmune 
diseases as well as a variety of cancers. Consequently, the search for apoptotic-based therapies 
has received much attention and of vital importance to this quest is the characterisation of the 
specific mediators of apoptosis and their regulation as well as the identification of novel genes or 
proteins that can have a regulatory effect on apoptosis. It is thus the aim of this study to assist in 
this characterisation and also to identify novel candidate genes potentially involved in apoptosis. 
In a previously performed pilot study, three novel candidate genes potentially involved in apoptosis 
were identified by performing promoter-trap mutagenesis experiments. These genes were lipoic 
acid synthetase (LIAS), cyclophilin A (CYPA) and ribosomal protein L9 (RPL9). Since the 
methodology for this pilot study involved the use of functionally haploid cells, it was aimed in this 
study to verify these results in a diploid mouse cell line. Candidate gene knockdown was achieved 
by means of RNA interference and apoptosis assays were performed. A potential role for LIAS and 
CYPA in apoptosis was successfully verified in this study; however this could not be achieved for 
RPL9 and the gene was thus excluded from further study. In addition, nucleotide sequences 
isolated during the promoter-trap mutagenesis experiments in the pilot study were also 
investigated in order to identify additional novel candidate genes involved in apoptosis. By 
performing nucleotide BLAST searches, two potential candidate genes were identified, namely 
AHNAK nucleoprotein (AHNAK) and serum amyloid A-like 1 (SAAL1). Further bioinformatic 
analyses were performed with the four candidate genes in order to ascertain possible associations 
with apoptosis or cancer. Lastly, to further characterise the four candidate genes, the relative gene 
expression was investigated by means of quantitative PCR in two cancer and control cell lines. The 
results revealed significant differential expression for the majority of genes in the cancer cell lines 
when compared to the control cell lines.  
In conclusion, this study identified and characterised four novel genes potentially involved in 
apoptosis. Results obtained during this study can aid in the complete characterisation and 
functional annotation of these genes. Potential ties to apoptosis and associations with cancer are 
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discussed for all four candidate genes and the possibilities of therapeutic strategies for anticancer 
treatments involving these candidate genes are noted. 
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Opsomming 
 
Apoptose verteenwoordig ‘n fyn georganiseerde en hoogs gekonserveerde natuurlike vorm van 
seldood. Dit vertoon unieke morfologiese and biochemiese eienskappe wat uitloop in die beheerde 
afbreek van ‘n sel vanuit die binnekant waarna dit onopsigtelik deur fagositiese selle verywder 
word. Apoptose is uiters belangrik vir die bewaring van sel en weefsel homeostase, maar dit vervul 
ook menigde afwerende and beskermde funksies. Vanweë sy noodsaaklikheid is apoptose hoogs 
gereguleer and ‘n groot aantal proteïene is al aangewys as bemiddelaars en beskermers van die 
proses. Verder, wangereguleerde en veranderde vlakke van apoptose kan ernstige patalogiese 
nagevolge hê; inderdaad, ‘n sentrale rol vir apoptose in verskeie siektes is al bevestig, insluitend 
neurologiese en outo-immuun siektes asook ‘n verskeidenheid van kankers. As gevolg hiervan 
ontvang die soektogte vir apoptose-gebaseerde terapieë vele aandag en uiters noodsaaklik vir 
hierdie soektogte is die karakterisering van die spesifieke bemiddelaars van apoptose en hul 
regulering asook die identifisering van nuwe gene of proteïene wat ‘n regulerende effek kan hê op 
apoptose. Dit is dus die doel van hierdie studie om by te dra tot hierdie karakterisering en ook om 
nuwe kandidaat gene wat moontlik betrokke kan wees in apoptose te identifiseer. 
In ‘n vorige loodsprojek is drie gene moontlik betrokke in apoptose geïdentifiseer deur middel van 
promoter-strik mutagenese eksperimente. Hierdie gene is lipoic acid synthetase (LIAS), cyclophilin 
A (CYPA) en ribosomal protein L9 (RPL9). Aangesien die metodiek in the loodsprojek gebruik 
gemaak het van funksionele haploïede selle, was dit die doel van hierdie studie om die resultate te 
bevestig in ‘n diploïede muis sellyn. Ribonukleïensuur (RNS) steuring is uitgevoer vir die 
uitklopping van die kandidaat gene en apoptose toetse is ook gedoen. Die bevestiging van ‘n 
moontlike rol vir LIAS en CYPA in apoptose was suksesvul in hierdie studie; alhoewel dit was nie 
bereikbaar vir RPL9 nie en hierdie geen is dus uitgesluit in verdere studies. Bykomend is 
nukleotied volgordes wat geïsoleer is tydens die promoter-strik mutagenese eksperimente in die 
loodsprojek ook nagesien om moontlike addisionele nuwe kandidaat gene te identifiseer wat 
moontlik betrokke kan wees by apoptose. Twee potensiële kandidaat gene, naamlik AHNAK 
nucleoprotein (AHNAK) en serum amyloid A-like 1 (SAAL1), was geïdentifiseer deur middel van 
nukleotied BLAST soektogte. Addisionele bioinformatiese analises is uitgevoer op die vier 
kandidaat gene om moontlike redes vir ‘n assosiasie met apoptose of kanker vas te stel. Laastens, 
om die kandidaat gene verder te karakteriseer, is daar ondersoek ingestel op die relatiewe geen 
uitdrukking van die kandidaat gene in twee kanker en twee normale sellyne. Die resultate het 
betekenisvolle differensiële regulering getoon vir meeste van die gene in die kanker sellyne in 
vergelyking met die normale sellyne.  
Ten slotte, vier kandidaat gene moontlik betrokke in apoptose is in die huidige studie geïdentifiseer 
en gekarakteriseer. Die resultate verwerf in hierdie studie kan moontlik bydra tot die volkome 
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karakterisering en funksionele annotering van die kandidaat gene. Moontlike skakels met apoptose 
en assosiasies met kanker is bepreek vir die vier kandidaat gene en die moontlikheid van 
terapeutiese strategieë gebaseer rondom die kandidaat gene word ook genoem.  
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Chapter 1: Literature review 
 
1.1 Cell death 
When animals find themselves under a stressful and/or dangerous situation, the well-known “fight-
or-flight” response is set into motion (Cannon, 1929). On an organismal level, this represents a 
complex process, regulated by a multitude of systems and hormones (Charmandari et al., 2005). In 
terms of a cellular level, a somewhat similar response can be expected; fight-comply-or-flight. The 
cellular stress response (CSR) can entail a series of offence and defence mechanisms, aimed at 
survival, or a temporary increase in tolerance levels. As a last resort, the flight response serves to 
remove damaged cells through cell death pathways when the applied stress is too severe (Kültz, 
2005). Cellular stress can be explained as any state that threatens homeostasis and examples of 
stresses that can lead to the drastic step mentioned above includes hypoxia (oxygen limiting 
conditions), DNA damage, starvation, synthetic drugs, radiation and increased generation of 
reactive oxygen species (ROS) (Chrousos, 1992; Fulda, 2010; Kültz, 2005). Cell death, however, 
is not limited to the CSR but also fulfils other vital roles. Numerous examples of cell death in 
embryonic development and organogenesis emphasizes the crucial role of cell death in the specific 
removal of cells in a spatial and temporal manner, where the most famous examples is likely the 
removal of interdigital webs on the limbs of amniotes (e.g. humans, mice and birds) and the 
removal of the tail section in tadpoles (Penaloza et al., 2006). Equally important is the role of cell 
death in physiological cell and tissue homeostasis (Lockshin and Zakeri, 2007). As cells reach the 
end of their lifespan, new cells are produced to replace them and it is this intricate balance 
between cell death and cell proliferation that maintains cellular homeostasis (King and Cidlowski, 
1998; Lawen, 2003). Interestingly, this can occur at quite an alarming pace in the human body, 
with erythrocytes showing the fastest exchange rate with about 360 billion cells dying each day, 
that is more than 4 million cells per second (Bratosin et al., 2002; Lockshin and Zakeri, 2007). In 
more physical terms, if humans were to constantly produce new cells without removing the old 
ones, an 80-year-old person would have an intestine of approximately 16 km in length and bone 
marrow and lymph nodes with a total weight of 2 tons (Melino, 2001). Owing to its importance, the 
decision to initiate cell death, as well as the particular method behind its execution, is tightly 
controlled and several escape routes are available until a certain event or phase is reached that 
fatally commits the cell to death. This switch from reversible to irreversible cell death has been 
adequately termed the “point-of-no-return”; however pinpointing and describing this “point” has 
been proven difficult due to discrepancies in literature (Galluzzi et al., 2007; Kroemer et al., 2005; 
Kroemer et al., 2009). Certain biochemical events have been proposed, including large-scale 
caspase (a family of cysteine proteases) activation, sustained loss of the mitochondrial trans 
membrane potential (ΔΨm), complete mitochondrial outer membrane permeabilisation (MOMP) 
and the display of phosphatidylserine (PS) residues on the outside of the cell, although these 
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events can occur independently of cell death and without any serious consequences. In the light of 
this shortcoming, a set of morphological characteristics has been suggested by the Nomenclature 
Committee on Cell Death (NCCD) that states that a cell is perceived as ‘dead’ when at least one of 
the following criteria is met: 1) the integrity of the cell membrane is significantly compromised, 2) 
cellular and nuclear fragmentation has occurred and 3) the resulting fragments are removed by 
adjacent cells (Galluzzi et al., 2007; Kroemer et al., 2005; Kroemer et al., 2009). In view of the 
above mentioned criteria, it is important to note that the definition of a ‘dying’ cell can be different to 
that of a ‘dead’ cell. The process of dying can take place through several pathways or 
mechanisms, each having their own set of characteristics. At the end, the different pathways or 
mechanisms can converge to produce one or more of the above mentioned criteria for a ‘dead’ cell 
(Kroemer et al., 2005; Kroemer et al., 2009). 
 
1.1.1 Types of cell death 
Several different types of cell death exist. Aiding in their characterisation, each type of cell death 
can be described in terms of functionality, morphology, immunology and enzymology (Kroemer et 
al., 2009). When classifying the different types of cell death, it has been suggested to rely on the 
major morphological characteristics of each type, since other characteristics has been shown to 
exhibit non-exclusivity in addition to a general lack of clear cut distinction in terms of biochemical 
properties (Galluzzi et al., 2007). There are three widely recognised types of cell death, namely 
apoptosis, autophagy and necrosis. Historically, roman numerals were assigned to each of these, 
designating apoptosis, autophagy and necrosis as type I, II and III cell death respectively; however 
the use of this nomenclature has been discouraged by the NCCD (Kroemer et al., 2009). One 
aspect that has led to some discrepancies with regards to the nomenclature of cell death types is 
the interchangeable use of programmed cell death (PCD) and apoptosis. PCD refers to cell death 
that is specifically genetically predetermined or implicitly physiological and although this mostly 
occurs by means of apoptosis, it is not to be used as a synonym (Galluzzi et al., 2007). Evidence 
supporting this statement includes the ability of apoptosis to be induced, for example by natural or 
synthetic apoptotic inducers, and the realisation that necrosis, originally thought of as accidental 
and pathological, can also be predetermined (Galluzzi et al., 2007). In an attempt to distinguish 
above mentioned from truly accidental necrosis, the terms “programmed necrosis” and 
“necroptosis” was coined (Degterev et al., 2005; Moquin and Chan, 2010). 
The different types of cell death will be discussed briefly below, while apoptosis, the focus of this 
study, will be discussed in more detail in the section to follow. 
Autophagy 
Autophagy is a self-degradative process where a cell literally eats itself, as described by its 
meaning derived from the Greek words “autos” (self) and “fageo” (eat). The process is 
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morphologically characterised by massive vacuolisation of the cytoplasm and its contents in 
double-membraned structures, referred to as autophagosomes, without being accompanied by 
chromatin condensation (Fig. 1.1) (Hotchkiss et al., 2009; Kroemer et al., 2005). This key event is 
followed by fusion of the autophagosomes with lysosomes, forming autolysosomes. Lysosomes 
contain acid hydrolases capable of digesting the contents of the autophagosomes, thus producing 
metabolic substrates (Giansanti et al., 2011; Hotchkiss et al., 2009). The functional role of 
autophagy in the cellular environment is however under heavy debate with the two options 
representing opposing views. Autophagy is suggested to be critical for cell survival under 
conditions of nutrient deprivation owing to its ability to provide the cell with essential metabolites, 
amino acids and energy by recycling redundant or non-essential macromolecular components or 
organelles (Debnath et al., 2005; Degterev and Yuan, 2008; Hotchkiss et al., 2009). In addition, 
autophagy assists in cellular differentiation and development, in maintaining intracellular 
homeostasis by removing damaged or dysfunctional organelles and also forms one of the two 
major protein degradation pathways in the cell (Debnath et al., 2005; Degterev et al., 2005; 
Mizushima and Levine, 2010). In contrast, autophagy is also viewed as a method of cell death. 
Evidence for this statement includes the presence of autophagic vacuoles in dying cells as well as 
the ability to perform non-apoptotic cell death in apoptosis-deficient cells (Debnath et al., 2005; 
Shimizu et al., 2004). An important aspect to consider when investigating the role of autophagy in 
cell death is to determine if the observed cell death occurs through autophagy or with autophagy 
(Galluzzi et al., 2007).  
Necrosis 
Necrosis is traditionally described as an unregulated, passive and messy form of cell death 
(Edinger and Thompson, 2004; Hotchkiss et al., 2009). The pathway is often classified in a 
negative manner, that is, a form of cell death lacking characteristics of both apoptosis and 
autophagic cell death, but prominent morphological features has provided a more positive 
definition (Denecker et al., 2001; Golstein and Kroemer, 2007). This includes cellular and organelle 
swelling leading to the early rupture of the plasma membrane (Fig. 1.1) (Golstein and Kroemer, 
2007). As a result, cellular contents are spilled into the surrounding area and an inflammatory 
response is initiated through the activation of antigen-presenting cells by, for example, calreticulin, 
the heat shock protein Hsp70 and oligonucleosomes (Melcher et al., 1999; Proskuryakov et al., 
2003). Cells normally undergo necrosis after severe physical and physicochemical (detergents, 
heat, cold, irradiation etc.) injuries, infections (bacterial, viral and protozoan), toxic insults or acute 
hypoxia and was hence suggested to be an accidental form of cell death (Denecker et al., 2001; 
Edinger and Thompson, 2004; Hotchkiss et al., 2009; Proskuryakov et al., 2003). However, 
accumulating evidence suggests otherwise. This includes the involvement of extracellular 
mediators, ligands and receptors in the induction of necrosis, mediation of the process by 
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Figure 1.1: Transmission electron microscope images of A) an autophagosome showing the distinctive 
double-membrane structure surrounding a mitochondrion, indicated by A, (adapted from Wells 2005) and B) 
a necrotic cell showing the disrupted plasma membrane and preserved nucleus (Adapted from 
http://www.cyto.purdue.edu/archive/flowcyt/research/cytotech/apopto/data/chap10.htm). 
key kinases and proteases, cross-talk with other cell death types and a proposed capability to 
serve as a substitute in cases of apoptosis-deficient cells (Denecker et al., 2001; Hotchkiss et al., 
2009; Moquin and Chan, 2010; Proskuryakov et al., 2003). In addition, the pro-inflammatory 
response initiated by the leaked cellular contents may be important in enforcing an antitumour or 
antiviral response, suggesting that cell death by necrosis might take place with a specific purpose 
(Denecker et al., 2001; Hotchkiss et al., 2009). The terms “programmed necrosis” and 
“necroptosis” has since been coined to distinguish the traditional, accidental form of necrosis from 
a more controlled, specific version; with “programmed” implying that necrosis can be induced on 
specific cues or signals, which is subsequently followed by signalling pathways (Degterev et al., 
2005; Edinger and Thompson, 2004; Moquin and Chan, 2010). 
Other types of cell death 
Apart from apoptosis, autophagy and necrosis, there are many other ways for a cell to die. Many of 
these types are less well known and not as frequently studied as the above mentioned types. 
Alternative cell death types include mitotic catastrophe, anoikis, excitotoxicity, Wallerian 
degeneration, paraptosis, pyroptosis, pyronecrosis, entosis and cornification (Kroemer et al., 2005; 
Kroemer et al., 2009). Most of these cell death types only take place in certain cell types and/or is 
dependent on a specific set of circumstances, for example, cornification only occurs in cells of the 
epidermis while pyroptosis involves distinct routes of caspase 1 activation. Some of these cell 
death types resemble apoptosis, autophagy or necrosis in some way or another, including sharing 
some morphological features; thus, their classification as individual cell death types is still a matter 
of debate (Kroemer et al., 2005; Kroemer et al., 2009). 
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1.2 Apoptosis 
The existence of a mechanism serving as a counterbalance for mitosis was suggested as early as 
1914 (Majno and Joris, 1995). It was only 57 years later that the critical experiment, displaying a 
discrete drop-off in cells, was performed by John Kerr, who coined the term “apoptosis” a year later 
(Kerr, 1971; Kerr et al., 1972; Majno and Joris, 1995). The term “apoptosis” stems from the ancient 
Greek language and describes the “falling of petals/leaves from flowers/trees” (Kerr et al., 1972). 
The initial characterisation of the apoptotic process took place in PCD studies in the nematode 
Caenorhabditis elegans (Degterev and Yuan, 2008). In 1993, Yuan et al. presented a molecular 
mechanism for PCD in the nematode and also suggested conservation of this mechanism in 
mammals. Since then the four individual apoptosis genes in C. elegans has each been expanded 
into large and much more complex multi-protein families in mammalians (Fig. 1.2) (Degterev and 
Yuan, 2008). The C. elegans apoptosis genes and their conserved mammalian protein families, 
respectively, are egl-1 and BH3-only proteins; ced-9 and the anti-apoptotic Bcl-2 family proteins; 
ced-4 and Apaf-1 and related proteins; and ced-3 and the caspase protein family (Lawen, 2003). 
High homology in key regions suggests that the mammalian counterparts of the ced and egl-1 
genes most likely arose through gene duplication events which were subsequently followed by 
selection and specification (Degterev and Yuan, 2008). Specification of the individual genes allows 
for different apoptotic responses from different apoptotic signals, mediated by different apoptotic 
regulators. It also provides the apoptotic process with a back-up plan; if, for example, the activity of 
one caspase is lost, the up-regulation of another can potentially compensate for this loss (Degterev 
and Yuan, 2008). Apoptosis shows a remarkable level of conservation ranging from nematodes to 
humans and exploring the process in the model organism Drosophila melanogaster, which 
possesses a similar mechanism for the execution of apoptosis, has proven useful in modelling 
human diseases (Hay et al., 2004; Vernooy et al., 2000).  
In 1972 John Kerr and colleagues referred to apoptosis as a “vital biological phenomenon”; in the 
years to follow numerous studies have shown just how vital this form of cell death is (Hay et al., 
2004). The ability of apoptosis to control cell numbers is crucial for sculpting structures and organs 
during embryonic development, while in adults it functions to maintain normal tissue homeostasis 
(Baehrecke, 2002; Lockshin and Zakeri, 2007; Penaloza et al., 2006). Apoptosis also provides a 
protective function by removing gametes or other embryonic cells with damaged DNA or aberrant 
chromosomal contents during development and by removing pathogen-infected cells, damaged 
cells or cells displaying inappropriate proliferation in adult tissues (Baehrecke, 2002; Benedict et 
al., 2002; Green and Evan, 2002). 
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Figure 1.2: The functional homologues, as indicated by the matching colours, of various apoptotic proteins 
found in nematodes, mammalians and fruit flies. Adapted from Riedl and Shi, 2004. 
1.2.1 The apoptotic process 
The controlled demolition of a building has been used as a metaphor to describe the apoptotic 
process; being dismantled from within, the destruction of the cell rarely, if not at all, affects the 
surrounding cells (Taylor et al., 2008). The process has several characteristics, both biochemical 
and morphologic, that can distinguish it from other cell death types. Morphologically, the process 
begins with shrinkage of the cell, in contrast to necrosis where swelling of the cell occurs (Fadeel 
and Orrenius, 2005; Lawen, 2003). The apoptotic cell begins to loose contact with neighbouring 
cells and pseudopods are retracted (Kroemer et al., 2005; Lawen, 2003; Taylor et al., 2008). While 
the cellular organelles remain intact throughout the process, with only dilation of the endoplasmic 
reticulum and swelling of cisternae have been reported, several changes occur within the nucleus 
(Fadeel and Orrenius, 2005; Kroemer et al., 2005; Lawen, 2003). Compact masses of condensed 
chromatin undergo large-scale DNA fragmentation by endonucleases, producing a typical “DNA 
ladder” when the extracted DNA is analysed on an agarose gel (Kroemer et al., 2005; Lawen, 
2003). The high level of DNA fragmentation is a distinctive event in apoptosis and, along with the 
observation that cellular organelles remain unaffected, it represents another noticeable contrast to 
necrosis (Fadeel and Orrenius, 2005; Taylor et al., 2008). Fragmentation of the nuclear DNA is 
followed by convolution of the nucleus, which ultimately buds off into several fragments (Lawen, 
2003). In a similar manner, the plasma membrane becomes active and undergoes a prolonged 
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period of dynamic blebbing where pieces of the membrane buds off, encapsulating cellular 
contents, including intact organelles and nuclear fragments, and forming small vesicles known as 
apoptotic bodies (Fig. 1.3) (Fadeel and Orrenius, 2005; Lawen, 2003; Taylor et al., 2008). During 
this process, the plasma membrane can also be modified by the externalisation of PS residues 
(Lawen, 2003). Lastly, the resulting apoptotic bodies are effectively and quietly removed through 
engulfment by phagocytic cells and/or neighbouring cells (Fadeel and Orrenius, 2005; Lawen, 
2003; Taylor et al., 2008). Since the contents of the apoptotic cell is neatly contained within the 
apoptotic bodies and discretely removed, there is little or no leakage into the surrounding area; 
thus preventing the inflammatory response seen in necrosis (Fadeel and Orrenius, 2005). The 
complete apoptotic process, including corpse clearance, can take place within a matter of hours 
and is said to occur at a rate 20 times faster than that of mitosis; making sightings of a dying cell a 
rare event (Fadeel and Orrenius, 2005; Melino, 2001).  
Apoptotic stimuli can be divided into four main groups based on the method of apoptosis induction 
(Kam and Ferch, 2000). The first group is DNA damage stimuli and includes ionising radiation. The 
second group employs receptor-based mechanisms to induce apoptosis and entails the binding of 
ligands to death receptors or the withdrawal of growth factors. The third group functions to 
stimulate the apoptosis pathway and consist of biochemical agents like phosphatases and kinase 
inhibitors. Lastly, stimuli like ultraviolet light, heat and free radicals belong to the group that results 
in physical cell damage (Kam and Ferch, 2000). In addition, the signalling pathway activated within 
a cell by a specific stimulus can also depend on the specific cell type (Kolesnick and Krönke, 
1998).  
 
1.2.2 Molecular pathways in apoptosis 
Apoptosis can follow one of two main signalling pathways, namely the extrinsic or intrinsic 
pathways (Fig. 1.4), while cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells have a third 
option known as the Perforin/Granzyme B pathway (Fadeel and Orrenius, 2005; Lawen, 2003). 
The extrinsic pathway, also known as the death-receptor pathway, is stimulated by receptor-based 
mechanisms as well as certain chemotherapeutic drugs and is said to play a pivotal role in 
conserving tissue homeostasis, particularly in the immune system (Fadeel and Orrenius, 2005; 
Fulda and Debatin, 2006). The extrinsic pathway is initiated outside the cell through the binding of 
a membrane-bound death receptor (DR) and its corresponding ligand (Lawen, 2003). Death 
receptors involved in this pathway are members of the tumour necrosis factor (TNF) receptor gene 
superfamily and includes Fas (also known as CD95), TNF receptor (TNFR) and TNF-related 
apoptosis-inducing ligand-receptor (TRAIL-R). The corresponding ligand for each receptor, 
respectively, are Fas-L (CD95L), TNFα and TRAIL (Fulda and Debatin, 2006; Kam and Ferch, 
2000). In order to facilitate downstream signal transduction, a region of approximately 80 amino
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Figure 1.3: Scanning electron microscope image of a trophoblast cell undergoing apoptosis. A - Shrinkage of 
cells. B - Nuclear condensation. C - Further cellular shrinkage and packaging of cellular contents. D - 
Membrane blebbing. Arrow points to an apoptotic body. Obtained from 
http://www.reading.ac.uk/cellmigration/apoptosis.htm. 
acids, which has been termed the death domain (DD), is shared between these receptors (Kidd, 
1998). The binding of the ligand to the corresponding receptor sets in motion a series of events; 
firstly, the receptor undergoes trimerisation and DDs are clustered together, which is followed by 
the recruitment of an adapter molecule such as the Fas-associated death domain (FADD) and 
TNF-receptor-associated death domain (TRADD) proteins (Fulda and Debatin, 2006; Kam and 
Ferch, 2000; Lawen, 2003) . In addition to a DD, the adaptor molecules also contain another 
unique domain, known as the death effector domain (DED) (Kidd, 1998; Lawen, 2003). Once it is 
recruited to the membrane receptor, the adaptor molecule in turn facilitates the recruitment of 
either pro-caspase 8 or 10 (Fulda and Debatin, 2006; Kidd, 1998). The pro-caspase contains a 
similar DED in its pro-domain and an interaction is established through this domain with the 
corresponding DED of the adaptor molecule (Kidd 1998). This final recruitment completes the 
formation of the death-inducing signalling complex (DISC) (Fulda and Debatin, 2006; Lawen, 
2003). The DISC facilitates transactivation of the pro-caspase molecules by bringing them in close 
proximity to each other (Lawen, 2003). Once activated, the caspases are free to activate 
downstream pro-caspases, initiating a caspase cascade (see figures 1.4 and 1.5) (Lawen, 2003). 
In contrast to the extrinsic pathway, the intrinsic pathway is initiated from within the cell. The 
pathway is also known as the mitochondrial pathway as this organelle plays a central role in 
executing apoptosis through this pathway (Fadeel and Orrenius, 2005). The pathway is stimulated 
by intracellular stresses such as oxidative stress and DNA damage but can also be induced by 
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Figure 1.4: The extrinsic and intrinsic pathways of apoptosis. Adapted from 
http://www.hixonparvo.info/model.html. 
chemotherapeutic drugs (Fadeel and Orrenius, 2005; Fulda and Debatin, 2006). Upon stimulation, 
an attack is launched on the mitochondria, presumably mediated by members of the Bcl-2 protein 
family, resulting in permeabilisation of the outer membrane, (Green and Kroemer, 2004). As a 
result, proteins normally found within the intermembrane space of the mitochondria are released 
into the cytosol (Green and Kroemer, 2004). One such protein is cytochrome c; which upon release 
binds apoptotic protease activating factor-1 (Apaf-1) in the cytosol (Lawen, 2003). Pro-caspase 9 is 
also recruited and the apoptosome complex is formed. The complex is rather large in size, 
approximately 1 MDa, and consists of seven molecules of each of its building blocks as well as 
seven (deoxy)-adenosine triphosphate ((d)ATP) molecules (Lawen, 2003). A similar type of 
homotypic interaction takes place here as with DISC formation in the extrinsic pathway. Both Apaf-
1 and pro-caspase 9 contain a nucleotide binding domain known as the caspase-recruitment 
domain (CARD) and it is a CARD-CARD interaction that allows for the conversion of pro-caspase 9 
to the active caspase 9 state (Fadeel and Orrenius, 2005; Fulda and Debatin, 2006). Similarly to 
caspase 8 and 10 in the extrinsic pathway, active caspase 9 now has the ability to further activate 
downstream pro-caspases 3, 6 and 7 (see figures 1.4 and 1.5) (Lawen, 2003). The mitochondria 
Stellenbosch University  http://scholar.sun.ac.za
10 
 
 
 
Figure 1.5: Activation of the caspase cascade in the various apoptotic pathways. Adapted from Taylor et al., 
2008. 
can also contribute to caspase-independent apoptosis through the release of apoptosis inducing 
factor (AIF) and endonuclease G (EndoG) from the intermembrane space. When released, these 
proteins translocate to the nucleus and contributes to chromatin condensation and DNA 
fragmentation (Fig. 1.4) (Fadeel and Orrenius, 2005; Fulda and Debatin, 2006).  
A third pathway in apoptosis-mediated cell death is restricted to CTLs and NK cells and mainly 
functions during an immune response by targeting virally infected or transformed cells (Barry et al., 
2000; Goping et al., 2003; Trapani and Smyth, 2002). The granzyme B, or perforin/granzyme B, 
pathway initiates with the transfer of cytoplasmic granules, containing, amongst other proteins, 
perforin and granzyme B, to the target cell (Barry et al., 2000; Trapani and Smyth, 2002). The 
particular delivery method of the granules and its contents is however under debate and several 
different mechanisms have been proposed (Trapani and Smyth, 2002). The perforin protein is 
referred to as a lytic molecule, since it is known to disrupt the cell membrane by means of pore 
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formation, while granzyme B belongs to a family of structurally related serine proteinases 
displaying a unique substrate specificity and capacity to cleave at aspartic residues (Barry et al., 
2000; Goping et al., 2003; Trapani and Smyth, 2002). Granzyme B has the ability to cleave and 
activate pro-caspases 3 and 8, hence activating the caspase cascade which culminates in cell 
death. In addition, granzyme B also holds the ability to cleave and activate the pro-apoptotic 
molecule Bid, which upon activation translocate to the mitochondria where it stimulates MOMP 
(Fig. 1.5) (Barry et al., 2000; Goping et al., 2003). 
 
1.2.3 Apoptosis related molecules 
Of major importance to the process of apoptosis is caspases, a large protein family of cysteine 
proteases which is highly conserved (Hengartner, 2000; Turk and Stoka, 2007). Caspases share a 
characteristic cysteine residue in their active site and cleaves their substrates after an aspartic acid 
residue (Hengartner, 2000). To date, 11 different human caspases has been identified, which can 
be grouped according to their substrate preferences, functional or structural similarities 
(Hengartner, 2000; Ho and Hawkins, 2005; Turk and Stoka, 2007). Caspases can either function in 
apoptosis (caspases 2, 3, 6, 7, 8, 9 and 10), in the inflammatory response (caspases 1, 4 and 5) or 
in keratinocyte differentiation (caspase 14) (Turk and Stoka, 2007). Apoptotic caspases can further 
be categorised as initiator/activator caspases (caspases 2, 8, 9 and 10) or effector/executioner 
caspases (caspases 3, 6 and 7). A structure-function relationship is also present in apoptotic 
caspases; initiator caspases all share a long pro-domain containing either a DED or CARD 
domain, while the effector caspases are distinguished by shorter prodomains (Fig. 1.6) (Ho and 
Hawkins, 2005; Turk and Stoka, 2007). Caspases are synthesised as inactive zymogens, referred 
to as pro-caspases (Ola et al., 2011). Activation, which involves removal of the prodomain, can 
take place through one of three mechanisms; in most cases a pro-caspase undergoes proteolytic 
cleavage by another, active caspase, creating a caspase-cascade (Hengartner, 2000). Other 
mechanisms include an induced proximity model, which suggests the close proximity of multiple 
zymogens is sufficient to induce transactivation (for example activation of multiple pro-caspase 8 
molecules in the DISC complex) and association with a regulatory subunit, which is apparently 
required for pro-caspase 9 activation. In the latter example, the apoptosome complex functions as 
a holoenzyme and the relevant subunits are seen as regulatory components rather than mere 
adaptors (Hengartner, 2000).  As one can infer from the name, initiator caspases function during 
the initial stages of apoptosis, propagating the initial apoptotic stimuli, while effector caspases 
function during the later stages by cleaving approximately 400 different, but specific mammalian 
substrates (Green and Kroemer, 1998; Taylor et al., 2008). Cleavage of substrates like caspase-
activated DNase (CAD), nuclear lamins, cytoskeletal proteins and epidermal growth factor directly 
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Figure 1. 6: Protein structures of the caspase and Bcl-2 protein families. Adapted from Degterev and Yuan, 
2008. 
results in some of the characteristic morphological features of apoptosis like DNA fragmentation, 
nuclear shrinking and budding and membrane blebbing (Devarajan et al., 2002; Hengartner, 2000).  
Another important family regulating apoptosis is the Bcl-2 protein family. The family comprises of 
both pro-apoptotic and anti-apoptotic proteins and it is the ratio between these opposing proteins 
that determines which protein subfamily reigns in the cell (Kidd, 1998; Kroemer et al., 1998). The 
mammalian Bcl-2 family consists of 12 core members and can also be divided into three groups 
based on structural similarities (Coultas and Strasser, 2003; Ola et al., 2011; Youle and Strasser, 
2008). All Bcl-2 family proteins share regions of homology known as the Bcl-2 homology (BH) 
regions, which are important for interactions between the family members. A total of four BH 
regions exist (BH1-4) and the structural grouping of a protein is based on the number and type of 
BH regions it contains (Fig. 1.6) (Coultas and Strasser, 2003; Ola et al., 2011). The first group of 
proteins contain all four BH regions and are anti-apoptotic in nature. Examples include Bcl-2, Bcl-
XL, Bcl-w, Mcl-1 and A1. The remaining two groups are pro-apoptotic and are distinguished by the 
number of BH regions they contain. One group of proteins contain either two or three BH regions, 
in any combination, and include the Bax, Bak, Bok, Bcl-XS and Bcl-GL proteins, while the last group 
of proteins contain only one specific BH region, namely BH3, and are thus also referred to as the 
BH3-only proteins. Members of this group include Bid, Bik, Hrk, Bim, Noxa and Puma (Coultas and 
Strasser, 2003; Giam et al., 2008; Ola et al., 2011; Youle and Strasser, 2008). Pro-apoptotic 
members function to induce apoptosis through permeabilisation of the mitochondrial outer 
membrane while anti-apoptotic members function to prevent this from happening and also by 
preventing caspase activation (Coultas and Strasser, 2003; Hengartner, 2000). However, the exact 
functional mechanism of the proteins is still unclear (Coultas and Strasser, 2003). What is known is 
that regulation of apoptosis by the Bcl-2 family proteins are mediated through their interaction with 
each other and two models has been proposed for the activation of Bax and Bak (Giam et al., 
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2008; Ola et al., 2011). In the direct model, BH3-only proteins are divided into ‘sensitizers’ and 
‘activators’, the latter being inactivated by anti-apoptotic proteins under normal physiological 
conditions. Apoptotic stimuli activate the sensitizers which bind and sequester the anti-apoptotic 
proteins, leaving the activator BH3-only proteins free to directly activate Bax and Bak, which in turn 
oligomerises and induces MOMP. In contrast, in the indirect model, anti-apoptotic proteins bind 
and inactivate Bax and Bak. Apoptotic stimuli signal the BH3-only proteins to bind the anti-
apoptotic proteins, allowing Bax and Bak to oligomerise. In this model there is no interaction 
between the BH3-only proteins and Bax and Bak (Giam et al., 2008; Ola et al., 2011). 
Even though caspases are seen as the central executioners of apoptosis and is responsible for 
many of the characteristic features, apoptosis without caspase activation is still possible 
(Hengartner, 2000; Tait and Green, 2008). In 2008, Tait and Green defined caspase-independent 
cell death (CICD) as “death that ensues when a signal that normally induces apoptosis fails to 
activate caspases”, while Pradelli et al. (2010) took it one step further by defining CICD as any type 
of cell death, apart from necrosis, that ensues if apoptosis fails to take place. The former group 
implies that CICD can still be included under the classification of apoptosis, since it only depends 
on the failure of caspase activation. In contrast, the latter group suggests that caspase activation is 
synonymous with apoptosis; the one can not take place without the other.  Typically, CICD displays 
a relatively varying phenotype, which includes features from apoptosis, autophagy and necrosis 
(Kroemer et al., 2009; Tait and Green, 2008). As previously mentioned, the intrinsic pathway of 
apoptosis can proceed without the activation of caspases and it is in this example of CICD that the 
flavoprotein AIF plays a crucial role (Modjtahedi et al., 2006; Tait and Green, 2008). AIF was the 
first protein identified as a major component of CICD and since then studies in model organisms 
such as Saccharomyces cerevisiae, C. elegans, D. melanogaster and Mus musculus have 
contributed to significant progression in the understanding of AIF’s role in CICD (Susin et al., 
1999). AIF is produced as a 67 kDa precursor protein containing a mitochondrial localisation signal 
(MLS) at its N-terminus (Hangen et al., 2009; Norberg et al., 2010). This MLS region is cleaved off 
upon import into the mitochondria and the resulting 62 kDa protein is embedded into the inner 
mitochondrial membrane (IMM) by means of a hydrophobic transmembrane region (Norberg et al., 
2010; Yu et al., 2009). AIF exclusively exerts is apoptotic function when the cell death process is 
induced by certain stimuli; the protein is released from the IMM, most likely by calpains or 
cathepsins, to produce the soluble and mature 57 kDa form which is subsequently released into 
the cytoplasm by means of MOMP (Joza et al., 2009; Norberg et al., 2010). From here, AIF is 
targeted to the nucleus by two nuclear localisation signals where it induces chromatin 
condensation and large-scale DNA fragmentation (Joza et al., 2009; Norberg et al., 2010). The 
exact mechanism for this apoptotic activity remains unclear, however electrostatic interaction 
between AIF and DNA is known to be mediated by multiple positively charged amino acids and 
that the binding of AIF to DNA is not sequence-specific (Candé et al., 2002; Hangen et al., 2009; 
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Norberg et al., 2010). Interestingly, AIF is described as a bi-functional protein based on the 
observation that it also performs an important function in healthy cells (Candé et al., 2004; Hangen 
et al., 2009). Indeed, these two functions are restricted to different regions within the protein 
structure itself; the C-terminal region is required for apoptotic function of AIF, while internal regions 
are responsible for the non-apoptotic function (Hangen et al., 2009; Ye et al., 2002). The second 
function of AIF was elucidated upon discovery of significant homology with bacterial nicotinamide 
adenine dinucleotide (reduced, NADH) oxidases, that is, AIF performs important physiological 
redox functions, suggested to regulate and maintain respiratory complexes (Maté et al., 2002; 
Norberg et al., 2010; Wang et al., 2011; Ye et al., 2002). Specifically, AIF mainly acts upon 
complex I however associations with complexes III and IV have also been suggested (Hangen et 
al., 2009). The ability of AIF to induce apoptosis has been shown to be dependent on the cell type 
as well as the specific apoptotic stimulus involved (Joza et al., 2009; Norberg et al., 2010). With 
regards to the latter, the release of AIF from the IMM is likely to occur upon any stimulus that 
disrupts the intracellular Ca2+ homeostasis, since calpains are Ca2+-dependent enzymes (Norberg 
et al., 2010). In addition, AIF has been shown to be the major facilitator of cell death following 
excessive activation of Poly(ADP-ribose) polymerase-1 (PARP-1) (Wang et al., 2011; Yu et al., 
2009).  
 
1.2.4 The genetics of apoptosis related proteins – implications of mutations 
The p53 protein is notoriously associated with cancer since it is estimated that the corresponding 
gene, TP53, is mutated in 50% of all tumours; a statement that emphasises the importance and 
major role of genetics in cancer (Amaral et al., 2010). The genetic foundation of cancer, which is 
further complicated by environmental influences, and the realisation that tumour cells can harbour 
mutations that favour their survival, suggests that mutations in other apoptosis-related genes can 
also be of significance in the genesis, as well as progression, of tumours. Indeed, numerous 
studies have identified mutations in a variety of genes involved in the signalling pathways of 
apoptosis. It is however important to remember that no single genetic mutation should be seen as 
a ‘causative mutation’ but rather as a ‘contributing mutation’, since multiple mutations in different 
genes are required for the development of cancer (Vogelstein and Kinzler, 2004). In terms of the 
caspase family, mutation-screening studies have mainly focussed on caspase 8, with mutations 
being identified in cases of advanced gastric, invasive colorectal, hepatocellular and head and 
neck carcinomas (Olsson and Zhivotovsky, 2011). For other caspases, mutations have been 
observed in colon, oesophageal and head/neck carcinomas for caspase 7; multiple myeloma, 
hepatocellular and adenocarcinomas for caspase 3; breast, gastric, colon and adenocarcinomas 
for caspase 5; and gastric and colon carcinomas for caspases 1 and 4 respectively (Ghavami et 
al., 2009). Even though the frequencies of these mutations were quite low, they contribute to the 
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substantial heterogeneity seen in different tumours. One also has to keep in mind that apart from 
mutations, post-translational modifications, altered gene expression and epigenetic modifications 
are also able to deregulate these proteins in tumour cells. Mutations in the TRAIL-R1 and TRAIL-
R2 genes have previously been identified in metastatic breast cancers (Shin et al., 2001). These 
two genes are located on chromosome 8p21-22; a region that has recently been suggested to 
harbour a metastatic susceptibility locus for tumours (Macartney-Coxson et al., 2008). The second 
major protein family involved in apoptosis pathways, the Bcl-2 family, can also present with 
mutations in certain tumour types. A t(14:18) translocation between the heavy chain 
immunoglobulin (Ig) segments and the anti-apoptotic Bcl-2 gene is known to be associated with 
follicular lymphomas (Müllauer et al., 2001). A second translocation with the light chain Ig genes on 
chromosomes 2 or 22 is also possible, however these occur less frequently. Both of these 
translocations result in the increased expression of Bcl-2 and ultimately suppression of apoptosis 
(Müllauer et al., 2001). Frameshift mutations in the pro-apoptotic member Bax have been identified 
in colon adenocarcinomas with a microsatellite mutator phenotype (MMP) (Rampino et al., 1997). 
Tumours positive for MMP display significant genomic instability at microsatellites due to 
replication slippage. The Bax gene contains an eight-nucleotide deoxyguanosine track which was 
shown to contain frameshift mutations in 51% of MMP+ colon adenocarcinomas; an alternation that 
was absent in MMP- tumours. These frameshift mutations would render the Bax gene 
unresponsive to transcriptional activation by p53 (Rampino et al., 1997).  The consequences of 
genetic mutations in apoptosis-related proteins is however not limited to cancers. Mutations in the 
death receptor Fas gene have been shown to be the causative factor for autoimmune 
lymphoproliferative syndrome (ALPS) type Ia while mutations in the Fas ligand gene (Fas-L) 
produces ALPS type Ib (Straus et al., 2001). Interestingly, mutations in caspase 10 is associated 
with ALPS type II, suggesting that the disorder is a result of a defective pathway. ALPS is a 
disorder of lymphocyte homeostasis and symptoms include splenomegaly (enlarged spleen), 
chronic lymphadenopathy (enlarged lymph nodes), autoimmune phenomena and lymphoma 
(Straus et al., 2001).  
 
1.2.5 Implications of mismanaged apoptosis 
As previously mentioned, apoptosis is vital to maintain a normal, homeostatic state and stringent 
measures of control are in place to ensure appropriate levels of activity. Based on these facts, one 
can only assume that deregulation of apoptosis can have severe pathological consequences. In 
fact, it was estimated that inappropriate levels of apoptosis is a contributing factor in 50% of main 
medical illnesses lacking adequate preventative measures and therapies (Reed, 2002). 
Throughout decades of research deregulated apoptosis has been found to be associated with an 
array of pathological disorders and the mode of action in these diseases can be ascribed to either 
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too little apoptosis or too much. Disorders included in the former category include cancer, 
restenosis, autoimmune diseases and disorders of prolonged or chronic inflammation, while 
disorders from the latter category include neurodegenerative disorders (for example Alzheimer’s, 
Parkinson’s, and Huntington’s disease), acquired immunodeficiency syndrome (AIDS), ischemia-
reperfusion injury and heart failure (Fadeel and Orrenius, 2005; Hotchkiss et al., 2009; Lawen, 
2003; Reed, 2002). Highlighted below is a disorder from each category.  
It is said that defective apoptotic machinery can be found in more than 50% of malignant tumours 
(Hotchkiss et al., 2009). These tumours are characterised by uncontrolled proliferation paralleled 
by evasion of apoptosis (Green and Evan, 2002). Malignant cells can employ various mechanisms 
to evade apoptosis and these mechanisms can be directed at both the extrinsic and intrinsic 
pathway of apoptosis (Fulda, 2010). Evasion of the extrinsic pathway can involve down regulation 
of DR surface expression, abnormal expression of decoy DR (capable of binding the appropriate 
ligands but fails to initiate downstream signalling) and altered expression or phosphorylation of pro-
caspase 8. In terms of the intrinsic pathway, malignant cells survive by altering the ratio of Bcl-2 
family proteins to favour their survival, reduction of cytochrome c, thus rendering the molecule 
incapable of activating pro-caspase 9, and through down regulating Apaf-1 expression and/or 
activity (Fulda, 2010). However these mechanisms not only ensures the malignant cell’s own 
survival and proliferation by resisting natural cellular defences but also results in apoptotic 
resistance towards many cancer therapies, as the objective of many of these therapies is to induce 
apoptosis (Fulda and Debatin, 2006; Fulda, 2010). Furthermore, genetic mutations in apoptosis-
related genes, as discussed previously, have also been implicated in a variety of malignant 
tumours. The realisation of apoptosis’ involvement in tumourigenesis has spurred many 
researchers to focus on unravelling the apoptotic process with the aim of developing new therapies 
for cancer treatment.  
Increased levels of apoptosis have been implicated in various forms of neurodegenerative 
disorders. Alzheimer’s disease is the most common of these disorders and is characterised by 
pronounced neuronal cell loss (Eckert et al., 2003). Also associated with Alzheimer’s is the 
accumulation and oligomerisation of the amyloid beta (Aβ) peptide, forming plaques in the cerebral 
and brain vasculature (Eckert et al., 2003; Kam and Ferch, 2000). These Aβ plaques can lead to 
apoptotic neuronal cell death, most likely through the generation of free radicals like nitric oxide 
and ROS, resulting in increased oxidative stress (Eckert et al., 2003; Kam and Ferch, 2000; 
Takuma et al., 2005). Moreover, caspases 3, 8 and 9 have been implicated in Alzheimer’s through 
the examination of post-mortem tissues while Bcl-2 and Bax expression have been shown to be 
down- and up-regulated, respectively; both complications  resulting in increased neuronal cell loss 
by means of apoptosis (Eckert et al., 2003; Olson and Kornbluth, 2001). Parkinson’s disease is 
another neurodegenerative disorder characterised by neuronal cell loss, more specifically, a loss of 
dopaminergic neurons (Kam and Ferch, 2000; Olson and Kornbluth, 2001). As with Alzheimer’s, 
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the cell loss is also believed to be due, at least in part, to increased ROS production and a 
combination of neurorestorative and anti-apoptotic therapies has been proposed to be of benefit to 
patients with Parkinson’s (Eberhardt and Schulz, 2003; Olson and Kornbluth, 2001). Huntington’s 
disease is characterised by a polyglutamine tract in the Huntingtin protein caused by the expansion 
of a cytosine-adenine-guanine (CAG) repeat in the corresponding gene (Fadeel and Orrenius, 
2005).  Accumulation of the aberrant protein is associated with neuronal cell loss, possible through 
the activation of pro-caspase 8, while knockout of caspase 1 in a mouse model displayed slower 
disease progression (Fadeel and Orrenius, 2005; Reed, 2002). Additional evidence supporting a 
possible role for apoptosis in neurodegenerative diseases can be concluded from imaging studies 
where apoptotic nuclei was observed in post-mortem tissues from Alzheimer’s, Parkinson’s and 
Huntington’s patients (Olson and Kornbluth, 2001).  
 
1.2.6 Apoptosis-based therapies – contributing to the fight against cancer 
The ability of tumour cells to effectively evade the induction of apoptosis is a characteristic that has 
severely limited the progress in the fight against cancer. Furthermore, traditional therapeutic 
strategies such as chemotherapeutic drugs and radiotherapy have also been subjected to failure 
due to the tumour cell’s ability to actively prevent apoptosis from taking place (Azmi et al., 2011). 
The most commonly used chemotherapeutic drugs are cytotoxic in nature and include drugs such 
as methotrexate, doxorubicin, carboplatin and vinca alkaloids (table 1.1) (Nussbaumer et al., 
2011). As mentioned previously, tumour cells often harbour genetic alternations, such as mutations 
and genome aberrations, that lend them this unique ability; however, these alternations remain a 
continuing force that aims to initiate apoptotic pathways (Sayers, 2011). Thus, removing the 
blockade against apoptosis employed by tumour cells or, alternatively, activating other/additional 
apoptotic proteins/pathways has become an attractive approach in identifying new therapeutic 
protocols for cancer treatment. Additionally, the use of different strategies in combination has also 
received much attention (Azmi et al., 2011; Sayers, 2011).  Since many chemotherapeutic drugs 
rely on the pro-apoptotic members of the Bcl-2 family to mediate apoptosis, the anti-apoptotic 
members which regulate the activity of these proteins have become prime targets for the 
development of novel cancer therapies to assist traditional methods (Yip and Reed, 2008). In 
addition, extensive research into the mechanisms of apoptosis resistance in tumour cells has 
revealed that the anti-apoptotic members of the Bcl-2 family are commonly overexpressed in 
tumours, especially in complex and aggressive cancers such as prostate, pancreatic, ovarian and 
metastatic breast cancers (Azmi et al., 2011; Yip and Reed, 2008). As a result, a variety of 
strategies aiming to reduce or inhibit these proteins has been devised, including the use of 
antisense oligonucleotides, antibodies, synthetic peptides and small molecule inhibitors (SMIs) 
(Azmi et al., 2011). Early success was seen in gene silencing strategies and phase III clinical trials  
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Table 1.1: Common chemotherapeutic drugs used in the treatment of cancers  
ALL – acute lymphoblastic leukaemia. Information obtained from Nussbaumer et al., 2011 and the National Cancer Institute, http://www.cancer.gov/. 
Drug Class Function/stimulus for intrinsic apoptotic pathway Commonly prescribed for 
Methotrexate Antimetabolites Binds and inhibits dihydrofolate reductase (produces 
tetrahydrofolate) resulting in the inhibition of DNA, RNA, and 
protein synthesis 
Maintenance therapy for childhood ALL; 
non-Hodgkin’s lymphoma; 
choriocarcinoma; lung cancer 
Doxorubicin DNA interactive 
agent 
Intercalating agent - binds between the base pairs of DNA, 
preventing DNA replication and protein synthesis 
Broad spectrum – acute leukaemia; 
lymphomas; variety of solid tumours 
Carboplatin DNA interactive 
agent 
Cross-linking agent - binds DNA to induce intra- and interstrand 
cross-linking of DNA 
Advanced ovarian cancer; lung cancer 
Vincristine Antitubulin agent Binds microtubules and spindle proteins to interfere with 
formation of mitotic spindle, resulting in cell cycle arrest 
Lung cancer; breast cancer; lymphomas; 
acute leukaemia;  
Etoposide Topoisomerase 
inhibitor 
Prevents DNA replication and repairs by binding and inhibiting 
topoisomerase II 
Small-cell bronchial carcinoma; testicular 
cancer; certain lymphomas 
5-Fluorouracil Antimetabolite Pyrimidine analogue – incorporates into RNA and inhibits RNA 
processing 
Breast cancer; skin cancer; cancers of the 
gastrointestinal tract 
Actinomycin-D DNA interactive 
agent 
Intercalating agent - binds between the base pairs of DNA, 
preventing DNA replication and protein synthesis 
Paediatric cancers; testicular sarcomas; 
AIDS-related Kaposi’s sarcoma 
Bleomycin DNA cleaving 
agent 
Induces single- and double-strand DNA breaks Head and neck cancer; testicular cancers; 
Hodgkin’s and non-Hodgkin’s lymphoma 
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suggests that G3139, an antisense oligonucleotide targeting Bcl-2, shows great promise for the 
treatment of myeloid leukaemia. However, the strategy faces several hindrances, such as the short 
half-life of the oligonucleotides as well as enzymatic degradation, and chemical modifications are 
needed to improve the therapeutic potential of these antisense oligonucleotides (Azmi et al., 2011). 
Current research is now focussed on use of small molecule inhibitors (SMIs), low molecular mass 
organic molecules that function to inhibit the anti-apoptotic Bcl-2 proteins. SMIs are designed to 
bind and occupy the hydrophobic groove of these proteins, thereby preventing their 
heterodimerisation with pro-apoptotic family members. Currently, there are seven SMIs in various 
stages of clinical trials for the treatment of cancers such as lymphoma, multiple myeloma, 
leukaemia, pancreatic cancer, small cell lung cancer and head and neck cancer (Azmi et al., 
2011).  
The majority of traditional chemotherapeutic drugs, as well as radiotherapy, function to induce 
apoptosis by activating the intrinsic pathway (table 1.1); unfortunately though, this may result in the 
selection of tumour cells resistant to this pathway (Sayers, 2011). Designing therapeutic strategies 
targeting the extrinsic pathway is thus also of vital importance. In addition, activation of the 
extrinsic pathway may be advantageous in tumours where the intrinsic pathway signalling is 
limited, such as those harbouring mutations in the TP53 gene. As mentioned previously, caspase 8 
is activated in the extrinsic pathway, which in turn is able to cleave and activate Bid, a pro-
apoptotic Bcl-2 family member that has the ability to facilitate MOMP by engaging Bax or Bak. This 
process serves as an alternative mechanism for the induction of the intrinsic pathway and 
importantly, is independent of p53 (Sayers, 2011). In terms of activating the extrinsic apoptotic 
pathway in tumour cells, the death ligand TRAIL is proving to be a promising candidate based on 
the observation that normal cells are relatively insensitive to apoptosis induction by TRAIL 
(Ashkenazi and Herbst, 2008; Sayers, 2011). TRAIL or TRAIL receptor agonists can be 
administered systemically or via non-replicating recombinant adenoviral vectors (Sayers, 2011). 
The TRAIL-mediated strategy is also amendable to use in a combination of strategies and ABT-
737, one of the SMIs targeting Bcl-2 proteins currently in clinical trials, has been shown to greatly 
enhance the TRAIL-mediated apoptosis in pancreatic cancer cell lines (Huang and Sinicrope, 
2008). An alternative method to administer death receptor ligands to a tumour cells would be to 
utilise immune effector cells, such as macrophages, T cells, dendritic cells and NK cells. These 
cells have the ability to express multiple death ligands and would make excellent delivery vehicles 
(Sayers, 2011). In fact, a recent study showed that adoptively transferred transgenic T cells was 
able to deliver Fas-L to renal cancer cells and that this step was essential to the observed 
therapeutic effect (Sayers, 2011; Shanker et al., 2009). Lastly a promising avenue in novel anti-
cancer therapies that is currently being explored is the design and use of nanoparticles (Brannon-
Peppas and Blanchette, 2012; Brigger et al., 2012). These submicronic colloidal systems could 
potentially serve as a mechanism of gene delivery as well as an improved mechanism for the 
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delivery of antisense oligonucleotides by providing increased stability and protection. In addition, 
nanoparticles are also capable of specifically targeting chemotherapeutic drugs to a cancer cell, 
which has the potential of improving drug efficacy while minimising harmful side-effects (Brannon-
Peppas and Blanchette, 2012; Brigger et al., 2012).  
 
1.3 Aims and objectives 
The aim of this study is to aid in the characterisation of genes involved in apoptosis, as well as to 
identify novel candidate genes possibly involved in resistance to apoptosis. The following 
objectives were set out to achieve these aims: 
 To verify the involvement of three novel candidate genes, identified in a previously 
performed pilot study, in resistance to apoptosis induced by C2-ceramide and camptothecin 
by generating stable knockdown cell lines for each of the candidate genes and repeating 
the apoptosis assays as performed in the pilot study. 
 To identify additional novel candidate genes possibly involved in resistance to apoptosis by 
analysing nucleotide sequences obtained in a previously performed pilot study. 
 To characterise the identified novel candidate genes by using a bioinformatic approach. 
 To investigate the gene expression levels of the novel candidate genes, as well as other 
genes known to be involved in apoptosis, in normal and cancer cell lines. 
 
1.4 Background to the current study 
This study builds on a previously performed pilot study that aimed to identify novel genes involved 
in resistance to apoptosis induced by C2-ceramide in Chinese hamster ovary (CHO) cell lines. 
These cells were used due to their unique characteristic of being functionally haploid. The cell line 
was originally isolated in 1958 by Puck and colleagues and later described as functionally 
hemizygous (Siminovitch, 1976). The cell line thus provides an invaluable platform for functional 
studies: if the expression of a gene is abrogated either by disrupting its coding sequence or the 
sequences of its regulatory elements, a “knock-out” cell is effectively produced. In the pilot study, 
this was achieved by performing promoter trap mutagenesis experiments. The technique is based 
on the random insertion of an integration cassette, delivered by a retrovirus, into the host genome. 
The experiment is viewed as successful if insertion occurs within the promoter region of a gene. 
The integration cassette utilised in the pilot study was designed to provide dual-type positive 
selection in the form of Hygromycin B and Neomycin resistance genes, as well as negative 
selective by means of the Herpes simplex virus thymidine kinase gene (Fig. 1.7). 
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Figure 1.7: Schematic representation of the integration cassette used in the promoter-trap mutagenesis 
experiments. The cassette was transferred to the CHO22 cells by means of the MoMLV. LTR – long terminal 
repeat; U3 – promoter element; Hygro
R
 – Hygromycin B resistance gene; Neo
R
 – Neomycin resistance gene; 
tk – thymidine kinase gene from the Herpes simplex virus. 
Expressing the ecotropic receptor for the Moloney murine leukaemia virus (MoMLV), CHO22 cells 
were infected with the retrovirus carrying the promoter-trap vector containing the integration 
cassette. Transfectants were placed on media containing Hygromycin B or G418 to select positive 
recombinants and then treated with either C2-ceramide or camptothecin to induce apoptosis. 
Surviving colonies were screened and the top three colonies showing the highest level of 
resistance were isolated and cultured to obtain stable cell lines. The three cell lines were 
designated J304, J308 and J612. Apoptosis assays were performed to confirm apoptosis as the 
mode of cell death induced by the agents and to measure the resistance shown by the isolated J-
cell lines. Both the APOPercentage™ Apoptosis assay (Biocolor LTD, UK) and the Annexin-V 
FITC Apoptosis Detection Kit (BD Biosciences) used in the pilot study exploits the structural cell 
membrane changes of apoptotic cells to detect and quantify apoptosis. In physiologically normal 
cells, phosphatidylserine molecules are located on the inside of the cell, on the inner cell 
membrane. However, upon apoptotic stimuli, these molecules are translocated to the outside of the 
cell by what has been described as a “flip-flop” mechanism (Fadok et al., 1992). The 
APOPercentage™ Apoptosis assay utilizes this “flip-flop” mechanism to import a purple-red dye 
into the dying cell, while the Annexin-V FITC Apoptosis Detection Kit contains fluorophore-labelled 
Annexin-V molecules which selectively binds to the exposed phosphatidylserine molecules. In 
addition, a Caspase 3 Colourimetric assay (BioVision Incorporated) was performed which allows 
detection of early/mid apoptosis. These assays allows for the quantification of the amount of 
apoptotic cells in a sample.  
For the purpose of the pilot study, cell lines J304, J308 and J612, along with wild type CHO22 cells 
serving as a control, were treated for 24 hours with C2-ceramide and camptothecin at 
concentrations ranging from 0-100 µM and 0-10 µg/ml respectively. The amount of apoptotic cells 
in each cell line sample were quantified with each of three apoptosis assays. These cell lines were 
subsequently analysed to determine if they displayed a significant level of resistance to apoptosis 
(p < 0.05). Figures 1.8 – 1.10 are examples of graphs generated during the analysis. Similar 
results were obtained in all three apoptosis assays. Compared to the wild type CHO22 cell line, the 
promoter-trapped cell lines displayed significant resistance to apoptosis upon treatment with both 
C2-ceramide and camptothecin. The resistance persisted upon increasing concentrations of the 
apoptotic inducer, while the amount of CHO22 cells continued to decrease dramatically. In  
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Figure 1.8: Results of testing for resistance to apoptosis in promoter-trapped cell lines, as compared to wild 
type CHO22 cells, by means of the APOPercentage
™
 assay following treatment with C2-ceramide for 24 hrs. 
Values are the averages ± standard deviation from triplicate experiments. * Indicates significantly different 
from wild type for p < 0.05. 
 
 
Figure 1.9: Results of testing for resistance to apoptosis in promoter-trapped cell lines, as compared to wild 
type CHO22 cells, by means of the Annexin-V assay following treatment with Camptothecin for 24 hrs. 
Values are the averages ± standard deviation from triplicate experiments. * Indicates significantly different 
from wild type for p < 0.05. 
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Figure 1.10: Results of testing for resistance to apoptosis in promoter-trapped cell lines, as compared to wild 
type CHO22 cells, by means of the Caspase-3/CPP32 assay following treatment with C2-ceramide for 24 
hrs. Values are the averages ± standard deviation from triplicate experiments. * Indicates significantly 
different from wild type for p < 0.05. 
addition, results from the assays with C2-ceramide as apoptotic inducer were also comparable to 
those of the assays with camptothecin treatment. The previously mentioned assays were specific 
for apoptosis. The success of the assays consequently excluded the presence of necrotic cell 
death since none of the assays is applicable to this form of cell death. However, it was necessary 
determine whether the recombinant cell lines delivered resistance to apoptosis per se or to CTL-
mediated killing, which can lead to apoptosis (Groscurth and Filgueira, 1998). Thus, in order to 
exclude CTL killing as the method of cell death, a standard 51Chromium (51Cr) release CTL killing 
assay was performed in collaboration with Dr K. Gould at Imperial College London (UK). The assay 
measures the release of 51Cr from 51Cr-labelled target cells, in this case cells from each of the 
respective J-cell lines, upon lysis by CTL effector cells (Brunner et al., 1968; Wonderlich et al., 
2001). The Y10 cell line, presenting an epitope recognised by the CTL on the major 
histocompatibility complex 1 (MHC1) receptor, was used as a reference for susceptibility to CTL 
killing, thus acting as a positive control. In contrast, the wild type CHO22 cells were used as a 
negative control since it lacks a recognisable epitope on the cell surface, making it resistant to CTL 
killing. All three J-cell lines followed the Y10 cell line across all effector: target ratios (1.25:1 – 
10:1), indicating susceptibility to CTL killing (Fig. 1.11). In order to obtain the unknown hamster 
sequences surrounding the retrovirus integration site, a modified polymerase chain reaction PCR 
technique, namely inverse PCR, was performed. In this technique, established by Saiki and 
colleagues in 1985, unknown genomic areas flanking known sequences are amplified by allowing 
self-ligation of genomic DNA fragments following restriction enzyme digestion with a frequent 
cutter. The circular fragments are linearized by a specific restriction enzyme that cuts within the 
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Figure 1.11: Line graph showing results from CTL killing assay performed with recombinant J-cell lines 
isolated from promoter-trap mutagenesis experiments, with % specific cell lysis referring to the amount (in 
percentage) of cells dying due to CTL killing at various effector: target ratios. (Effector – CTL; Target – cells 
from respective J-cell line).  
known retrovirus sequence. PCR primers are designed to complement the known sequences and 
anneal at either ends of the linear fragment. Amplified products  consist of two types of fragments; 
one of a specific size containing the known sequence and one of unknown size containing the 
unknown flanking sequences. The latter product can now be subjected to sequencing. A schematic 
representation of inverse PCR, as performed in the pilot study, is shown in figure 1.12. Products 
obtained from the inverse PCR technique were sequenced and the resulting sequences were 
aligned to the mouse genome using BLAST on the NCBI website. Three alignments to genes were 
made, one in each cell line. The particular genes were Lipoic Acid Synthetase (LIAS) in cell line 
J304 (Fig. 1.13), Ribosomal Protein L9 (RPL9) in cell line J308 (Fig. 1.14) and Cyclophilin A 
(CYPA) in cell line J612 (Fig. 1.15). RPL9 and LIAS are located on chromosome 4p13 and 4p14 
respectively, while CYPA maps to chromosome 7p11.2-p13. These genes are discussed further in 
chapter two. 
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Figure 1.12: A simplified schematic representation of inverse PCR as performed in the pilot study. 1) 
Enzymatic digestion of genomic DNA with frequently cutting enzyme, followed by self-ligation to form circular 
fragments. 2) Linearization of circular fragments with a specific enzyme cutting within known sequences. 
(LTR – long terminal repeat; Hygro
R
 – Hygromycin B resistance gene; U3 – promoter element; tk – thymidine 
kinase gene; Neo
R
 – Neomycin resistance gene). 
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Figure 1.13: Results obtained from the BLAST search for the genomic sequence generated from CHO-J304 
showing a significant match to the mouse lipoic acid synthetase (LIAS) gene. 
 
Figure 1.14: Results obtained from the BLAST search for the genomic sequence generated from CHO-J308 
showing a significant match to the mouse ribosomal protein L9 (RPL9) gene. 
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Figure 1.15: Results obtained from the BLAST search for the genomic sequence generated from CHO-J612 
showing a significant match to the mouse peptidylprolyl isomerase A (PPIA) gene, also known as cyclophilin 
A (CYPA). 
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Chapter 2: Investigating the role of three novel candidate genes in apoptotic 
resistance 
 
The practical methodology (excluding analysis of results) of this chapter was performed in 
collaboration with Dr Mervin Meyer at the University of Western Cape (UWC), Department of 
Biotechnology.  
2.1 Introduction 
During the pilot study three novel candidate genes were identified to potentially be involved in 
resistance to apoptosis induced by C2-ceramide and camptothecin. This part of the current study 
aimed to verify their involvement in apoptosis by generating stable mouse knockdown cell lines for 
each of the respective genes, namely LIAS, RPL9 and CYPA, and repeating the apoptosis assays 
performed in the pilot study. Stable knockdown cell lines were generated by taking advantage of 
the RNA interference (RNAi) process. This verification aims to build on the results obtained in the 
pilot study by making use of a diploid model compared to the haploid model used in the pilot study. 
In addition, a more specific method of gene expression knockdown will be used. A positive 
outcome would provide supporting evidence for either a direct or indirect role in the apoptotic 
pathway for the candidate genes. 
 
2.1.1 RNA interference 
RNAi is a process that occurs naturally in early developmental pathways and responses to viral 
infection in vertebrates, invertebrates and plants (Caplen et al., 2001; Elbashir et al., 2001; Sashital 
and Doudna, 2010). The process is mediated by short interfering RNAs (siRNAs) of about 21 
nucleotides in length which is processed from double-stranded RNA (dsRNA) by the RNase III-like 
nuclease named Dicer (Elbashir et al., 2001; Hammond, 2000; Holen, 2005). These siRNAs 
associate with proteins from the Argonaute family to form the RNA-induced silencing complex 
(RISC). The sequence-specific siRNA is denatured and the guide strand is used by RISC to target 
the complementary mRNA in the host cell, while the passenger strand is degraded (Fig. 2.1) 
(Hammond, 2000; Sashital and Doudna, 2010; Shan, 2010). The process of RNAi became an 
important tool for functional gene studies upon the discovery that specific gene expression 
knockdown could be achieved through the successful introduction of 21 bp siRNAs into a cell 
(Elbashir et al., 2001; Shan, 2010). The delivery of siRNAs into a host cell can occur either directly 
by means of liposomes, electroporation, transfection or microinjection, or indirectly via a vector. In 
the latter methodology, the sense and antisense siRNA sequences can either be transcribed by
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Figure 2.1: An illustration of RNAi process. Adapted from Rutz and Scheffold, 2004. 
individual promoters or by a single promoter in the form of a short hairpin RNA (shRNA, Fig. 2.2) 
which is then subsequently processed by the native Dicer enzyme (Shan, 2010; Tuschl, 2002). 
Vector-mediated siRNA delivery holds the advantage of eliminating the danger of RNAse 
contamination compared to the direct delivery of synthetically synthesised siRNAs. However, the 
process of generating siRNA expression vectors, along with the transfection, might prove to be 
more time consuming and laborious (Tuschl, 2002). The current study employed the vector-
mediated strategy in conjunction with the use of a shRNA construct, subsequently processed into 
the target specific siRNAs. Another advantage of the vector-mediated strategy is the production of 
a more stable and sustainable gene expression knockdown effect which, in addition, also allows for 
the generation of stable knockdown cell lines (Berns et al., 2004; Fraser, 2004; Hannon, 2002; 
Shan, 2010; Tuschl, 2002). 
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Figure 2.2: Typical example of a shRNA construct. U6 – a type of promoter; Term. – Termination signal. 
Obtained from http://www.addgene.org/tools/protocols/plko/. 
2.1.2 Apoptosis Assays 
 In an editorial to Science journal in 1998, Pierre Golstein noted the publication of 20 000 articles 
on the topic of cell death within a time span of five years (Golstein, 1998). Recently, a literature 
search for ‘apoptosis’ in the title or abstract fields in the NCBI PubMed database produced 189 391 
publications, with 76.34% of these published in the last decade (as on 19/07/12). Increased 
research and continued progress in this field have urged the improvement of traditional apoptosis 
detection methods as well as the development of new techniques. Currently, several apoptosis 
assays are available and many of these can be purchased commercially in the form of kits. Among 
the most popular are terminal deoxynucleotidyl transferase-mediated dUTP nick end labelling 
(TUNEL) assays, Annexin V binding assays, the APOPercentage™ assay and caspase 3 activity 
assays, of which the latter two are employed in this study. Apoptosis assays are designed around 
its unique characteristics, which includes the morphological and biochemical features.  
The APOPercentageTM apoptosis assay (Biocolor LTD, UK) exploits the structural plasma 
membrane changes of apoptotic cells to detect and quantify apoptosis. In physiologically normal 
cells, PS molecules are located on the inside of the cell, on the inner plasma membrane. However, 
upon apoptotic stimuli, these molecules are translocated to the outside of the cell by what has 
been described as a “flip-flop” mechanism (Fadok et al., 1992). The APOPercentage™ assay 
utilizes this mechanism to import a purple-red dye into the dying cell. Traditionally, apoptotic cells 
were visualised by bright-field microscopy and quantified by spectrophotometric measurement, 
proving the technique to be quite laborious (Meyer et al., 2008). However, the assay has recently 
been modified to allow for the use of flow cytometry. In addition, the modification also rendered the 
assay more cost-effective, allowed for apoptosis detection of cells in suspension and also rendered 
the technique amendable to high-throughput analysis (Meyer et al., 2008).  
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Activation of the caspase cascade during apoptosis culminates in the activation of caspase 3 
(Watanabe et al., 2002). This executioner caspase recognises its cellular substrates through the 
peptide sequence DEVD (aspartic acid – glutamic acid – valine – aspartic acid); proteolytic 
cleavage occurs after the second aspartic acid residue (Wang et al., 2005a). Apoptotic caspase 
activity assays involve the detection of active caspase 3 by utilising synthetic substrates. These 
substrates contain the DEVD-peptide sequence and traditionally contained fluorogenic tags based 
on coumarin dye (Wang et al., 2005a). Improvement of this technique includes the use of 
rhodamin-labelled substrates which has longer excitation and emission wavelengths (Wang et al., 
2005a).  The technique can also be performed as a colourimetric assay (Gurtu et al., 1997).  
The TUNEL assay is designed to detect DNA fragmentation by modifying the 3’ end of fragments 
with labelled nucleotides through transferase activity (Gavrieli et al., 1992; Watanabe et al., 2002). 
This allows for the visualisation of accumulated DNA fragments by either fluorescent microscopy or 
a colourimetric assay (Watanabe et al., 2002). The Annexin V assay is based on the Ca2+-
dependent binding of the annexin V protein to externalised PS residues (Vermes et al., 1995). The 
protein is also labelled to allow for the detection of cells with fluorescent microscopy (Watanabe et 
al., 2002). As PS externalisation also occurs in necrosis, the assay is used in conjunction with a 
dye exclusion test to determine the integrity of the plasma membrane; if the dye is excluded, the 
cell is undergoing apoptosis, as opposed to necrosis where permeabilisation of the plasma 
membrane is an early event (Vermes et al., 1995). Other methods of apoptosis detection include 
the visualisation of morphological characteristics by means of standard transmission electron 
microscopy (TEM) and various mitochondrial assays, for example the detection of cytochrome c 
release (Watanabe et al., 2002).  
As with any molecular technique, certain advantages and limitations have been described for each 
of the apoptosis assays (Watanabe et al., 2002). Although TEM permits definitive identification of 
apoptotic cells, it’s quite time consuming and only small regions of tissues can be assayed at a 
time. TUNEL assays can be performed on a variety of tissues but fails to distinguish between 
apoptosis and necrosis. The APOPercentage™ assay circumvents the problem associated with the 
Annexin V assay; since the former assay entails the uptake of a dye there is no need to determine 
plasma membrane integrity with a dye exclusion test as with the latter assay. A requirement for 
caspase 3 activity assays is homogenisation of the tissue; hence the specific apoptotic cell can’t be 
identified. Even though limitations exist, many of these assays are well accepted and widely used 
in apoptosis research. It is however recommended that a combination of two assays, based on 
different principles, be used in a study to detect and confirm the presence of apoptosis (Watanabe 
et al., 2002).  
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2.1.3 Apoptotic Inducers  
A plethora of apoptotic inducers is available today for research purposes and many of these have 
also been utilised in anticancer therapies. Inducers of apoptosis can take many different forms and 
can either be natural compounds or synthetically produced. Natural compounds capable of 
inducing apoptosis include dietary flavonoids (for example from grapes), extracts from various 
medicinal plants or trees, plant polyphenols and phenolic compounds (for example curcumin), 
lectins, terpenoids and isoprenoids (Chen et al., 2005; Taraphdar et al., 2001; Zhang et al., 2004). 
Various organic copper compounds have also been shown to induce apoptosis in human cancer 
cells (Daniel et al., 2004). Popular examples of synthetic apoptotic inducers are cytotoxic drugs 
and their derived analogues. These include doxorubicin, etoposide, cytarabine, methotrexate, 
cysplatin and taxol (Friesen et al., 1999; Taraphdar et al., 2001).  
For the purposes of this study, two synthetic compounds were selected to serve as apoptotic 
inducers for each of the apoptosis assays performed, namely C2-ceramide and camptothecin. 
Ceramide is bioactive sphingolipid that forms part of the sphingomyelin pathway, an evolutionary 
conserved pathway from yeast to humans (Andrieu-Abadie and Levade, 2002; Hannun and Obeid, 
2008). Naturally produced ceramide species differ in the length of their fatty acid moiety, which 
ranges from C14 to C26, however synthetic short chain analogues, such as C2- or C6-ceramide, has 
been produced and are frequently used in studies by means of exogenous administration (Huang 
et al., 2011a; Novgorodov et al., 2011). Apoptotic induction by ceramide is mediated by a variety of 
downstream targets; ceramide-induced activation of protein phosphatase 2A (PP2A) is capable of 
activating the pro-apoptotic Bax protein and inducing cytochrome c release while ceramide-
induced activation of cathepsin D results in the truncation and activation of Bid, which is 
subsequently followed by cytochrome C release and caspase 9 and 3 activation (Heinrich et al., 
2004; Xin and Deng, 2006). Other mediators of ceramide’s pro-apoptotic effect include protein 
kinase Cζ and the c-JUN N-terminal kinase (JNK) pathway (Mathias et al., 1998; Wang et al., 
2005b). Camptothecin is an alkaloid originally isolated from the Camptotheca acuminate tree 
indigenous to China (Hsiang et al., 1985). It displays potent antitumour activities and possesses 
several features that make it pharmacologically unique (Hsiang et al., 1985; Pommier, 2006). The 
sole target of camptothecin is topoisomerase I, an essential enzyme responsible for unwinding 
supercoiled DNA generated by replication, transcription and chromatin remodelling (Hsiang et al., 
1985; Pommier, 2006). Inhibition of topoisomerase I by camptothecin results in significant DNA 
damage and subsequent apoptosis.  
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2.2 Materials and methods 
2.2.1 Generation of stable knockdown cell lines for LIAS, RPL9 and CYPA 
2.2.1.1 Cell culture 
NIH-3T3 cells were used during this study. This fibroblast cell line originates from a NIH Swiss 
mouse embryo and was first established by George Todaro and Howard Green in 1962 (Todaro 
and Green, 1963). Characteristics of the cell line include inhibition by temazepam and other 
benzodiazepines and sensitivity to leukaemia and sarcoma virus propagation. NIH-3T3 cells were 
obtained from Dr A. Madiehe at the Medical Research Council, South Africa. During the study the 
cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal 
calf serum (FCS) and maintained in an incubator at 37°C and 5% CO2. Cells were cultured until a 
confluency of 70% were reached, upon which passaging were performed using sterile phosphate 
buffer saline (PBS, pH 7.0) and 0.125% trypsin solution pre-equilibrated to 37°C. All reagents, 
unless otherwise specified, were supplied by Gibco® (Life Technologies™).  
2.2.1.2 Short hairpin-RNA (shRNA) design  
Two shRNA constructs were designed for each of the novel candidate genes, namely LIAS, RPL9 
and CYPA. This was done by making use of iRNAi (v. 1.0, nucleobytes.com), a standalone 
software package designed to identify suitable shRNA constructs in your template sequence 
according to specified parameters. Selected parameters for shRNA design included a target size of 
19 nucleotides, start and end points of AA and TT respectively as well as default sequences for the 
hairpin loop structures. Restriction enzyme cut sites for Bgl II (5’ end) and Hind III (3’ end) were 
incorporated in order to facilitate cloning of the constructs into vectors; however, the 5’ end was 
designed in such a way that the Bgl II site would become non-functional upon ligation of the 
shRNA into the vector. In addition, scramble controls, mutated shRNA constructs that are non-
specific, were also designed in order to serve as negative controls. Figure 2.3 contains an example 
of a complete shRNA while table 2.1 contains the sense target sequences for each of the novel 
candidate genes. The shRNA constructs were synthesised by Inqaba Biotech™.  
2.2.1.3 Construction of expression vectors 
Several techniques common to cloning experiments were performed during the preparation and 
construction of the expression vectors. This includes restriction enzyme digests, ligation reactions, 
colony PCRs and plasmid isolations. Below follows a short description of each of these techniques.  
The restriction enzymes used in this section were purchased from Fermentas™ (Thermo Fisher 
Scientific) (Hind III and Ase I) and New England Biolabs Inc. (Bgl II and BamH I) and all digest 
reactions were performed according to the manufacturer’s specifications. For the most part, the 
digest reactions were performed with 1 µg of vector DNA and 5 U of the restriction enzyme. 
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Figure 2.3: Representative example of the shRNA constructs designed with iRNAi. The sense target 
sequence for LIAS KD1 is represented. Colours represent the different parts of the shRNA construct: red – 
vector sequence forming part of restriction enzyme cut site, with Bgl II (non-functional) at the 5’ end and Hind 
III at the 3’ end on the sense strand; orange – shRNA sequence forming part of the respective restriction 
enzyme cut sites; black – spacer sequences and termination sequence (3’ end of top strand); blue – target 
sequence complementary to the respective genes (in this example LIAS KD1); green – hairpin loop 
sequence. 
Table 2.1: Target sequences of the shRNA constructs designed for each of the three novel 
candidate genes  
shRNA Sense target sequence 
LIAS KD1 5’ – TTGCAGAGTGGGGTCTGGA – 3’ 
LIAS KD2 5’ – TGTGGAGACTGTCCCCGAG – 3’ 
RPL9 KD1 5’ – ACACCGGCCCAAAGACAAC – 3’ 
RPL9 KD2 5’ – TTACATCTGCTCTTAGAGC – 3’ 
CYPA KD1 5’ – GTCCATCTATGGGGAGAAA – 3’ 
CYPA KD2 5’ – GCATACGGGTCCTGGCATC – 3’ 
KD – knock down. 
Following incubation for 2 hrs at the required temperature, a final inactivation step was performed 
by means of incubation for 20 min at 65°C. Digested vectors were used as is if the digestion 
produced non-compatible ends; however, if this was not the case, the vectors were treated with 
shrimp alkaline phosphatase (SAP, Roche Applied Sciences) in order to remove 5’ phosphate 
groups, preventing self-ligation. 
Ligation reactions were generally performed during the cloning of fragments into the respective 
vectors. These reactions, incubated overnight, were performed in a total volume 20 µl and 
contained 1.0 Weiss unit of T4 ligase, purchased from Fermentas™ (Thermo Fisher Scientific). 
In order to perform the colony PCRs, competent Escherichia coli cells had to be transformed with 
the vectors. The E. coli MC1061 strain (Casadaban and Cohen, 1980) was used for this purpose 
and was prepared for competency by incubating the strain overnight at 37°C streaked out on a 
Luria Broth (LB) medium plate containing 10 mM MgSO4. A single colony was then grown up by 
means of incubation at 37°C, with shaking, in 20 ml TYM broth (tryptone, yeast extract, NaCl and 
MgCl2) until a desired optical density of 0.2 (measured at 550 nm) was reached. The incubation 
step was then repeated after transferring the cells to 100 ml TYM broth. A volume of 400 ml fresh 
TYM broth was then added and the cells were further incubated under the same conditions until an 
optical density between 0.4 and 0.6 was reached.  Ice cold water was used to rapidly cool down 
the cells, which were then collected by centrifugation for 10 min at 3000 g in a 4°C room. 250 ml 
Stellenbosch University  http://scholar.sun.ac.za
 43 
 
ice cold transfection buffer 1 (potassium acetate, MnCl2, KCl, CaCl2 and glycerol) were added to 
the cells for resuspension, which was then incubated for 30 min at 0°C. Cells were then pelleted by 
centrifugation for 8 min at 6000 g and resuspended in 50 ml ice cold transfection buffer 2 (MOPS, 
CaCl2, KCl and glycerol). For storage purposes, cell were frozen as 300 µl fractions in liquid 
nitrogen and stored at -80°C.  
Bacterial transformations was performed by adding 100 µl of the competent cells, thawed on ice, to 
10 µl of the vector DNA solution, gently mixing the solution and incubating it on ice for 30 min. 
Cells were heat-shocked by means incubation for 45 s at 42°C where after 500 µl of pre-warmed 
LB medium was added to the cells. To allow for the expression of the antibiotic resistance markers, 
the solution was first incubated for one hour at 37°C before plating out the cells on nutrient rich 
agar plates supplemented with 50 µg/ml kanamycin sulphate (Sigma-Aldrich®).  
Recombinant cells were used as template for colony PCR reactions aimed at verifying the 
successful modification of the vector. The template solution was prepared by suspending a single 
recombinant colony, grown on agar plates, in 20 µl of sterile deionised water. A PCR reaction 
containing 1 µl of the template solution and 10 pmol/µl specific primers (table 2.2) was incubated 
for 35 cycles comprising of a denaturation (45 s at 95°C), annealing (45 s at a primer-specific 
annealing temperature (TA)) and extension step (45 s at 72°C), followed by a final extension step 
(10 min at 72°C). Primers were synthesised by Inqaba Biotech™. PCR products were separated on 
a 1% agarose gel and sizes were determined by means of comparison with a pTZ molecular 
marker (pTZ18R vector digested with the restriction enzyme Hinf I).  
A plasmid isolation protocol was followed in order to retrieve the modified vector construct following 
a successful colony PCR. For this isolation, an inoculum containing a single positive colony in 5 ml 
LB medium supplemented with 50 µg/ml kanamycin sulphate (Sigma-Aldrich®) was prepared and 
incubated overnight at 37°C with shaking. Following incubation, cells were obtained by centrifuging 
1 ml of the culture for 5 min at 5000 g. 200 µl ice cold GTE buffer (glucose-tris-
ethylenediaminetetraacetic acid) was added to the pellet for resuspension, which was then allowed 
to incubate for 5 min at room temperature. Next, 1 % sodium dodecyl sulphate (w/v) solution and 
400 µl 0.2 M NaOH were added and after gentle mixing through inversion, the solution was 
incubated for 5 min on ice. This was followed by another 5 min incubation step on ice upon the 
addition of 300 µl ice cold potassium acetate (5 M, pH 5.5). A 10 min centrifugation step at 14 000 
g was performed to remove all the cell debris while the supernatant containing the vector DNA was 
transferred to a new eppendorf tube to which 0.6 volumes of isopropanol had already been added. 
The vector DNA was precipitated by incubation for 30 min at -20°C and pelleted by centrifugation 
for 15 min at 14 000 g. A wash step was performed with 500 µl 70% ethanol, after which the pellet 
was dried and resuspended in 50 µl 1 x TE buffer (tris and ethylenediaminetetraacetic acid).  
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Table 2.2: Details of primers used for colony PCRs performed during vector construction 
See text in section 2.3.1.1 for PCR product sizes. F – forward; R – reverse; bp – base pair; TA – annealing 
temperature. 
Two mammalian expression vectors were used in this study, namely pEGFP-C1 and pDsRed-
Express-C1 (Fig. 2.4), and were purchased from Clontech. The pEGFP-C1 vector has been 
optimised for higher expression and brighter fluorescence in mammalian cells while the translation 
efficiency in eukaryotic cells was improved by converting the sequences flanking EGFP to a Kozak 
consensus translation initiation site. Selection of transfected eukaryotic cells with the G418 
(neomycin sulphate) antibiotic is made possible by the presence of a resistance cassette 
consisting of the neomycin/kanamycin resistance gene, Tn5, and polyadenylation signals from the 
Herpes simplex virus thymidine kinase (HSV-TK) gene, driven by a SV40 early promoter. Cells 
transfected with this vector can also be easily identified by the fluorescent signal emitted by the 
expressed green fluorescent protein (GFP) using fluorescent microscopy. The pDsRed-Express-
C1 expresses a variant of the Discosoma sp. red fluorescent protein which contains nine amino 
acid substitutions aimed at improving the solubility of the protein as well as detection time. As with 
the pEGFP-C1 vector, this vector contains a Kozak consensus translation initiation site and the 
resistance cassette. The presence of this vector can also be detected in cells by fluorescent 
microscopy since it expresses red fluorescent protein (RFP). The pEGFP-C1 and pDsRed-
Express-C1 vectors are hereafter referred to as GFP and RFP vectors, respectively.  
Since the multiple cloning site (MCS) in both of the vectors were not going to be used for the 
cloning of the shRNA constructs, the Bgl II and Hind III restriction enzyme cut sites in this region 
were removed to prevent inappropriate restriction enzyme digestions (see below). This was done 
by digesting the vectors with Bgl II and BamH I (Fig. 2.5). Since Bgl II and BamH I ends are 
compatible, re-circulisation of the vectors were allowed which would leave only a BamH I restriction 
site functional. Deletion of the Bgl II and Hind III restriction sites in the MCS were verified by means 
of colony PCR performed with the 1-F and 1-R primer pair (table 2.2). 
 
Primer name  Primer 
orientation 
Sequence (5’-3’) Length (bp) TA (°C) 
1-F F CTGGCCGTCGTTTTAC 16 58 
1-R R CAGGAAACAGCTATGA 16 
2-F F ACTACTACGTGGACTCCAAGC 21 60 
2a-R R TAGGTGGCATCGCCCTCG 18 
2b-R R TCGTAGGGGCGGCCCTC 17 
3-F F ACTACTACGTGGACTCCAAGC 21 60 
3-R F ATTATGATCAGTTATCTAGATCC 23 
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Figure 2.4: Vector maps of the pEGFP-C1 (A) and pDsRed-Express-C1 (B) vectors. The images show the 
Ase I restriction enzyme cut site used for the cloning of the U6 promoter as well as the MCS. These images 
were created with the freely available SnapGene
™
 Viewer software version 1.3.3 (GSL Biotech LLC) in 
conjunction with the sequence and map files of the vectors, as created by SnapGene 
(www.snapgene.com/resources). 
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Figure 2.5: Sequences of the MCS regions of the pEGFP-C1 (A) and pDsRed-Express-C1 (B) vectors. The 
region removed by means of digestion with Bgl II and BamH I is highlighted. These images were created with 
the freely available SnapGene
™
 Viewer software version 1.3.3 (GSL Biotech LLC) in conjunction with the 
sequence and map files of the vectors, as created by SnapGene (www.snapgene.com/resources). 
Both vectors were further modified by inserting a human U6 promoter sequence upstream of the 
fluorescent markers. A fragment containing the U6 promoter sequence was cloned into both 
vectors after digestion with Ase I. The fragment was generated by PCR amplification of the human 
U6 promoter region and was designed to contain recognition sites for Bgl II and Hind III 
downstream of the promoter sequence, which would allow for the cloning of the shRNA constructs 
into this site. Colony PCR, with primers 2-F and either 2a-R (GFP vector) or 2b-R (RFP vector) 
(table 2.2), was performed to verify the presence of the fragment in the vectors.  
To allow for the cloning of the shRNA’s constructs, 1 µg of both vectors were first digested 
overnight with 1 U Hind III, since this enzyme requires a larger overhang to digest properly, 
followed by digestion with 1 U Bgl II to remove the section between these two enzyme recognition 
sites. Digest products were separated on an 1% agarose gel and the appropriately sized linearized 
vector was obtained and purified by means of the GFX™ PCR DNA and Gel Band Purification Kit 
(Amersham Biosciences), performed according to the manufacturer’s specifications. Purified vector 
DNA were diluted into aliquots with a final concentration of 10 ng/µl, which were then subsequently 
used for the cloning of the various shRNA’s constructs into the vectors. For this 10 ng of the vector 
DNA was added to 1 U of T4 DNA ligase, 20 M of double-stranded oligos and 10 x reaction buffer 
and incubated overnight. After ligation the constructed vectors were transformed in MC1061 
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competent cells as described earlier. Successful cloning was verified by means of colony PCR 
(primer pair 3-F and 3-R, table 2.2) and pure, high quality vector DNA was achieved by means of 
the Qiagen® Midi-prep Plasmid Purification Kit (SABiosciences™), performed according to 
manufacturer’s specifications.  
2.2.1.4 Transfection 
Transient and stable transfection experiments were performed concurrently following the same 
protocol. NIH-3T3 cells used for transfection were cultured as described in section 2.3.1.1. The 
METAFECTENE® Lipid Reagent (Biontex) was used in all transfection experiments according to 
the manufacturer’s specifications. A solution containing 10 µl METAFECTENE® reagent and 1 ml 
DMEM, without FCS, per 2 µg of vector construct was prepared and incubated at room 
temperature for 20 min to allow for the formation of DNA-lipid complexes. The solution was gently 
mixed with the cultured NIH-3T3 cells, previously washed with PBS, and incubated at 37°C for 24 
hrs in a 5% CO2 incubator to allow adequate time for transfection. Success of the transfection 
experiments, as described below, were determined for both transient (within 48 hrs) and stable 
transfections, while only stable transfections were selected for and maintained in DMEM containing 
500 µg/ml G418 (Sigma-Aldrich®).  
2.2.1.5 Visualisation of transfected cells 
Fluorescent microscopy was performed in order to verify the presence of the respective vectors 
within the cells by means of detection of the fluorescent GFP and RFP signals from the GFP and 
RFP vectors respectively. Cells were also counterstained with 4’,6-diamidino-2-phenylindole 
(DAPI, Sigma-Aldrich®) to locate and identify cells. Cells were placed on microscopic slides and 
mounted with VECTASHIELD® Hard-Set™ Mounting Medium as per manufacturer’s specifications. 
Visualisation was performed on a Zeiss fluorescent microscope.  
2.2.1.6 Total RNA extraction 
The TRIzol® LS protocol was followed for total RNA extraction. An amount of 0.3-0.4 ml TRIzol® LS 
reagent per 10 cm3 culture flask was added to homogenised monolayer-grown cells. Upon transfer 
to a 15 ml conical tube, 0.2 ml chloroform per 0.75 ml TRIzol® LS reagent was added to the 
homogenate where after the solution was shaken vigorously for 15 sec. The solution was 
incubated at room temperature for 10 min and centrifuged for 30 min at 3000 rpm at 4°C in order to 
complete the phase separation step. In a clean conical tube, 0.5 ml isopropyl alcohol per 0.75 ml 
TRIzol® LS reagent was mixed with the top aqueous phase obtained after centrifugation. Adequate 
RNA precipitation was achieved by allowing the mixture to incubate at room temperature for 15 min 
followed by centrifugation of the mixture for 30 min at 3000 rpm at 4°C. An amount of 1 ml 70% 
ethanol per 0.75 ml TRIzol® LS reagent was used to wash the RNA pellet where after it was dried 
at room temperature and subsequently resuspended in 100 µl diethylpyrocarbonate-treated water. 
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The Agilent 2100 Bioanalyzer (Agilent Technologies) was used to determine the concentration of 
the RNA (measured at 260 nm) as well as to analyse the integrity of the RNA. Isolated RNA was 
described as pure if the 260/280 nm ratio lied between 1.8 and 2.1. Gel electrophoresis (2% (w/v) 
denaturing agarose gel containing formaldehyde) was also performed. Total RNA was stored at -
80°C as 20 µl aliquots.  
2.2.1.7 First-strand cDNA synthesis 
The Transcriptor First Strand cDNA Synthesis kit from Roche Applied Sciences was used to 
reverse transcribe the extracted total RNA into single strand cDNA. In a total volume of 20 µl, 1 µg 
total RNA was mixed with 2.5 µM Anchored-oligo(dT)18 Primer, 1 x Transcriptor Reverse 
Transcriptase Reaction Buffer (containing 8 mM MgCl2), 20 U Protector RNase Inhibitor, 4 mM 
Deoxynucleotide Mix and 10 U Transcriptor Reverse Transcriptase. The reaction was incubated at 
55°C for 30 min followed by a final inactivation step of 5 min incubated at 85°C. The concentration 
of the synthesised cDNA was determined with a NanoDrop Spectrophotometer.  
2.2.1.8 Validation of gene expression knockdown by means of quantitative PCR  
Quantitative PCR (qPCR) was performed to verify the levels of gene expression for the candidate 
genes in the respective knockdown cell lines. Gene-specific primers were designed with the 
Primer3 (Rozen and Skaletsky, 2000) software using the default parameters. A blast search 
confirmed the specificity of the primers, which were also optimised beforehand with traditional end-
point PCR. A TA of 60°C was used for all primers; additional details for the primers are available in 
table 2.3. In all qPCR reactions, a standard reaction mix was prepared containing LightCycler® 
FastStart DNA MasterPLUS SYBR Green Reaction Mix (Roche Applied Science), 0.5 µM of each 
primer and 200 ng cDNA in a final volume of 20 µl which, following gentle mixing, was transferred 
to capillary tubes. Tubes were centrifuged for 5 sec at 700 g to eliminate any possible air bubbles. 
Non-template controls were included in all experiments. The qPCR were performed on the 
LightCycler® 1.5 instrument and the following cycling parameters were used in all runs: a pre-
incubation step of 10 min at 95°C followed by 40 cycles of a three part amplification step consisting 
of denaturation for 15 sec at 95°C, annealing for 15 sec at a TA dependent on the primer set and 
extension for 20 sec at 72°C. A melt curve, ranging from 60°C-95°C was also performed on 
completion of the amplification step.  
The relative standard curve quantification method was followed to quantify the level of gene 
expression of the candidate genes. This method requires that the expression levels of the target 
and reference gene(s) be measured in a serial dilution format in order to construct a standard 
curve. Based on an analysis previously performed with the Microsoft® Excel®-based software 
BestKeeper (Pfaffl et al., 2004), two reference genes, namely glyceraldehyde-3-phosphate 
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Table 2.3: Details of primers used for qPCR performed for the validation of candidate gene 
expression knockdown 
Gene Primer 
orientation 
Sequence (5’-3’) Length 
(bp) 
Product length 
(bp) 
LIAS F TTAAGACCGCAAGAAATCCC 20 102 
R ACCGACGTCAGGACAACATA 20 
CYPA F CAGACGCCACTGTCGCTTT 19 132 
R TGTCTTTGGAACTTTGTCTGCAA 23 
RPL9 F CGGTCTGTGTACGCTCACTT 20 152 
R ATCCTTCTGGGCTTGAGAGA 20 
GAPDH F GGTGGCAGAGGCCTTTG 17 215 
R TGCCGATTTAGCATCTCCTT 20 
HPRT1 F GACTGTAGATTTTATCAGACTG 22 89 
R GTCTGGCCTGTATCCAACACTTC 23 
F – forward; R – reverse; bp – base pair. 
dehydrogenase (GAPDH) and hypoxanthine phosphoribosyltransferase 1 (HPRT1) were selected. 
Standard curves were constructed by generating a dilution series consisting of four points ranging 
from a 10 x dilution to a 10 000 x dilution of the synthesised cDNA. Primer sequences for the 
reference genes were sourced from validated primer database RTPrimerDB (Pattyn et al., 2003) 
(table 2.3). All primers were synthesised by Inqaba Biotech™. The freely-available Microsoft® 
Excel®-based software REST© (Pfaffl et al., 2002) was used to perform the analysis of the qPCR 
results. 
2.2.2 Apoptosis Assays 
Cells from each of the stable knockdown cell lines were cultured and maintained as described in 
section 2.3.1.1. For the apoptosis assays, approximately 2.5 x 104 cells were seeded into six well 
tissue culture plates. Both assays were performed in triplicate, at multiple concentration points for 
both C2-ceramide (Sigma-Aldrich
®) and camptothecin (Sigma-Aldrich®) and for each of the 
knockdown cell lines. 
2.2.2.1 APOPercentage™ Assay 
Cells from each of the knockdown cell lines were subjected to apoptosis induction by both inducers 
and subsequent analysis with the APOPercentage™ assay (Biocolor LTD, UK). Spent medium 
were removed from tissue culture plates containing cultured confluent cells and replaced with 2 ml 
fresh DMEM medium containing the apoptotic inducer. Concentrations ranged between 0 and 100 
µM in intervals of 20 µM for C2-ceramide and between 0 and 10 µg/ml in intervals of 2 µg/ml for 
camptothecin; zero concentration points served as negative controls. The medium was removed 
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after 24 hrs, where after the cells were washed with 1 ml PBS. Since one of the morphological 
characteristics in apoptosis is the “rounding up” of cells, it could result in some of the cells loosing 
adherence; hence, the collected medium was spun down to retrieve any cells that might have been 
removed along with the medium. The spent medium was removed from this collection and the cells 
were washed with PBS. Cells in the tissue culture plates, as well as the collected cells, were 
incubated in 1 ml APOPercentage™ dye for one hour at 37°C. Following removal of the dye, cells 
were washed with 1 ml PBS in order to remove any remaining dye. Cells in the tissue culture 
plates were harvested by means of trypsinisation (incubated with 1 ml 0.125% trypsin solution until 
cells became partially detached), resuspended in 1 ml ice-cold fluorescence-activated cell sorting 
(FACS) buffer and transferred to a FACS calibrated tube. Cells retrieved from the collected 
medium were also resuspended and added to the same tube. The cellular fluorescence of 10 000 
cells per sample were  measured by means of flow cytometry using the FL3 (red) channel on a 
FACScan™ (Becton Dickinson, BD) instrument, which, in conjunction with the CellQuest™ Pro (BD) 
software, allowed for the quantification of the amount of viable cells.  
2.2.2.2 Caspase-3/CPP32 Colourimetric Assay Kit 
As with the APOPercentage™ assay, cells from each of the knockdown cell lines were subjected to 
apoptosis induction, followed by analysis with the Caspase-3/CPP32 Assay Kit (BioVision Inc.). 
Spent medium were removed from tissue culture plates containing cultured confluent cells. 1 ml of 
a 0.125% trypsin solution was added to loosen the cells in the wells, where after the cells were 
resuspended in 2 ml fresh DMEM medium and recovered by centrifugation. A volume of 500 µl 
Cytofix/Cytoperm™ (BD) was added to the cells followed by incubation on ice for 20 min. Cells 
were recovered by centrifugation and washed twice with 100 µl Perm/Wash buffer™ (BD). Upon the 
second resuspension step in Perm/Wash™, 20 µl of the fluorescein isothiocyanate-conjugated 
polyclonal active caspase 3 antibody, provided in the kit, were added and the solution incubated in 
the dark at room temperature for 30 min. The solution was spun down and resuspended in 1 ml 
Perm/Wash™, followed by another centrifugation and resuspension in 500 µl Perm/Wash™. Finally, 
the solution was transferred to a FACS calibrated tube and a total of 10 000 cells per sample were 
analysed with the FACScan™ instrument using the FL1 (green) channel. As with the 
APOPercentage™ assay, the amount of viable cells was quantified with the CellQuest™ Pro 
software.  
2.2.2.3 Analysis of results 
Output from the CellQuest™ Pro software provides counts of the amount of cells displaying a 
fluorescent signal in a sample; from the counts, the percentage of live cells in each sample were 
then calculated by taking 10 000 cells as the total amount. Results were then subjected to basic 
statistical analysis in Microsoft Excel, which included the calculation of a sample-based estimate of 
standard deviation, standard error of the mean, two sample F-test for variances and two sample T-
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tests. A p-value of less than 0.05 was seen as significant for the T-tests. Only data obtained from 
the knockdown cell lines transfected with the GFP vectors carrying shRNA constructs for each of 
the candidate genes were used for this analysis.  
 
2.3 Results and discussions 
2.3.1 Generation of stable knockdown cell lines for LIAS, RPL9 and CYPA 
2.3.1.1 Construction of shRNA-expressing vectors 
The construction of the shRNA-expressing vectors involved various steps; firstly, the MCS regions 
in the GFP and RFP vectors had to be removed. Since the expression of the shRNA constructs 
were to be driven by a U6 promoter and not by the native cytomegalovirus (CMV) early promoter, a 
U6 promoter fragment cloned into both of the vectors upstream of the native promoters contained 
recognition sites for Bgl II and Hind III in order to allow for the cloning of the shRNA constructs 
downstream of the new promoter. However, the MCS region downstream of the CMV promoter 
also contained recognition sites for these enzymes; thus these sites had to be removed in order to 
prevent multiple digestions taking place during cloning of the shRNA construct into the vectors. 
This was accomplished by means of vector digestions with the restriction enzymes Bgl II and 
BamH I. The deletion of the MCS regions in both of the vectors were successful as verified with 
agarose gel electrophoresis following a colony PCR (Fig. 2.6). A PCR product confirming the 
deletion of the MCS had a size of 170 bp, while the control vector delivered a PCR product of 210 
bp. Next, the U6 promoter fragment was cloned into both of the vectors, upstream of the CMV 
promoter. This RNA Polymerase III promoter have been shown to efficiently induce target-specific 
mRNA cleavage in eukaryotic cells without the need for downstream transcriptional elements while 
allowing transcription to be terminated by stretch of four or more tyrosine residues (Dykxhoorn et 
al., 2003; Yu et al., 2002). The presence of this fragment was successfully verified by means 
colony PCR and subsequent agarose gel electrophoresis, since it produced the appropriate band 
of 800 bp (Fig. 2.7). Lastly, the KD1 and KD2 shRNA constructs for each of the candidate genes 
were cloned into both of the vectors between the Bgl II and Hind III recognition sites downstream of 
the U6 promoter. Again, following the colony PCR, the agarose gel electrophoresis showed the 
successful uptake of these constructs into the vectors; producing PCR products of 530 bp 
compared to the 469 bp products of the control vector (Fig. 2.8). An example of the final vector 
product can be seen in figure 2.9.  
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Figure 2.6: Representative example of the successful deletion of the MCS region between the Bgl II and 
Hind III cut sites in the expression vectors as confirmed by colony PCR and agarose gel electrophoresis. 
Lane 1 – pTZ molecular marker; Lane 2-8 - colonies showing successful deletion of the MCS region from the 
GFP vector; Lane 9 – control GFP vector. 
 
 
 
Figure 2.7: Representative example of the successful cloning of the U6 promoter fragment into the 
expression vectors as confirmed by colony PCR and agarose gel electrophoresis. Lane 1 – pTZ molecular 
marker; Lane 2-5 – colonies showing the U6 promoter fragment cloned into the GFP vector; Lane 6 – 
negative control; Lane 7-10 – colonies showing the U6 promoter fragment cloned into the RFP vector. 
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Figure 2.8: Representative example of the successful cloning of shRNA constructs into the expression 
vectors as confirmed by colony PCR and agarose gel electrophoresis. Lane 1 – pTZ molecular marker; Lane 
2 – control GFP vector; Lanes 3-7 – colonies showing successful cloning of LIAS shRNA constructs into the 
GFP vector; Lanes 8-10 – colonies showing successful cloning of CYPA shRNA constructs into the GFP 
vector.  
 
 
 
Figure 2.9: Representative example of the final product following vector construction. Illustrated in the figure 
is a GFP vector containing a shRNA construct for LIAS driven by the U6 promoter. 
2.3.1.2 Transfection of NIH-3T3 cells with shRNA-expressing vectors 
NIH-3T3 cells were transfected with the various shRNA-containing vectors using the 
METAFECTENE® Lipid Reagent. Transient and stable transfection experiments were performed 
concurrently and both were deemed successful by means of fluorescent microscopy (Fig. 2.10) 
and gene expression analysis (see section 2.3.1.3). Transfection efficiencies, as calculated with 
the Zeiss microscope, averaged above 70% for both the GFP and RFP vectors, although the 
former showed higher and more consistent transfection efficiencies. Selection for the stable 
transfections produced multiple colonies resistant to G418 when cultured in DMEM medium 
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Figure 2.10: Representative photographs, taken with a Zeiss fluorescent microscope, of NIH-3T3 cells 
transfected with the shRNA-containing vectors. A – NIH-3T3 transfected cells counterstained with DAPI; B – 
NIH-3T3 cells transfected with RFP vector containing a shRNA for LIAS; C – NIH-3T3 transfected cells 
counterstained with DAPI; D – NIH-3T3 cells transfected with GFP vector containing a shRNA for RPL9. 
supplemented with the antibiotic; thus also indicating the successful uptake of the vectors into the 
cells.  
2.3.1.3 Validation of gene expression knockdown 
Following successful transfection of the various vectors into NIH-3T3 cells, total RNA was 
extracted and cDNA was synthesised. The total RNA extraction generated pure, non-degraded 
RNA as revealed by the analysis with the Agilent 2100 Bioanalyzer (Fig. 2.11) and agarose gel 
electrophoresis. The cDNA synthesis reactions produced pure cDNA with high concentrations as 
determined by NanoDrop analysis. 
In order to verify the successful gene expression knockdown of the candidate genes by the 
shRNA’s, qPCR was performed to determine the relative expression levels of LIAS, RPL9 and 
CYPA in the knockdown cell lines expressing the shRNA constructs for the respective genes. This 
technique is a modification of the traditional end-point PCR technique which allows for the 
concurrent detection and quantification of a DNA template in real time by means of fluorescent 
chemistries, such as SYBR® Green I (Pfaffl, 2001). More information regarding qPCR is available 
in chapter 4. The cDNA synthesised from the extracted total RNA was used as the template for the 
qPCR experiment and the results obtained were interpreted by the relative standard curve method. 
As required by this method, standard curves were constructed for both the reference genes as well 
as the target genes. These standard curves revealed reaction efficiencies ranging between 1.93-
1.98 indicating near-optimal doubling of the template in each cycle. 
The analysis revealed significant reductions in the expression levels for all three candidate genes 
in the knockdown cell lines, indicating a successful gene expression knockdown effect brought 
about by the shRNA constructs (Fig. 2.12). Cell lines transfected with the GFP vectors showed a
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Figure 2.11: Representative example for determining the integrity of extracted total RNA as confirmed with 
the Agilent 2100 Bioanalyzer. The image shows the 18S and 28S peaks of RNA extracted from a LIAS 
knockdown cell line transfected with a GFP vector.  
 
 
 
Figure 2.12: Relative expression ratio plot produced by the REST
©
 software used for the analysis of the 
qPCR results for the validation of candidate gene expression knockdown. Bars indicate the ratios of the 
collective KD1 and KD2 expression levels, as measured in a log2 scale, for each candidate gene in the 
knockdown cell lines as compared to the normal expression levels of each gene in the wild type NIH-3T3 
cells. Values are the averages ± standard error from duplicate experiments.  
larger decrease in expression levels in comparison to the cell lines transfected with the RFP 
vectors; suggesting that even though the two expression vectors shared a promoter, the GFP 
vector facilitated higher expression of the shRNA constructs. Comparable results were obtained for 
both the KD1 and KD2 cell lines for each of the candidate genes, indicating that in each case both 
constructs successfully targeted the specific candidate gene.  
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2.3.2 Apoptosis assays 
2.3.2.1 FACScan™ and CellQuest™ Pro analysis 
Two apoptosis assays, namely APOPercentage™ and Caspase-3/CPP32, were performed to 
determine the level of apoptosis present in the knockdown cell lines following apoptosis induction 
with both C2-ceramide and camptothecin. Cells were analysed with the automated flow cytometer 
FACScan™ system, which, in conjunction with the CellQuest™ Pro software allows for the 
quantification of live and dead cells. A number of 10 000 cells per sample (i.e. a collection of cells 
from a particular knockdown cell line treated with an apoptotic inducer and assayed by an 
apoptosis assay) were analysed for fluorescence by the FACScan™ system as they pass through a 
focussed laser beam in a moving fluid stream, one cell at a time. The CellQuest™ Pro software 
then uses the data generated by the FACScan™ system and produces single parameter 
histograms depicting two peaks representing the number of live (M1) and dead (M2) cells. Figure 
2.13 shows a representative example of the results produced by the software. All the histograms 
for the LIAS knockdown cell lines showed a high M1 peaks with both C2-ceramide and 
camptothecin apoptosis induction as assayed by both the APOPercentage™ and Caspase-
3/CPP32 assays. The height of the peaks slightly declined with a corresponding increase in 
concentration of the apoptotic inducers; however it still remained higher than the M2 peak 
Histograms for the CYPA knockdown cell lines showed results similar to those of LIAS. High M1 
peaks were observed in knockdown cell lines where apoptosis were induced by both C2-ceramide 
and camptothecin and assayed by both APOPercentage™ and Caspase-3/CPP32 assays. These 
peaks also remained higher than the M2 peaks with increasing concentrations of the apoptotic 
inducer. These results are indicative of possible resistance to apoptosis based on the high amount 
of live cells present when compared to the results from the wild type NIH-3T3 cells, which showed 
increasingly higher M2 peaks upon apoptosis induction. In contrast to LIAS and CYPA, the 
histograms for the RPL9 knockdown cell lines tended to resemble those of the wild type cells. M1 
peaks decreased in height with increasing concentrations for both C2-ceramide and camptothecin 
as assayed by both the APOPercentage™ and Caspase-3/CPP32 assay. These results thus 
suggest that RPL9 knockdown cell lines are susceptible to apoptosis induction.  
2.3.2.2 Analysis of results 
Basic statistical analysis was performed in Microsoft® Excel® with the results obtained from the 
CellQuest™ Pro software in order to test for significant data. For this analysis, only results obtained 
from knockdown cell lines transfected with the GFP vectors carrying shRNA constructs for the 
respective candidate genes were used; these results were selected since these cell lines displayed 
a higher degree of gene expression knockdown as facilitated by the RNAi technique and also due 
to a higher level of overall consistency among the results obtained from these cell lines.The 
experiments were performed in triplicate and from these values the sample-based standard 
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Figure 2.13: Representative example of results obtained from the CellQuest
™
 Pro software following flow 
cytometry. Figures illustrate the cell plots of wild type NIH-3T3 cells and cells transfected with GFP vector 
containing a LIAS shRNA construct, both assayed with the APOPercentage
™ 
assay. A – untreated LIAS 
knockdown NIH-3T3 cells; B – LIAS knockdown NIH-3T3 cell treated with 60 µM C2-ceramide; C – untreated 
wild type NIH-3T3 cells; D – Wild type NIH-3T3 cells treated with 60 µM C2-ceramide. M1 – region showing 
live cells; M2 – region showing dead cells. 
deviation and standard error of mean were calculated. Apart from a few exceptions, relatively small 
values were obtained with most ranging between zero and three. The two-sample F-test revealed 
that samples of both equal and unequal variances were present and based on these results the 
appropriate t-test was performed. The t-tests revealed significant values for both LIAS and CYPA 
knockdown cell lines when compared to the wild type NIH-3T3 cell line, however the RPL9 
knockdown cell lines had less significant values which decreased even more if a p-value of 0.001 
were to be used. Table A1 and A2 in addendum A provides a summary of the descriptive statistic 
obtained in this analysis.  
As with many molecular techniques, absolute specificity is fundamental to a successful RNAi 
experiment and the possibility that the experiment outcomes are a result of or influenced by some 
other off-target cross-reaction should always be considered. In this study, two separate knockdown 
cell lines for each candidate gene were created by designing two different siRNAs targeting the 
same gene. This methodology served to verify the specificity of the experiment; a validation 
method also suggested by Fraser (Fraser, 2004). Since both knockdown cell lines for each 
candidate gene behaved similarly when treated with the apoptotic inducers, it can be concluded 
that the effect seen after knockdown was not due to a cross reaction but that the knockdown of 
these genes were responsible to the changes in sensitivity to apoptosis induction.  
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APOPercentage™ assay 
APOPercentage™ assays revealed significant resistance to apoptosis in LIAS and CYPA 
knockdown cell lines (Fig. 2.14-2.17). This can be seen in the remarkably slower decrease in live 
cells upon increasing concentrations of apoptotic inducers compared to that of the NIH-3T3 wild 
type cell line. In both LIAS and CYPA knockdown lines, the resistance effect was evident even at 
high concentrations of the inducers. While the percentage of live wild type cells dropped to 
between 7% and 21% at the highest concentration of the apoptotic inducers, the percentage of live 
cells in both LIAS and CYPA knockdown cell lines remained high, averaging at about 70%. On the 
other hand, RPL9 knockdown cell lines displayed sensitivity to apoptosis by showing approximately 
the same trend as the wild type cell line (Fig. 2.18 and 2.19). The knockdown cell lines showed 
only a slightly higher percentage of live cells compared to that of the wild type at most of the 
concentration points, with the exception of the 80 µM C2-ceramide concentration point where the 
amount of live knockdown cells were 17.65% higher. However, this effect was not seen in any of 
the camptothecin concentration points. With the exception of the above mentioned difference, both 
apoptotic inducers showed comparable results in terms of inducing apoptosis in the wild type cells 
and failing to induce apoptosis in the knockdown cell lines. In addition, KD1 and KD2 cell lines for 
each candidate gene also showed similar results; the highest differences in percentage of live cells 
between these two lines, across all genes, were 4.7% and 4.3% (Fig. 2.14 and 2.16, respectively). 
These were also the only two instances where the differences in percentages were higher than 
3%.  
Caspase-3/CPP32 Colourimetric Assay Kit 
Results from the Caspase-3/CPP32 assay were comparable to that of the APOPercentage™ 
assay. LIAS and CYPA knockdown cells showed a substantially smaller and less rapid decline in 
the percentage of live cells over the range of increasing apoptotic inducer concentrations 
compared to the NIH-3T3 wild type cell lines (Fig. 2.20-2.23). The percentage of knockdown cells 
resisting apoptosis remained above 70% compared to the percentage of wild type cells which 
ranged between 9.6% and 14.6%; a smaller margin than observed in the APOPercentage™ assay 
results. The sensitivity of RPL9 knockdown cell lines to apoptosis was also seen in the Caspase-
3/CPP32 assay (Fig. 2.24 and 2.25). The knockdown cells followed the same declining trend as 
the wild type cells with only small differences in the percentage of live cells between the 
knockdown and wild type cell lines. A similar effect as seen in the APOPercentage™ assay at 80 
µM C2-ceramide was observed in the Caspase-3/CPP32 assay; although in this assay it occurred 
earlier, at 60 µM C2-ceramide, and the difference between the knockdown and wild type cells 
averaged at 29.05%. Again, this was not seen at any camptothecin concentration points. Overall, 
both apoptotic inducers were effective in inducing apoptosis in wild type cells, while knockdown cell 
lines displayed comparable resistance to apoptosis upon induction of both chemicals. As in the  
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Figure 2.14: Results of testing for resistance to apoptosis in LIAS knockdown cell lines, as compared to wild 
type NIH-3T3 cells, by means of the APOPercentage
™
 assay following treatment of camptothecin for 24 hrs. 
Values are the averages ± standard deviation from triplicate experiments. * Indicates significantly different 
from wild type for p < 0.05. KD – knock down. 
 
 
Figure 2.15: Results of testing for resistance to apoptosis in LIAS knockdown cell lines, as compared to wild 
type NIH-3T3 cells, by means of the APOPercentage
™
 assay following treatment of C2-ceramide for 24 hrs. 
Values are the averages ± standard deviation from triplicate experiments. * Indicates significantly different 
from wild type for p < 0.05. KD – knock down. 
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Figure 2.16: Results of testing for resistance to apoptosis in CYPA knockdown cell lines, as compared to wild 
type NIH-3T3 cells, by means of the APOPercentage
™
 assay following treatment of camptothecin for 24 hrs. 
Values are the averages ± standard deviation from triplicate experiments. * Indicates significantly different 
from wild type for p < 0.05. KD – knock down.  
 
 
Figure 2.17: Results of testing for resistance to apoptosis in CYPA knockdown cell lines, as compared to wild 
type NIH-3T3 cells, by means of the APOPercentage
™
 assay following treatment of C2-ceramide for 24 hrs. 
Values are the averages ± standard deviation from triplicate experiments. * Indicates significantly different 
from wild type for p < 0.05. KD – knock down. 
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Figure 2.18: Results of testing for resistance to apoptosis in RPL9 knockdown cell lines, as compared to wild 
type NIH-3T3 cells, by means of the APOPercentage
™
 assay following treatment of camptothecin for 24 hrs. 
Values are the averages ± standard deviation from triplicate experiments. * Indicates significantly different 
from wild type for p < 0.05. KD – knock down.  
 
 
Figure 2.19: Results of testing for resistance to apoptosis in RPL9 knockdown cell lines, as compared to wild 
type NIH-3T3 cells, by means of the APOPercentage
™
 assay following treatment of C2-ceramide for 24 hrs. 
Values are the averages ± standard deviation from triplicate experiments. * Indicates significantly different 
from wild type for p < 0.05. KD – knock down.  
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Figure 2.20: Results of testing for resistance to apoptosis in LIAS knockdown cell lines, as compared to wild 
type NIH-3T3 cells, by means of the Caspase-3/CPP32 assay following treatment of Camptothecin for 24 
hrs. Values are the averages ± standard deviation from triplicate experiments. * Indicates significantly 
different from wild type for p < 0.05. KD – knock down.  
 
 
Figure 2.21: Results of testing for resistance to apoptosis in LIAS knockdown cell lines, as compared to wild 
type NIH-3T3 cells, by means of the Caspase-3/CPP32 assay following treatment of C2-ceramide for 24 hrs. 
Values are the averages ± standard deviation from triplicate experiments. * Indicates significantly different 
from wild type for p < 0.05. KD – knock down. 
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Figure 2.22: Results of testing for resistance to apoptosis in CYPA knockdown cell lines, as compared to wild 
type NIH-3T3 cells, by means of the Caspase-3/CPP32 assay following treatment of Camptothecin for 24 
hrs. Values are the averages ± standard deviation from triplicate experiments. * Indicates significantly 
different from wild type for p < 0.05. KD – knock down.  
 
 
Figure 2.23: Results of testing for resistance to apoptosis in CYPA knockdown cell lines, as compared to wild 
type NIH-3T3 cells, by means of the Caspase-3/CPP32 assay following treatment of C2-ceramide for 24 hrs. 
Values are the averages ± standard deviation from triplicate experiments. * Indicates significantly different 
from wild type for p < 0.05. KD – knock down.  
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Figure 2.24: Results of testing for resistance to apoptosis in RPL9 knockdown cell lines, as compared to wild 
type NIH-3T3 cells, by means of the Caspase-3/CPP32 assay following treatment of Camptothecin for 24 
hrs. Values are the averages ± standard deviation from triplicate experiments. * Indicates significantly 
different from wild type for p < 0.05. KD – knock down.  
 
 
Figure 2.25: Results of testing for resistance to apoptosis in RPL9 knockdown cell lines, as compared to wild 
type NIH-3T3 cells, by means of the Caspase-3/CPP32 assay following treatment of C2-ceramide for 24 hrs. 
Values are the averages ± standard deviation from triplicate experiments. * Indicates significantly different 
from wild type for p < 0.05. KD – knock down. 
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APOPercentage™ assays, cells transfected with knockdown constructs one and two showed 
similar results, with only slight differences in the percentage of live cells and the two largest 
differences, 4.3% and 3.3%, also being the only two instances above 3% (Fig. 2.20 and 2.24 
respectively).  
 
2.4 Conclusions 
Both LIAS and CYPA are relatively novel to apoptosis and specific roles for these genes in the 
apoptotic process are yet to be elucidated. This section aims to explore the possibility of a 
functional role for LIAS and CYPA in apoptosis and to possibly ascertain reasons why resistance to 
apoptosis would be associated with knockdown of these genes.  
 
2.4.1 Potential roles for LIAS in apoptosis 
The LIAS gene encodes for an enzyme known as lipoic acid synthetase (LIAS). This enzyme is 
located in the mitochondria where it fulfils a crucial role in the biosynthesis of α-lipoic acid (LA), 
which in turn is an essential co-factor for four multi-enzyme complexes, namely pyruvate 
dehydrogenase (PDH), α-ketoglutarate dehydrogenase (KGDH), the branched-chain α-keto acid 
dehydrogenase (BCKDH) complex and the glycine cleavage system (GCS)  (Booker, 2004; 
Morikawa et al., 2001). Even though the exact biosynthetic pathway of LA remains unclear in 
mammalian cells, the pathway is well characterised in E. coli and thus served as a model for 
identifying homologs of the particular enzymes in various other species (see figure 2.26 and table 
2.4) (Schonauer et al., 2009). Indeed, a yeast (LIP5) and mouse (Lias) homolog for LIAS have 
been identified (Morikawa et al., 2001; Sulo and Martin, 1993). In E. coli, the de novo synthesis of 
LA utilises octanoyl-acyl carrier protein (octanoyl-ACP) as a substrate (Cronan et al., 2005; Jordan 
and Cronan, 2003; Schonauer et al., 2009). To produce LA, LipA (the homolog for LIAS) catalyses 
the insertion of two sulphur atoms at positions C-6 and C-8 of octanoyl-ACP. This reaction can 
either precede or follow the transfer of octanoyl-ACP to a target protein, which is facilitated by the 
enzyme LipB. Target proteins are the E2 subunits and H-protein of the PDH, KGDH and BCKDH 
and GCS, respectively. An additional salvage pathway has also been described in E. coli that is 
associated with LA taken up exogenously by the cell. This pathway requires the action of the LplA 
enzyme and corresponding homologs has also been identified in mouse and human (Cronan et al., 
2005; Jordan and Cronan, 2003; Schonauer et al., 2009).  
The function of LIAS is clear enough, biosynthesis of LA, and the enzyme itself seems to have no 
other potential function or link to the apoptotic pathway. A more likely candidate though, is the 
product of LIAS’s enzymatic function. De novo synthesis of LA takes place at the site where it is
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Figure 2.26: Pathway for LA metabolism according to the KEGG Pathway Database (hsa00785, accessed 
25/07/2012) 
Table 2.4: Homologs of enzymes involved in LA metabolism across various speciesa  
a
According to GeneCards
®
 Database (accessed 25/07/2012) 
needed as an essential co-factor (Cronan et al., 2005). PDH and KGDH are mitochondrial enzyme 
complexes that take part in the tricarboxylic acid cycle (TCA), while BCKDH and GCS is involved in 
the metabolism of branched-chain amino acids (leucine, isoleucine and valine) and the 
decarboxylation of glycine, respectively, in the same cellular compartment (Cronan et al., 2005; 
Perham, 2000). All four enzyme complexes are described as lipoyl dependent (Cronan et al., 
2005).  
PDH and KGDH represent key enzymes in the TCA cycle and both contribute to the production of 
NADH. In addition, PDH also serves as the link between glycolysis and the TCA cycle (Cronan et 
Pathway Homo sapiens Mus musculus Saccharomyces cerevisiae Escherichia coli 
De novo LIAS Lias LIP5 LipA 
De novo LIPT2 Lipt2 LIP2 LipB 
Salvage LIPT1 Lipt1 AIM22 (putative) LplA 
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al., 2005). Since PDH and KGDH can not function without LA as a co-factor, one can assume that 
a decrease in LA would significantly impair the activities of these enzyme complexes. In this case, 
decreased PDH and KGDH activity could result in decreased NADH levels and several studies has 
shown that this can lead to decreased NADH-linked (also referred to as state 3) respiration 
(Humphries et al., 1998; Lucas and Szweda, 1999; Nulton-Persson et al., 2003; Nulton-Persson 
and Szweda, 2001). Moreover, these groups also showed that inactivation of LA directly resulted in 
decreased NADH-linked respiration through inhibition of PDH and KGDH (Applegate et al., 2008; 
Humphries and Szweda, 1998). In addition, another group reported that silencing of LIAS by 
means of siRNA constructs resulted in decreased mitochondrial LA levels, including LA bound to 
the E2 subunits of PDH and KGDH (Padmalayam et al., 2009). Compromised NADH-linked 
respiration has the potential to negatively affect ATP synthesis; another consequence reported by 
one of the above mentioned groups (Nulton-Persson and Szweda, 2001). This in turn could result 
in the up-regulation of glycolysis in order to meet the energy demand of the cell. High glycolytic 
rates have been shown to successfully compensate for defective mitochondrial respiration in cells 
harbouring different mitochondrial backgrounds (von Kleist-Retzow et al., 2007). Even though the 
glycolytic pathway seems inadequate in meeting the energy demand of a cell since it only 
produces 2 moles ATP per mole glucose compared to the 36 moles ATP produced from 
respiration, the pathway can occur at a much faster rate the respiration, lending it the ability to 
sustain growth of even highly proliferating cells like lymphocytes and those of unicellular organisms 
like S. cerevisiae (Feron, 2009; Gatenby and Gillies, 2004; Ristow, 2006; Vander Heiden et al., 
2009; Warburg, 1956).  
The above mentioned cascade of events illustrates a phenotype similar to that seen in many 
tumours; a phenotype referred to as a Warburg effect. In 1956, Otto Warburg hypothesised that all 
cancers resulted from strikingly high rates of glycolysis in conjunction with attenuated mitochondrial 
respiration (Warburg, 1956). The latter part of his hypothesis was suggested to be the result of a 
“damaged respiration”; subsequently forcing the cell to compensate with increased glycolysis 
(DeBerardinis et al., 2008; Warburg, 1956). This unique phenotype results in the conversion of 
glucose to lactate, which is an expected outcome under hypoxic conditions; however, the 
phenotype is also present under normal oxygen tension and is thus described as anaerobic 
glycolysis (Tennant et al., 2009; Warburg, 1956; Wu et al., 2007). Two distinct characteristics of 
the Warburg effect represent potential mechanisms for resistance to apoptosis, especially with 
regards to the malignant transformation of cells. Firstly, high glycolytic rates result in the 
accumulation of lactic acid and subsequent acidification of the immediate extracellular environment 
(Gatenby and Gillies, 2004; Grinstein et al., 1989). This is facilitated by the activity of H+ 
transporters, such as the Na+/H+ antiport, which functions to maintain normal intracellular pH by 
pumping H+ ions out of the cell (Grinstein et al., 1989). Intracellular acidosis typically results in 
apoptosis, and up-regulation of H+ transporters has been observed in tumour cells (Gatenby and 
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Gillies, 2004). In addition, the vacuolar H+-ATPase transporter has been shown to provide 
resistance to apoptosis in neutrophils (Gatenby and Gillies, 2004; Gottlieb et al., 1995). Moreover, 
the activity of H+ transporters has been suggested to play a vital role in cellular proliferative 
responses and is activated by various mitogens (Grinstein et al., 1989). An acidic extracellular 
environment has also been suggested to contribute to tumour invasion and metastasis (Gatenby 
and Gillies, 2004; Raghunand et al., 2003). Evidence supporting this statement includes increased 
activity of the vascular endothelial growth factor (VEGF), which plays a key role in angiogenesis, 
upon acidosis in human cancer cells and acid-mediated degradation of the extracellular matrix by 
cathepsins, as well as various other studies reporting increased invasion and metastatic abilities of 
cells cultured in acidic environments (Martínez-Zaguilán et al., 1996; Rozhin et al., 1994; 
Schlappack et al., 1991; Shi et al., 2001).  In addition, acidosis can be mutagenic and potentially 
clastogenic (Gatenby and Gillies, 2004). The process of carcinogenesis is often described as 
somatic evolution; cells acquiring unique and beneficial mutations are selected for in a manner 
analogous to Darwinian evolution. Tumour cells are thus able to proliferate in an acidic 
microenvironment to which they are adapted, either through mutations or epigenetic changes, 
while normal cell populations are destroyed (Gatenby and Gillies, 2004).  
A second characteristic present during a lack of LA, and also of the Warburg effect, that can 
potentially result in resistance to apoptosis is decreased NADH levels. During mitochondrial 
respiration, NADH is produced in the TCA cycle and is subsequently used to drive the flow of 
electrons through the electron transport chain (ETC) to produce ATP (Fernie et al., 2004). 
Complexes of the ETC are known sites of ROS production and constitute the primary intracellular 
source of oxygen radicals; thus, it would seem logical to expect reduced production of ROS under 
conditions of decreased NADH levels such as with a lack of LA availability (Cadenas and Davies, 
2000; Turrens, 2003). Likewise, Nulton-Persson and colleague Sweda suggested that the 
inactivation of TCA enzymes generating reducing equivalents would limit the production of ROS, 
such as O2
- and H2O2 (Nulton-Persson and Szweda, 2001). Moreover, by measuring metabolic 
rates and ROS production in resting and proliferating cells, Brand and colleague Hermfisse 
suggested that proliferating cells rely on the glycolytic breakdown of glucose to lactate to limit the 
production of ROS during the critical phases of DNA replication and cell division (Brand and 
Hermfisse, 1997). A role for ROS in apoptosis, as well as in its activation, is widely known (Cai and 
Jones, 1998; Chandra et al., 2000; Hampton and Orrenius, 1998). Several different ROS are 
known to induce apoptosis, while the generation of ROS has been reported in apoptosis induced 
by a variety of agents. In addition, antioxidants have been shown to effectively block apoptosis, 
while the broad-spectrum Bcl-2 anti-apoptotic protein also holds antioxidant properties (Cai and 
Jones, 1998; Chandra et al., 2000; Hampton and Orrenius, 1998). Thus, it would seem that one 
can suggest that the potentially limited production of ROS under conditions of LA deficiency could 
provide cells with the ability to resist ROS-mediated apoptosis. In addition to possibly limiting ROS 
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production, an aerobic glycolytic phenotype can also assist in the removal of ROS (Brand and 
Hermfisse, 1997; Nath et al., 1995; Spitz et al., 2000). Antioxidant properties in the form of H2O2 
scavenging have previously been reported for the end product of glycolysis, namely pyruvate. 
Furthermore, glycolytic intermediates can also be redirected into the pentose phosphate pathway, 
producing nicotinamide adenine dinucleotide phosphate (reduced, NADPH), which by virtue of its 
redox status is able to provide reducing equivalents to other essential antioxidants, thus assisting 
the cells’ natural antioxidant defence network (Brand and Hermfisse, 1997; Nath et al., 1995; Spitz 
et al., 2000; Vander Heiden et al., 2009). In contrast, it has also been shown that ROS are 
important mediators of mitogenic signalling in tumour cells; functioning to promote malignant 
transformation and cellular proliferation and suppressing apoptosis (Fruehauf and Meyskens, 
2007). Various signalling pathways such as certain growth factor receptor pathways, cytokine and 
interleukin pathways engage ROS in some way or another (Finch et al., 2006; Fruehauf and 
Meyskens, 2007; Thannickal and Fanburg, 2000; Valko et al., 2006). In addition, ROS also 
promote tumorigenesis by damaging nucleic acids, proteins and lipids (Fruehauf and Meyskens, 
2007; Valko et al., 2006). Removal of ROS seems to negatively affect tumour growth and 
proliferation, as shown by the overexpression of important components of the antioxidant defence 
network such as manganese superoxide dismutase (MnSOD), glutathione peroxidase and catalase 
in in vitro and in vivo studies (Finch et al., 2006; Liu et al., 2006; Ough et al., 2004). Being a potent 
antioxidant itself and, along with its redox partner dihydrolipoic acid (DHLA), being capable of 
regenerating another important antioxidant namely glutathione (Moini et al., 2002; Navari-Izzo et 
al., 2002), one can suggest that a lack of LA in the above mentioned scenario can have a negative 
impact on the cell’s ability to remove ROS; thus resulting in a thriving ROS-mediated mitogenic 
signalling capacity able to withstand apoptosis. 
The two scenarios mentioned above seem to contradict each other; is ROS harmful or beneficial to 
tumour cells? And what about normal cells? The answer might be both, although certain terms and 
conditions might apply. The effect of ROS on a cell seems to depend on the status (i.e. normal or 
malignant) of the cell and the initial redox status of that cell (Dozio et al., 2010; Fruehauf and 
Meyskens, 2007). For normal cells, low levels of ROS seems to be beneficial as it promotes 
physiological cell growth (Fruehauf and Meyskens, 2007; Trachootham et al., 2009). However, with 
increasing levels of ROS, damage to DNA and other essential molecules can occur, potentially 
resulting in the malignant transformation of the cell (Dozio et al., 2010; Fruehauf and Meyskens, 
2007; Trachootham et al., 2009). Tumour cells display inherently higher levels of ROS which, in 
comparison with the low levels present in normal cells, enables mitogenic signalling and assists in 
cellular proliferation (Dozio et al., 2010; Fruehauf and Meyskens, 2007; Trachootham et al., 2009). 
Again, as with normal cells, too much ROS can also be harmful to tumour cells, and can potentially 
result in the induction of apoptosis (Fruehauf and Meyskens, 2007; Trachootham et al., 2009). 
These events have led to the proposal of two therapeutic strategies in terms of modulating ROS 
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levels for the treatment of cancer; to either remove ROS in order to dampen mitogenic signalling 
and inhibit proliferation or to increase ROS above the threshold in order to facilitate activation of 
apoptotic pathways (Dozio et al., 2010; Fruehauf and Meyskens, 2007; Shi et al., 2008).  
Both therapeutic strategies seem to be applicable to LA, as reported by studies investigating the 
effect of its exogenous application to tumour cells. LA was shown to be capable of inducing 
apoptosis, although the particular mechanism differed with regards to the change in ROS levels 
(Dozio et al., 2010; Shi et al., 2008; Simbula et al., 2007; Wenzel et al., 2005). Some researchers 
reported that LA was able to induce apoptosis in tumour cells by indirectly increasing the 
production of ROS through facilitating increased mitochondrial respiration and electron flow 
through the ETC, while others reported a decrease in ROS preceding apoptosis (Dozio et al., 
2010; Shi et al., 2008; Wenzel et al., 2005). Simbula and colleagues also reported an increase in 
ROS production upon LA treatment, but failed to speculate why (Simbula et al., 2007). In addition, 
LA failed to induce apoptosis in normal cells (Van de Mark et al., 2003; Wenzel et al., 2005). Most 
of these researchers made note of these contrasting effects and also attributed it to be subjective 
to the status of the cell, the inherent redox status as well as experimental conditions (Shi et al., 
2008; Wenzel et al., 2005).  
LA also functions as a co-factor for the H-protein in the GCS (Booker, 2004; Dinopoulos et al., 
2005). This enzyme complex represents the major catabolic pathway for the amino acid glycine 
(Dinopoulos et al., 2005; Kikuchi et al., 2008). The pathway catalyses the oxidative cleavage of 
glycine to produce carbon dioxide, tetrahydrofolate and ammonium in a reversible reaction (Kikuchi 
et al., 2008). LA is covalently attached to the H-protein, designated as the carrier-protein, where it 
shuttles the reaction intermediate between the active sites of the other proteins that make up the 
enzyme complex in a manner that is similar to that seen in the keto acid dehydrogenase 
complexes (Kikuchi et al., 2008). Alternative pathways for glycine degradation do exist; however, 
the pathways seem to be limited in their capacity to degrade glycine when compared to the GCS 
(Kikuchi et al., 2008). Thus, adequate degradation of the amino acids needs to take place via the 
GCS, for which LA is required. LA deficiency can dramatically reduce the activity of the GCS; as 
supported by a case study by Hiraga and colleagues (1981). The group reported that a mutant H-
protein devoid of LA exhibited only 4% specific activity when compared to that of a normal H-
protein (Hiraga et al., 1981). In this particular case study, a patient presenting with this mutant H-
protein suffered from non-ketotic hyperglycinemia (NKH), also known as glycine encephalopathy. 
Patients suffering from this autosomal recessive disease exhibit severe neurological symptoms 
including mental retardation, seizures, progressive lethargy and hypotonia and usually die while 
still in infancy (Dinopoulos et al., 2005; Kikuchi et al., 2008). The neurological symptoms are 
suggested to result from the interaction between the accumulated glycine and inhibitory neurons in 
the spinal cord and brain stem as well as interactions with N-methyl-D-aspartate (NMDA) receptors 
in the cerebral cortex (Applegarth and Toone, 2006; Dinopoulos et al., 2005; Kikuchi et al., 2008). 
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It would seem reasonable to speculate that LA deficiency can potentially have pathological 
implications similar to that seen in patients with NKH, although the full complement of implications 
would most likely be limited to an in vivo environment and may not be applicable to a cell-culture 
based in vitro setting, as with this study. Neuronal cell lines could provide a more appropriate 
background to evaluate the effect of LA deficiency on NKH in an in vitro study. However, there 
seems to be no other possible connection between elevated glycine levels and resistance to 
apoptosis, suggesting that the apoptotic resistance seen in this study was not mediated by an 
effect on the GCS.  
Finally, LA is also an essential co-factor for the E2 component of the BCKDH complex (Booker, 
2004; Naik and Huang, 2004). This complex is responsible for the degradation of the branched-
chain amino acids (BCAA), namely leucine, isoleucine and valine (Ribeiro et al., 2008; Ævarsson 
et al., 2000). Reduced functionality of the BCKDH complex results in the accumulation of the 
BCAA and their corresponding branched-chain keto-acids. A heritable genetic disease described 
by this pathophysiology has also been characterised and is referred to as maple syrup urine 
disease (MSUD) (Ribeiro et al., 2008; Ævarsson et al., 2000). Similarly to NKH, MSUD also 
presents with severe neurological deficits while the classical, and most severe form of the disease, 
displays a high fatality rate among infants (Ævarsson et al., 2000). Symptoms of MSUD include 
seizures, apnea, mental retardation, ataxia and psychomotor delay (Naik and Huang, 2004; Ribeiro 
et al., 2008). The molecular mechanisms behind MSUD are however still an uncertainty although 
complications such as neurotoxicity, demyelination and reduced mitochondrial respiration has been 
proposed (Jouvet et al., 2000; Ribeiro et al., 2008). MSUD displays significant mutational 
heterogeneity and include mutations in the E2 subunit of the complex, resulting in impaired or 
complete lack of function for this subunit (Herring et al., 1991; Naik and Huang, 2004). A deficiency 
for LA is likely to have a similar effect on the BCKDH; however, as noted with the GCS and NKH, it 
is likely that MSUD will only be expressed in full in an in vivo setting or partially in in vitro studies 
with neuronal cells. The same conclusion can thus be reached since it seems that there is no other 
link between apoptotic resistance and accumulated BCAA.  
A significant amount of research spanning several decades provide valid arguments for the 
beneficial role of exogenously administered LA. This includes beneficial and preventative roles in 
diseases such as Alzheimer’s, Parkinson’s, Multiple Sclerosis, hemochromatosis, lipotoxicity, 
obesity, angiotensin II-induced renal injury and certain risk factors for cardiovascular diseases 
(Bharath et al., 2002; Holmquist et al., 2007; Kim et al., 2004; Lee et al., 2006; Marracci et al., 
2002; Mervaala et al., 2003; Smith et al., 2004; Wollin and Jones, 2003). In addition, LA also 
shows great promise in diabetes-associated cataracts, nephropathy, atherosclerosis and 
cardiovascular complications (Obrosova et al., 1998; Obrosova et al., 2003; Smith et al., 2004; Yi 
and Maeda, 2006). Most of these researchers’ suggestions are based on the antioxidant properties 
of LA and DHLA. However, studies investigating the effects of LA, or LIAS, deficiency are rare, 
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especially those not in conjunction with other illnesses. In 2011, Johannes Mayr and colleagues 
reported on the case of young boy diagnosed with LIAS deficiency (Mayr et al., 2011). Genetic 
analysis revealed a homozygous mutation in a highly conserved region of LIAS while immunoblot 
assays revealed a severe reduction in lipoylated PDH and KGDH. The group was however unable 
to determine the state of the GCS and BCKDH since a liver sample was not available. The child 
presented with seizures and muscle hypotonia as early as three days after birth, which 
progressively worsened. Additional symptoms included elevated glycine levels, pronounced lactic 
acidosis, poor feeding, brain edema, mild hypertrophic cardiomyopathy and severely retarded 
mental and motor development. The child succumbed to a severe respiratory tract infection at the 
age of four. The group suggested that the deficiency in functional LIAS resulted in a severe 
metabolic crisis, producing symptoms similar to that seen in NKH, which was subsequently 
complicated by brain damage caused by the edema (Mayr et al., 2011). In the same year, another 
group reported on the case study of 10 individuals from nine non-related families that presented 
with suspect symptoms (Navarro-Sastre et al., 2011). Lactic acidosis and hyperglycinemia were 
common among all the individuals, while major symptoms included a selection of neurological 
regression and encephalopathy, pulmonary hypertension and a failure to thrive. Symptoms 
presented very early in life and all individuals died before or at the age of 15 months. Genetic 
analysis revealed a common mutation in the NFU1 gene which encodes the iron-sulphur cluster 
assembly protein NFU1. NFU1 was shown to be specifically required for the formation of the iron-
sulphur cluster of LIAS; hence, the mutated NFU1 resulted in a significant reduction in LA 
synthesis and corresponding lipoylated proteins. Taking together their results, the group reported 
that the 10 individuals presented with biochemical features that correlates well with a deficiency in 
LA synthesis (Navarro-Sastre et al., 2011). Finally, a study by Yi and Maeda revealed that LIAS is 
required for the early embryonic development of mice by generating mice embryos carrying a null 
allele for LIAS (Yi and Maeda, 2005). Heterozygous mice expressing 50% of the normal mRNA 
levels were able to develop normally even though they presented with reduced glutathione levels. 
In contrast, mice embryos homozygous for the null allele failed to survive past 9.5 dpc (days post 
coitum). The timing of the lethal effect suggested that the lack of LA severely compromised the 
cellular metabolism of the embryo. The researchers speculated that LIAS is required for normal 
embryonic development due to LA’s role as an essential cofactor but also partly due to its 
antioxidant properties (Yi and Maeda, 2005).  
When taken together, the above mentioned studies clearly indicates that LIAS is required for 
normal early development in mammals, and that LIAS deficiency holds severe and lethal 
consequences. The fact that the individuals in the case studies survived the gestation period hints 
to some kind of bypass mechanism for the requirement of LIAS that is present in humans but 
absent in mice; a hint also alluded to by Navarro-Sastre and colleagues (Navarro-Sastre et al., 
2011). When comparing these results to those obtained in this study, one can conclude that the 
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critical necessity for LIAS is most likely temporal, as well as cell and/or tissue type dependent. The 
affected stage of life in both the case studies and the murine study represented the early 
developmental stage, while the symptoms presented in the case studies were mostly of 
neurological descent. The reduced PDH activities coupled with lactic acidosis reported in the case 
studies supports the hypothesis that a deficiency in LIAS can results in cellular environments of an 
acidic nature; in non-developing tissues, this might potentially result in mutations favouring 
apoptotic resistance and malignant transformation. Deficiency in LIAS would also result in a 
diminished antioxidant network, as supported by the finding that heterozygous mice for the null 
allele displayed reduced glutathione levels. Whether this decrease can promote resistance to 
apoptosis in non-developing tissues through reduced mitogenic signalling or resistance to ROS-
mediated apoptosis still needs to be confirmed. 
In conclusion, even though the postulations made in this chapter of LIAS deficiency and its role in 
apoptosis resistance (or malignant transformation) are speculative, it provides a foundation that 
can be explored further in future work. This would most likely need to include the investigation of 
the effect of LIAS deficiency in different cell and tissue types and also in vivo models in order to 
determine whether a lack of LA is able to adequately lead to malignant tumour formation over 
longer period’s of time.  
 
2.4.2 Potential roles for CYPA in apoptosis 
The second gene identified in this study to show a potential role in resistance to apoptosis is 
CYPA. This gene encodes a protein product of approximately 18 kDa in size, also designated as 
cyclophilin A (CYPA). The protein is ubiquitously expressed and is located in the cytosol (Galat, 
1993). It belongs to the cyclophilin family which comprises of 15 members in humans, including 
CYPB, CYPC and CYPD (Zhu et al., 2007). Proteins in this family are referred to as peptidylproline 
cis-trans-isomerases (PPIases), since they catalyse the cis-trans transfiguration of peptidylproline 
bonds in their substrates, and have also been identified as targets for cyclosporine A (CsA), an 
immunosuppressive drug used in cases of organ transplant and graft versus host disease (Galat, 
1993; Handschumacher et al., 1984). The binding affinity for CsA differs between the members of 
the family, with CYPA representing the major intracellular target (Galat, 1993; Wang and Heitman, 
2005). Binding of CsA abolishes the PPIase activity of these proteins (Galat, 1993). The protein 
family maintains a high level of phylogenetic sequence conservation, suggesting an important 
physiological role; however, CYPA-/- embryonic stem cells develop and differentiate as normal, 
indicating that CYPA is not essential for mammalian cell viability (Colgan et al., 2000). 
A major function for cyclophilins is made possible by their PPIase activity (Fig. 2.27). Although 
peptide bonds can exist in either a trans or cis configuration, the latter state is necessary for de 
novo protein folding as well as refolding following the transport of proteins across cellular 
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membranes (Wang and Heitman, 2005). Cyclophilins catalyse this isomerisation reaction, an 
otherwise rate-limiting step, by stabilising the transition state and accelerating the re-configuration 
(Wang and Heitman, 2005). Thus, cyclophilins are essential to various protein folding and 
modification processes, which includes the maturation of newly synthesised proteins, protein 
transport and the association of multiple proteins during complex formation as well as protein 
repair following damage by environmental stresses (Galat, 1993; Wang and Heitman, 2005; Yao et 
al., 2005). In particular, CYPA also exhibits certain immune-related functions; firstly as a potent 
chemo-attractant for leukocytes and monocytes and then also as mediator of human 
immunodeficiency virus (HIV)-1 infection (Sherry et al., 1992; Wang and Heitman, 2005; Xu et al., 
1992; Yao et al., 2005). With the latter function, CYPA has been shown to promote the formation 
as well as infectivity of HIV-1 virions by interacting with the HIV-1 Gag protein, by means of CD147 
interaction, or even both (Pushkarsky et al., 2001; Thali et al., 1994; Wang and Heitman, 2005; 
Yao et al., 2005).  
Compared with LIAS, determining a potential role for CYPA in resistance to apoptosis might prove 
to be more straightforward, although some contrasting reports do exist. Numerous studies have 
reported a vital role for CYPA in the execution of apoptosis. Recombinant CYPA proteins were 
shown to possess nuclease activity capable of facilitating DNA degradation during apoptosis 
(Montague et al., 1994; Montague et al., 1997). The DNase activity were dependent on Ca2+/Mg2+, 
a characteristic commonly seen in apoptotic nucleases (Robertson et al., 2000; Samejima and 
Earnshaw, 2005). In addition, the DNase activity resulted in the production of 3’-OH termini, which 
serves as the foundation for apoptosis detection by means on the TUNEL assay, and was 
abrogated by compounds that prevent DNA degradation and apoptosis (Montague et al., 1994; 
Montague et al., 1997). Since the addition of CsA failed to prevent DNA degradation, it was also 
concluded that this characteristic was separate from the protein’s isomerase activity. It was also 
hypothesised that CYPA does not act alone and might require a co-factor or additional protein to 
facilitate DNA degradation (Montague et al., 1997). Since then, a protein interaction has been 
established between CYPA and AIF (Candé et al., 2004). Through a series of experiments Candé 
and colleagues provided substantial evidence for the cooperation of these two proteins in the 
degradation of DNA and subsequent execution of apoptosis. The group showed that CYPA and 
AIF colocalised in the nucleus upon apoptosis induction and that a physical interaction was 
restricted to apoptotic cells. In accordance with the above mentioned studies, CsA had no effect on 
the CYPA-AIF interaction. Recombinant CYPA and AIF alone were unable to degrade naked 
supercoiled plasma DNA while a combination of the proteins resulted in non-specific DNA 
degradation. Levels of apoptosis in CYPA-deficient Jurkat cells were significantly lower compared 
to the wild type; a resistance that correlated with reduced large-scale DNA degradation. The same 
was true for cells devoid of AIF but expressing CYPA (Candé et al., 2004). Additional support for a 
direct CYPA-AIF interaction has been provided by other studies investigating the role of apoptosis 
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Figure 2.27: Illustration of the cis-trans isomerisation reaction catalysed by PPIases. P – proline; S – serine. 
Adapted from Lu et al., 2002.  
in various diseases. In a mouse model for amyotrophic lateral sclerosis (ALS), a disease 
characterised by progressive motor neuron loss, CYPA was shown to colocalise with AIF in the 
nuclei of motor neurons in diseased mice (Tanaka et al., 2011). A lack of CYPA was also shown to 
be neuroprotective in vivo after exposure of CYPA-/- mice to cerebral hypoxia-ischemia (Zhu et al., 
2007). The nuclear translocation of AIF was prevented in these mice while the translocation of 
CYPA was also prevented in AIF-deficient harlequin mice. The group also showed that the 
neuroprotective phenotype seen in CYPA deficient cells was not associated with other 
mitochondrial cell-death effectors, caspases or calpains, since none of these were affected by the 
lack of CYPA as compared with wild type cells (Zhu et al., 2007). The dependence of AIF on CYPA 
was also reported in yeast cells where disruption of the yeast CYPA homologue, CPR1, prevented 
cell death induced by the overexpression of the yeast AIF homologue, Aif1p (Wissing et al., 2004). 
This effect was specific to CPR1 since disruption of the CYPB homologue, CPR2, failed to rescue 
cells from apoptosis (Wissing et al., 2004). In contrast to the interaction with AIF, a protein normally 
associated with caspase-independent apoptosis and where the interaction does not seem to 
involve isomerase activities, CYPA was also reported to be directly involved in apoptosis by 
facilitating caspase activation through its isomerase properties (Capano et al., 2002). In this in vitro 
study, CYPA expression was inhibited by treatment with antisense oligodeoxynucleotides. Upon 
apoptosis induction with a combination of glutamate and nitric oxide, this resulted in substantially 
decreased activation of caspases 8, 9 and 6, while a weaker effect was seen in the activation of 
caspase 3. Treatment of cells with CsA revealed comparable results and since CsA inhibits CYPA 
through binding its PPIase domain, this was indicative of the involvement of CYPA’s isomerase 
activity. The authors suggested that CYPA is most likely a component in a complex involved in 
caspase processing (Capano et al., 2002). Taking together the above mentioned, CYPA seems to 
play a role in the execution of both caspase dependent and independent apoptosis, of which the 
involvement is of a pro-apoptotic nature. Based on this, it would seem likely that cells deficient in 
the CYPA protein would exhibit an inadequate apoptotic process, rendering the cell resistant to 
apoptotic induction.  
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Opposing roles for CYPA in terms of apoptosis and cellular proliferation is however apparent when 
taking into account studies measuring the expression of CYPA in cancer. Numerous studies have 
shown CYPA to be overexpressed in a variety of tumour cell lines and tissues, which includes 
cancers of the lung (non-small and small cell lung cancer), prostate, brain, pancreas, tongue and 
oesophagus (Campa et al., 2003; Choi et al., 2007; Huang et al., 2011b; Li et al., 2006; Qi et al., 
2008; Shen et al., 2004; Sun et al., 2011; Yang et al., 2007). These opposing roles might however 
be dependent on the state of the cell. In order for CYPA to function as a pro-apoptotic protein, an 
association with AIF is required and, as shown by Candé and colleagues, CYPA is unable to 
induce DNA fragmentation on its own (Candé et al., 2004). On the other hand, AIF is located in the 
mitochondria under physiological conditions and is only released upon apoptotic induction, which 
can include induction by camptothecin and ceramide (Candé et al., 2004; Joza et al., 2009; 
Modjtahedi et al., 2006; Susin et al., 1999). MOMP facilitates the release of AIF, which in turn is 
under the stringent control of the Bcl-2 family proteins (Susin et al., 1999; Valero et al., 2011). As 
described in chapter one, anti-apoptotic Bcl-2 family members bind and inhibit the pro-apoptotic 
members of the family, preventing them from initiating MOMP (Coultas and Strasser, 2003; 
Hengartner, 2000). As part of the defence strategy against apoptosis, tumour cells often prevent 
MOMP, and subsequent release of the apoptogenic proteins from the mitochondrial 
intermembrane space, by changing the ratio of the Bcl-2 family proteins to favour the anti-apoptotic 
members (Aouacheria et al., 2007; Fulda, 2010; Valero et al., 2011). Thus AIF often remains 
confined in the mitochondria in tumour cells; which would mean that CYPA is unable to perform its 
apoptotic function. The increased expression levels of CYPA can also potentially be associated 
with a state of malignancy. Tumour cells often face hypoxic conditions and the ability to maintain a 
proliferative state during hypoxia is a characteristic that is associated with poor prognosis and 
resistance to anticancer therapies (Birner et al., 2000; Harris, 2002). During hypoxia, tumour cells 
make certain changes in order to adapt to the low availability of oxygen, and this includes altering 
gene expression patterns. The transcription factor hypoxia inducible factor 1α (HIF-1α) is a major 
player in facilitating this adaptation by activating the expression of numerous hypoxia responsive 
genes through the binding of hypoxia-response elements (HRE) in the promoter regions of these 
genes (Harris, 2002). CYPA is potentially regulated by HIF-1α due to the presence of a HRE in the 
promoter region of this gene (Choi et al., 2007). The same study also revealed an association 
between increased CYPA expression and hypoxia; an association that was mediated by HIF-1α. 
Increased HIF-1α activity has been associated with tumour progression and the corresponding 
gene is also commonly overexpressed in a variety of tumours (Zhong et al., 1999). Thus, these 
reports provide a potential foundation for the high levels of CYPA in tumour cells and tissues. A 
likely role for the up-regulation of CYPA in tumours is one that opposes its role in apoptosis, i.e. 
cellular proliferation. A study performed by Li and colleagues (2006) revealed that the exogenous 
administration of CYPA to pancreatic tumour cells resulted in significant increases in cellular 
proliferation (Li et al., 2006). This effect is however not restricted to tumour cells, since exogenous 
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CYPA was also able to significantly stimulate the proliferation of human aorta smooth muscle cells 
and human lung microvascular endothelial cells (Yang et al., 2005).  
It is thus possible for CYPA to have opposing roles in the cell; roles that are determined by the 
state of a cell. Upon apoptosis induction in normal cells, like the cells used in this study, CYPA is 
likely to have an important cooperative function alongside AIF in the execution of apoptosis in such 
a way that without proper CYPA levels, apoptosis is likely to fail. However in tumour cells, where 
mechanisms to avoid apoptosis are set in motion, CYPA is left, and most likely induced, to fulfil 
other functions that might favour the tumour cell. A promising avenue for future studies would be to 
validate these statements in matched healthy and tumour sample sets from different types of 
tissues. In addition, the specific role for CYPA in tumour cells needs to validated in different tumour 
types.  
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Chapter 3: A bioinformatic approach to identifying novel candidate genes involved 
in apoptosis 
 
3.1 Introduction  
The field of bioinformatics has flourished in recent years along with the increase in genomic and 
proteomic data (Perez-Iratxeta et al., 2007). Data-intensive research has spurred the development 
of computational methods to ease analysis and databases, especially those of a cross-disciplinary 
nature, to serve as resources by collecting and integrating data. Indeed, the use of databases has 
increased significantly in the past decade (Perez-Iratxeta et al., 2007). Databases come in all 
shapes and sizes, and two examples are protein interaction and pathway databases. These 
databases are valuable tools that allow for genes and proteins to be organised within their larger 
biological context, making it possible for inferences to be made regarding their role in, for example, 
pathogenesis (Romero et al., 2004).  
Even though significant progress has been made in the understanding of apoptosis, a level of 
uncertainty remains, especially with regards to the regulatory mechanisms of apoptosis and its 
implications for disease (Ola et al., 2011). The identification of novel candidate genes or proteins 
that may potentially have a role in apoptosis is not only important for expanding our knowledge on 
the process but may also be important for the therapeutic potential of apoptosis; if these 
candidates were found to have some kind of regulatory effect on apoptosis, they could become 
potential targets for the development of therapeutic drugs.  
By investigating the protein interactions of a novel candidate, clues can be obtained to its 
molecular function and regulation. Similarly, identifying associated cellular pathways would reveal 
the functional environment of a candidate. As mentioned previously, protein interaction and 
pathway databases can greatly assist in this annotation of novel candidates. These databases can 
contain experimentally verified data retrieved from published literature or predicted data, and even 
though verified data would be of more noteworthy value, predicted data provides a framework for 
future experimental studies.  
The aim of this chapter is thus two-fold; firstly, to identify additional potential candidate genes 
involved in apoptosis by analysing nucleotide sequences obtained from the promoter-trap 
mutagenesis experiments performed in the pilot study. This was achieved by means of Basic Local 
Alignment Search Tool (BLAST) searches. Secondly, to perform a bioinformatic analyses on 
candidate genes identified in the pilot study, as well as candidate genes identified by the first aim. 
For this analyses, possible interacting proteins and a potential role in cellular pathways were 
investigated by means of a variety of freely available web-based databases; databases IntAct 
(Kerrien et al., 2012), STRING (Jensen et al., 2009), BioGRID (Stark et al., 2006), DOMINE 
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(Raghavachari et al., 2008; Yellaboina et al., 2011) and I2D (Brown and Jurisica, 2005; Brown and 
Jurisica, 2007) were used to identify possible interacting proteins, while the KEGG (Kanehisa and 
Goto, 2000; Kanehisa et al., 2012), Reactome (Croft et al., 2011; Matthews et al., 2009), 
HumanCyc (Romero et al., 2004) and UniPathway (Morgat et al., 2012) databases were used to 
investigate a potential role for the candidate genes in cellular pathways. Below follows a brief 
description of each of these databases, as well as a description for GeneCards®, a database 
commonly used throughout the methodology of this chapter.  
GeneCards® (http://www.genecards.org/):  
Established in 1997 by the Weizmann Institute of Science in collaboration with Life Map Sciences 
Incorporated, the GeneCards® database aimed to integrate data generated by the human genome 
project which was subsequently scattered over various specialised databases (Rebhan et al., 
1997). The latest database version (v. 3), released in 2010, boasts with more than 73 000 entries 
which includes cards for all known and predicted protein coding genes as well as pseudo- and 
RNA genes (Safran et al., 2010). Genome, transcriptome, proteome, function and disease data is 
sourced from more than 80 different electronic resources, including large public databases like 
ENSEMBL, UniProtKB, National Centre for Biotechnology Information (NCBI) and HUGO Gene 
Nomenclature Committee (HGNC). In addition, this human gene database takes it one step further 
by listing known orthologs and paralogs and providing links to reagents and products specific to 
your gene of interest. A section listing interactions and/or associations with various drugs and 
chemical compounds is also included. The GeneCards® database provides the researcher with a 
multifaceted tool that allows for the characterisation of genes from a nucleotide sequence starting 
point, beyond the analysis of gene expression and protein modification, right up to viewing 
implicated cellular pathways and identifying involvement in diseases, all the while providing 
molecular tools to aid research (Safran et al., 2010).  
IntAct (http://www.ebi.ac.uk/intact/):   
Hosted by the European Bioinformatics Institute, the IntAct database is a freely available protein 
interaction database that collects and collates data from literature and direct data submissions. 
Each data entry is curated and checks are performed on a database level before the final entry is 
submitted (Kerrien et al., 2012). In addition, the original author is consulted before the submission 
and the entry is manually updated in the case of comments from the author. IntAct is compliant 
with HUPO-PSI data standards and is also a member of the IMEx consortium, employing IMEx 
annotation standards to the majority of the protein-protein interaction data. Although the database 
focusses on protein-protein interactions, referencing more than 57 000 proteins (as of September 
2011), the database also branches out to protein interactions with small molecules, nucleic acids 
and genes (Kerrien et al., 2012). IntAct can be searched by using a protein’s gene name, PubMed 
ID, UniProtKB accession number or UniProtKB ID.  
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STRING (http://string-db.org/): 
The Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) is a comprehensive 
visual database that integrates information on known and predicted protein interactions (Jensen et 
al., 2009; Szklarczyk et al., 2011). The database is unique in its visual representation of a specified 
protein’s interaction network, which can be altered by repositioning the implicated proteins or by 
removing or adding additional proteins. STRING employs a variety of evidence types, which 
includes experimental data, co-expression data, homology data and data obtained from text-
mining. Confidence scores for an interaction are obtained by combining the probabilities from the 
different evidence types while correcting for the probability of randomly observing an interaction. 
The user can choose to remove a certain evidence type from the analysis and can also set a 
threshold confidence score for the analysis; thus making it possible to balance different levels of 
accuracy and coverage.  Another strength of the database is that it covers a vast variety of 
organisms; in fact, the latest version covers more than 1100 completely sequenced organisms 
(Jensen et al., 2009; Szklarczyk et al., 2011).  
BioGRID (http://thebiogrid.org/):  
The Biological General Repository for Interaction Datasets (BioGRID) database was first released 
in 2002 and has since been modified and expanded on several occasions (Breitkreutz et al., 2008; 
Stark et al., 2006; Stark et al., 2011). The database aims to capture and organise protein and 
genetic interaction data, especially those obtained from high-throughput studies. BioGRID places 
special attention on interaction data from S. cerevisiae and Schizosaccharomyces pombe by 
maintaining the data with monthly updates to provide a near-complete representation of all 
interactions available in literature. Additional focus is placed on interactions in a human platform, 
for obvious biomedical reasons. Other model organisms covered by the database include Macaca 
mulatta, M. musculus, D. melanogaster, Arabidopsis thaliana and Bacillus subtilis (Breitkreutz et 
al., 2008; Stark et al., 2006; Stark et al., 2011).  
DOMINE (http://domine.utdallas.edu/cgi-bin/Domine):  
The DOMINE database represents a thorough collection of known and predicted protein domain-
domain interactions (Raghavachari et al., 2008; Yellaboina et al., 2011).  A number of different 
computational approaches aimed at inferring domain-domain interactions have been developed 
due to the fact that interactions inferred from structural data can explain only a limited number of 
protein interactions. With this in mind, DOMINE utilises 15 different data sources, of which two 
provides known interactions inferred from 3D structures. Predicted domain-domain interactions 
obtained from computational approaches is also assigned confidence scores. Simply put, the 
individual approaches are weighted based on how well their predictions are confirmed by others; 
this allows for the calculation of a confidence score by summing the weights from each approach 
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that predicted a particular interaction. Based on the confidence score, predicted interactions can be 
classified as either of high, medium or low confidence (Raghavachari et al., 2008; Yellaboina et al., 
2011).   
I2D (http://ophid.utoronto.ca/ophidv2.201/):  
Formerly known as OPHID, the I2D, or Interologous Interaction Database, aims to elaborate the 
human interactome by supplementing the experimentally verified protein interactions with predicted 
interactions (Brown and Jurisica, 2005; Brown and Jurisica, 2007). As the name suggests, the 
database was constructed using an interologous approach; protein interactions from model 
organisms were transferred to human orthologs by utilising the BLASTp tool in combination with a 
reciprocal best-hit tactic (the top hit identified in a BLASTp search with the model organism protein 
had to produce a top hit that matched the original query protein when BLAST searched in the 
reverse direction). The model organisms used in the construction of the database included M. 
musculus, D. melanogaster, C. elegans and S. cerevisiae. Three evidence types, namely domain 
co-occurrence, gene co-expression and Gene Ontology (GO) term similarity, were used as support 
for the predicted interactions. As with all predicted interactions, these interactions needs to be 
experimentally verified, however increasing evidence suggests the protein-protein interactions are 
conserved through evolution (Brown and Jurisica, 2005; Brown and Jurisica, 2007).  
KEGG (http://www.genome.jp/kegg/):  
Throughout the years the Kyoto Encyclopaedia of Genes and Genomes (KEGG) database has 
become synonymous with the visualisation and elucidation of cellular pathways. The database is a 
comprehensive resource that integrates genomic, chemical and systemic functional information 
based on experimentally verified data (Kanehisa and Goto, 2000; Kanehisa et al., 2012). KEGG 
houses 15 different databases covering three focus areas, namely systems information (e.g. 
KEGG PATHWAY, KEGG DISEASE and KEGG BRITE), genomic information (e.g. KEGG 
GENOME, KEGG GENES and KEGG ORTHOLOGY) and chemical information (e.g. KEGG 
REACTION, KEGG ENZYME and KEGG COMPOUND). In-house software is used to manually 
draw the graphical representations of the pathways maps in KEGG PATHWAY (Kanehisa and 
Goto, 2000; Kanehisa et al., 2012). 
Reactome (http://www.reactome.org):  
Reactome is a freely available and open source database for human processes and pathways 
(Croft et al., 2011; Matthews et al., 2009). Pathways are manually curated and peer-reviewed, and 
annotations are cross-referenced with a variety of established bioinformatic databases, such as 
NCBI Entrez Gene, UniProt, KEGG COMPOUND and GO. Reactome pathways are also expanded 
to include processes such as the transport of proteins between cellular compartments and by 
including a variety of entities such as macromolecular complexes, small molecules, proteins and 
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nucleic acids. External databases, such as IntAct, BioGRID and STRING, are also consulted to 
provide molecular interaction data for pathway construction (Croft et al., 2011; Matthews et al., 
2009).  
HumanCyc (http://humancyc.org/):  
HumanCyc is a database for human metabolic pathways and forms part of the larger BioCyc 
collection (Romero et al., 2004). The database was constructed with the PathoLogic component of 
the Pathway Tools Software (Karp et al., 2002), a reusable software package able to create a type 
of model-organism database called a pathway/genome database (PGDB) (Romero et al., 2004). 
The PathoLogic component utilises the annotated genome of an organism to create a new PGDB 
(Karp et al., 2002). HumanCyc contains 305 metabolic pathways; curation, however, is an on-going 
process, leaving many of the pathways predicted (Romero et al., 2004). Although, as with 
predicted protein interactions, these predicted pathways based on the human genome provides a 
framework for the elucidation of interactions, and subsequent pathways, on an experimental level.  
UniPathway (http://www.grenoble.prabi.fr/obiwarehouse/unipathway):  
UniPathway is a resource for the exploration of metabolic pathways (Morgat et al., 2012). The 
database is completely manually curated, using primary literature as a source as well as external 
databases such as KEGG and MetaCyc. In addition, all reactions in UniPathway are linked to the 
corresponding entries in UniProtKB. A key concept in the database is that of UniPathway Linear 
Subpathway (ULS), which represents a set of enzymatic reactions known to occur in linear 
sequence with no known variance. These ULSs are used as building blocks upon which larger 
pathways is assembled while species-specific pathway variants form alternative paths through 
connected ULSs (Morgat et al., 2012).  
 
3.2 Materials and methods 
3.2.1 Identification of potential candidate genes 
A local alignment search was performed with eight sequences obtained from the promoter-trap 
mutagenesis experiments performed in the pilot study. The sequences were named as follows: 
MMJ304(BF)3’41, MMJ304G, MMJ308BFG, SEJJ302 BOTT3’41, SEJJ302 TOP3’41, 
SEJJ3021034, SWJ612MF43 and SWJ612TF43. The search was performed by utilising the 
BLASTn tool located on the NCBI webpage (http://blast.ncbi.nlm.nih.gov/). The search was 
conducted against the human genomic and transcript database while default options for the 
remaining parameters were selected. The top hit from each BLAST search were investigated 
further by submitting the identified gene(s) to a search in the GeneCards® database. This was 
done in order to elucidate the molecular function of the gene(s) and also to determine if the gene(s) 
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had any established associations with apoptosis or cancer. Characteristics of interest included 
cellular location of the corresponding protein, molecular function, participation in a molecular 
process, possible involvement in cellular pathways, protein-protein interactions, domains present in 
the corresponding protein and the presence of transcription factor binding sites in the promoter 
region of the gene.  
By assessing the results from the BLAST searches in terms of E-values (expect values), bit scores 
and percentage identities and the information obtained from the GeneCards® searches, two 
candidate genes were selected to undergo further bioinformatic analyses as described in section 
3.2.2.  
 
3.2.2 Bioinformatic analysis of selected candidate genes 
A total of four candidate genes, two identified in the pilot study and two identified as described in 
section 3.2.1, were subjected to further bioinformatic analyses. For these analyses, freely available 
web-based databases were used to investigate possible protein interactions for the candidate 
genes’ corresponding proteins as well as to identify any potential involvement in cellular pathways. 
A variety of databases were used for these analyses, and this includes IntAct, STRING, BioGRID, 
DOMINE and I2D for protein interactions and KEGG, Reactome, HumanCyc and UniPathway for 
the pathway analysis. This selection of databases was chosen based on three reasons; firstly, to 
include both experimentally verified and computationally predicted data; secondly, these databases 
exhibit different features (especially the pathway databases); and lastly, because the databases 
are constructed differently (especially the protein interaction databases). Default parameters were 
selected for all database searches performed with the exception of the STRING database. Here, 
the text-mining evidence type were removed from the analysis since this feature functions as an 
“automatic key-word” search in abstracts of published literature and can thus result in false 
positives. In addition, a confidence score of 0.500 was selected in order to restrict the results to 
interactions with a higher confidence level (default value is 0.4).  
The results obtained from the searches conducted in the protein interaction and pathway 
databases were investigated further in order to determine their relevance to this study. In terms of 
the protein interaction data, the molecular function for each interactant, as generated by all of the 
databases, were searched for in either GeneCards®, NCBI Entrez Gene, UniProtKB or InterPro. 
Only those functioning in processes such as apoptosis, cell death, cell survival, cell differentiation, 
cell division or cell cycle control, or those described as an oncogene or tumour suppressor, were 
deemed relevant. The same criteria were used to determine the relevance of the each pathway 
generated by the pathway databases.   
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3.3 Results and Discussion 
3.3.1 Identification of potential candidate genes 
The BLAST searches performed with the nucleotide sequences obtained from the pilot study 
produced alignments to either refseq mRNA sequences or genomic contigs (table 3.1). Each 
alignment produced one candidate gene, with the exception of sequence SWJ612MF43, where 
two genes were identified, namely autophagy protein 5 (ATG5) and cAMP-specific 3’,5’-cyclic 
phosphodiesterase 7B (PDE7B). Due to the nature of the promoter-trap mutagenesis experiments, 
this could indicate that the two genes share a promoter. Both ATG5 and PDE7B are located on 
chromosome 6, however, they are located at different regions (ATG5 – 6q21 and PDE7B – 6q23-
24) and thus the possibility remains that instead of sharing a common promoter, these genes share 
a similar stretch of nucleotides in their promoter regions. The true nature for this phenomenon was 
however not investigated since it was outside the scope of this project.  An interesting result was 
observed in the alignments of sequences MMJ304(BF)3’41 and SEJJ302 BOTT3’41; both of these 
alignments identified the same candidate gene, namely AHNAK nucleoprotein (AHNAK). The fact 
that this gene was identified twice, and was thus knocked-down in two different cell populations 
which showed resistance to apoptosis in the promoter-trap mutagenesis experiments performed 
the pilot study, provides increased support for AHNAK to potentially be involved in apoptosis. This 
phenomenon also occurred with sequences MMJ304G and MMJ308BFG. In this case, lipoic acid 
synthetase (LIAS) was identified as the candidate gene. In addition to the above mentioned 
statement, this observation provides even more support for a possible involvement in apoptosis 
since LIAS was also identified as a candidate gene in the pilot study. In terms of the E-values 
produced by each of the alignments, statistically significant results were obtained for three 
alignments, namely those of sequences MMJ304G, MMJ308BFG and SEJJ3021034. These 
alignments identified LIAS and serum amyloid A-like 1 (SAAL1) as candidate genes. The 
remaining alignments produced unfavourable E-values and could be an indication of false 
positives. Overall, the lengths of the alignments were relatively short, ranging between 21 and 67 
nucleotides, which can be attributed to the inverse-PCR technique used in the pilot study. This 
technique has however been improved since then and a subsequent study performed by a fellow 
researcher following the same protocol for BLAST analysis produced alignments which were 
considerably longer (Molenaar, 2012). The percentage identities for the alignments averaged at 
89.67%; gaps present in the alignments could potentially be explained by the fact that the BLAST 
searches were performed against the human genomic and transcript databases.  
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Table 3.1: Results obtained from the BLAST searches performed with sequences isolated from the pilot study 
Sequence Candidate gene Accession number Bit score 
(Total) 
E-value¥ Alignment 
Identity§ (%) 
MMJ304(BF)3’41 AHNAK nucleoprotein (AHNAK) (transcript variant 1) NM_001620.1 39.2 (42) 2.8 24/26 (93%) 
MMJ304G Lipoic acid synthetase (LIAS) (transcript variant 1) NM_006859.2 60.8 (66) 1E-06 46/55 (84%) 
 Lipoic acid synthetase (LIAS) (transcript variant 2) NM_194451.1 60.8 (66) 1E-06 46/55 (84%) 
MMJ308BFG Lipoic acid synthetase (LIAS) NT_016297.16 62.6 (68) 4E-07 53/67 (80%) 
 Lipoic acid synthetase (LIAS) NW_001838902.1 62.6 (68) 4E-07 53/67 (80%) 
SEJJ302 BOTT3’41 AHNAK nucleoprotein (AHNAK) (transcript variant 1) NM_001620.1 39.2 (42) 4.9 24/26 (93%) 
SEJJ302 TOP3’41 6-phosphofructo-2-kinase/fructo-2,6-bisphosphatase 3 
(PFKFB3) 
NT_008705.16 42.8 (46) 0.38 26/28 (93%) 
 6-phosphofructo-2-kinase/fructo-2,6-bisphosphatase 3 
(PFKFB3) 
NW_001837931.2 42.8 (46) 0.38 26/28 (93%) 
SEJJ3021034 Serum amyloid A-like 1 (SAAL1) NT_009237.18 53.6 (58) 2E-04 37/42 (89%) 
 Serum amyloid A-like 1 (SAAL1) NW_001838022.2 53.6 (58) 2E-04 37/42 (89%) 
SWJ612MF43 Autophagy protein 5 (ATG5) NT_025741.15 42.8 (46) 0.32 31/36 (87%) 
 cAMP-specific 3’,5’-cyclic phosphodiesterase 7B (PDE7B) NT_025741.15 39.2 (42)  3.8 21/21 (100%) 
 Autophagy protein 5 (ATG5) NW_001838990.2 42.8 (46) 0.32 31/36 (87%) 
 cAMP-specific 3’,5’-cyclic phosphodiesterase 7B (PDE7B) NW_001838990.2 39.2 (42) 3.8 21/21 (100%) 
SWJ612TF43 Gamma-glutamyl hydrolase (GGH) NM_003878.2 39.2 (42) 3.8 24/26 (93%) 
¥ - Expect value; § - nucleotide alignment identity (amount of identical nucleotides out of the total amount of nucleotides in the alignment) 
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The seven candidate genes identified by the BLAST searches were investigated by means of the 
GeneCards® searchable database in order to assign basic functional annotations. This 
characterisation would ultimately assist in the selection of candidate genes for further study. 
Characteristics such as molecular function, molecular process, cellular pathways and protein 
interactions were important, although additional characteristics were also determined to provide a 
more complete overview of each candidate gene. The results of this investigation can be found in 
table 3.2; however, even though the table contains complete information for most of the 
characteristics, it must still be regarded as a summary of the information available on the 
GeneCards® database, especially with regards to the predicted transcription factor binding sites.  
Basic functional annotations could be assigned to the majority of the candidate genes and a 
relatively large amount of heterogeneity between the genes could be observed in terms of 
molecular function and process involvement. With regards to the cellular pathways, most of the 
candidate genes were either involved in a metabolic pathway or a type of signalling pathway. In 
contrast to the rest of the candidate genes, very little information could be obtained for SAAL1. The 
GeneCards® database revealed no known specific function or cellular pathways for this gene.  
Potential links to apoptosis could be ascertained for some of the candidate genes. Determining the 
molecular function for ATG5 revealed that this gene is required for autophagy, a type of cell death, 
and may also potentially be involved in the modification of the cytoskeleton during apoptosis. As 
mentioned in chapter 1, morphological characteristics of apoptosis include cellular contraction, 
nuclear disintegration, cellular fragmentation and the formation of apoptotic bodies; characteristics 
such as these all involve modifications of the cytoskeleton (Ndozangue-Touriguine et al., 2008). 
Further support for a potential role in apoptosis is obtained from protein-protein interactions with 
caspase 8 and FADD, two proteins essential to the extrinsic pathway of apoptosis, as well as the 
predicted presence of a p53 transcription factor binding site in the promoter region for ATG5. A 
protein-protein interaction with caspase 8 was also revealed for PFKFB3, in addition to an 
interaction with TRADD, another protein involved in the extrinsic apoptotic pathway. The promoter 
region of PFKFB3 is also suggested to contain a binding site for c-Myc, a transcription factor that is 
known to play a role in cell proliferation and apoptosis (Nieminen et al., 2007). The candidate gene 
GGH was shown to be involved in the biosynthetic pathway of folate. This reveals a potential link to 
apoptosis since folate is necessary for the biosynthesis of purines and is thus vital for DNA 
synthesis and repair as well as maintaining the stability and integrity of DNA. Folate deficiency is 
known to increase the presence of DNA strand breaks and may also induce apoptosis (Novakovic 
et al., 2006). With regards to PDE7B, this gene functions to hydrolyse cyclic adenosine 
monophosphate (cAMP) and is thus central to its regulation. cAMP is an important second 
messenger molecule implicated in multiple signalling pathways and physiological processes and 
through these, cAMP is said to have both an anti-apoptotic and pro-apoptotic impact (Dou and 
Wang, 2010). 
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Table 3.2: Results obtained from the Genecards® database for each candidate gene identified by 
the BLAST searches 
Characteristic Summary of GeneCards® results 
AHNAK nucleoprotein (AHNAK) 
Alternative names Desmoyokin; neuroblast differentiation-associated protein 
AHNAK 
Cellular location of protein Nucleus 
Molecular function May be required for neuronal cell differentiation; protein binding 
Molecular process  Nervous system development 
Cellular pathways Phospholipase C signalling 
Protein domains PDZ 
Protein-protein interactions EGFR; IL6; DYSF; S100A10; HDAC2; CDKN2A 
Predicted transcription factor 
binding sites 
CREB; p53; c-Myc; NFκB 
Lipoic acid synthetase (LIAS) 
Alternative names Lipoate synthase; lipoyl synthase 
Cellular location of protein Mitochondrion 
Molecular function α-lipoic acid synthesis; sulphur insertion in lipoate-dependent 
enzymes; transferase activity; metal ion binding 
Molecular process  Inflammatory response; response to oxidative stress; lipoate 
biosynthetic process 
Cellular pathways Lipoic acid metabolism; metabolic pathways; protein 
modification 
Protein domains Aldolase-type TIM barrel; radical SAM; elongator protein 
3/MiaB/NifB 
Protein-protein interactions MCM2; OGDH; DLST; HSPD1; LIPT1; LIPT2 
Predicted transcription factor 
binding sites 
CREB; p53; c-Jun; GCNF; CUTL1 
EGFR – epidermal growth factor receptor; IL6 – interleukin 6; DYSF – dysferlin; S100A10 – S100 calcium 
binding protein A10; HDAC2 – histone deacetylase 2; CDKN2A – cyclin dependent kinase inhibitor 2A; 
CREB – cAMP responsive element binding protein; NFκB – nuclear factor kappa B; MCM2 – 
minichromosome maintenance complex component 2; OGDH – oxoglutarate dehydrogenase; DLST – 
dihydrolipoamide S-succinyltransferase; HSPD1 – heat shock 60kDa protein 1; LIPT1 – lipoyltransferase 1; 
LIPT2; lipoyltransferase 2; GCNF – germ cell nuclear factor; CUTL1 – cut-like homeobox 1. 
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Table 3.2 continued 
Characteristic Summary of GeneCards® result 
6-phosphofructo-2-kinase/fructo-2,6-bisphosphatase 3 (PFKFB3) 
Alternative names 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 
Cellular location of protein Cytosol 
Molecular function Synthesis and degradation of fructose-2,6-bisphosphate; kinase 
activity; protein binding; hydrolase activity 
Molecular process  Glycolysis; carbohydrate metabolic process 
Cellular pathways AMPK signalling; fructose and mannose metabolism 
Protein domains 6-phosphofructo-2-kinase; histidine phosphatase superfamily 
clade-1 
Protein-protein interactions CASP8; TRADD; HIF1A; CDK1; GCK; PPARG 
Predicted transcription factor 
binding sites 
PPARγ1; PPARγ2; SRF; CREB; Chx10; c-Myc; c-Jun; p300 
Serum amyloid A-like 1 (SAAL1) 
Alternative names FLJ41463; SPACIA1 
Cellular location of protein Extracellular region 
Molecular function Binding 
Molecular process  Acute-phase response 
Cellular pathways - 
Protein domains Armadillo-like helical; armadillo-type fold 
Protein-protein interactions USP19; MARK3; PHLDA3 
Predicted transcription factor 
binding sites 
NRSF form 1; NRSF form 2; c-Myc; ZEB1; CUTL1; NRF-2 
CASP8 – caspase 8; TRADD – tumour necrosis factor receptor type 1 (TNFR1)-associated death domain 
protein; HIF1A – hypoxia inducible factor 1-alpha; CDK1 – cyclin dependent kinase 1; GCK – glucokinase; 
PPARG – peroxisome proliferator-activated receptor gamma; PPARγ1 – peroxisome proliferator-activated 
receptor gamma 1; PPARγ2 – peroxisome proliferator-activated receptor gamma 2; SRF – serum response 
factor; CREB – cAMP responsive element binding protein; Chx10 – Ceh-10 homeodomain-containing 
homolog; USP19 – ubiquitin specific peptidase 19; MARK3 – MAP/microtubule affinity-regulating kinase 3; 
PHLDA3 – pleckstrin homology-like domain, family A, member 3; NRSF – neuron restrictive silencer factor; 
ZEB1 – zinc finger E-box binding homeobox 1; CUTL1 – cut-like homeobox 1; NRF-2; nuclear respiratory 
factor 2. 
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Table 3.2 continued 
Characteristic Summary of GeneCards® results 
Autophagy protein 5 (ATG5) 
Alternative names Apoptosis specific protein; autophagy related 5 homolog (S. 
cerevisiae) 
Cellular location of protein Cytosol; autophagic vacuole; protein complex 
Molecular function Required for autophagy; possible role in modification of 
cytoskeleton during apoptosis; protein binding 
Molecular process  Autophagy; blood vessel remodelling; negative regulation of 
apoptosis; heart contraction 
Cellular pathways Regulation of autophagy; RIG-I-like receptor signalling pathway; 
shigellosis 
Protein domains Autophagy-related protein 5  
Protein-protein interactions SIRT1; FADD; CASP8; RIPK1; ATG12; ATG10 
Predicted transcription factor 
binding sites 
ATF-2; p53; Hlf; c-Jun; NFIL3 
cAMP-specific 3’,5’-cyclic phosphodiesterase 7B (PDE7B) 
Alternative names Phosphodiesterase 7B; rolipram-insensitive phosphodiesterase 
type 7 
Cellular location of protein Cytosol 
Molecular function Hydrolyses cAMP; phosphoric diester hydrolase activity; 3’,5’-
cyclic nucleotide phosphodiesterase activity 
Molecular process  Signal transduction; synaptic transmission 
Cellular pathways cAMP-signalling; protein kinase A signalling; GPCR signalling; 
purine metabolism 
Protein domains 3’,5’-cyclic nucleotide phosphodiesterase; HD/PDEase 
Protein-protein interactions ADK; GUK1; GMPR; ITPA; ADCY1 
Predicted transcription factor 
binding sites 
Chx10; POU2F1; ALX1 
SIRT1 – sirtuin 1; FADD – Fas-associated death domain protein; CASP8 – caspase 8; RIPK1 – receptor 
interacting serine/threonine-protein kinase 1; ATG12 – autophagy protein 12; ATG10 – autophagy protein 
10; ATF-2 – activating transcription factor 2; Hlf – hepatic leukaemia factor; NFIL3 – nuclear factor interleukin 
3 regulated; cAMP – cyclic adenosine monophosphate; GPCR – G-protein coupled receptor; ADK – 
adenosine kinase; GUK1 – guanylate kinase 1; GMPR – guanosine monophosphate reductase; ITPA – 
inosine triphosphatase; ADCY1 – adenylate cyclase 1; Chx10 – Ceh-10 homeodomain-containing homolog; 
POU2F1 – POU class 2 homeobox 1; ALX1 – ALX homeobox 1. 
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Table 3.2 continued 
Characteristic  Summary of GeneCards® result 
Gamma-glutamyl hydrolase (GGH) 
Alternative names Conjugase; gamma-Glu-X-carboxypeptidase 
Cellular location of protein Extracellular region; lysosome; cytosol; melanosome 
Molecular function Hydrolysis of folylpoly-gamma-glutamates; exopeptidase 
activity; omega peptidase activity; hydrolase activity; gamma-
glutamyl-peptidase activity 
Molecular process  Glutamine metabolic process; response to zinc ion; response to 
insulin stimulus; response to ethanol 
Cellular pathways Folate biosynthesis 
Protein domains Peptidase C26, gamma-glutamyl hydrolase; peptidase C26 
Protein-protein interactions MYC; CEBPA; GH1; GSTM1; GSTK1; MGST1 
Predicted transcription factor 
binding sites 
c-Jun; p53; ATF-2; CUTL1; DDIT3; Chx10 
MYC – Myc proto-oncogene protein; CEBPA – CCAAT/enhancer binding protein (C/EBP) alpha; GH1 – 
growth hormone 1; GSTM1 – glutathione S-transferase mu 1;  GSTK1 – glutathione S-transferase kappa 1; 
MGST1 – microsomal glutathione S-transferase 1; ATF-2 – activating transcription factor 2; CUTL1 – cut-like 
homeobox 1; DDIT3 – DNA-damage-inducible transcript 3; Chx10 – Ceh-10 homeodomain-containing 
homolog.  
Based on the results obtained from the BLAST and GeneCards® searches, two candidate genes 
were selected for further bioinformatic analysis, namely AHNAK and SAAL1. Even though the 
alignments for AHNAK were short and presented with high E-values, the gene was also identified 
in the BLAST searches performed by a fellow researcher (Molenaar, 2012). These searches were 
also performed with sequences obtained from promoter-trap mutagenesis experiments and as 
mentioned previously, the alignments were considerably longer. The alignment to the AHNAK gene 
was 152 bp in length and had an E-value of 4 x 10-57 (Fig. 3.1). In addition, the BLAST searches 
were performed against both the mouse and human genomic and transcript databases. These 
results confirm AHNAK as a candidate gene. The GeneCards® search revealed predicted 
transcription factor binding sites for p53 and c-Myc and the gene is suggested to play a role in 
neuronal cell differentiation. As mentioned previously, very little information was obtained for 
SAAL1 with the GeneCards® search, although the gene is predicted to have a transcription factor 
binding site for c-Myc. SAAL1 was however also identified as a candidate gene by a fellow 
researcher (Fig. 3.2) (Molenaar, 2012). In addition to the significant results obtained from the 
BLAST searches, these two genes were selected based on their novelty to the apoptotic process, 
as confirmed with the GeneCards® search. Further bioinformatic analysis with databases 
containing known and predicted data may thus potentially assist in the functional annotation of 
these genes, especially for SAAL1, and may provide more substantial links to apoptosis. 
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Figure 3.1: BLAST search results of sequence RM118 showing verification of AHNAK as a candidate gene. 
Sequence was obtained from promoter-trap mutagenesis experiments and BLAST searched against the 
human genomic and transcript database using the BLASTn tool in the NCBI webpage. 
 
 
Figure 3.2: BLAST search result of sequence RM289 showing verification of SAAL1 as a candidate gene. 
Sequence was obtained from promoter-trap mutagenesis experiments and BLAST searched against the 
human genomic and transcript database using the BLASTn tool in the NCBI webpage. 
3.3.2 Bioinformatic analysis of selected candidate genes 
Bioinformatic analyses investigating potential protein-protein interactions and cellular pathways 
were performed for four candidate genes. In addition to AHNAK and SAAL1, LIAS and CYPA were 
selected for these analyses. These genes were identified in the pilot study and, unlike RPL9, the 
apoptotic resistance effect accompanying the knockdown of these genes were verified in diploid 
mouse cells, as described in chapter 2. The results obtained from the analysis were further 
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investigated by determining the molecular function or role of each protein interactant or cellular 
pathway by means of searches in either the GeneCards®, NCBI Entrez Gene, UniProtKB or 
InterPro databases. 
Investigating the protein interactions for AHNAK revealed a total of 153 interactions across all five 
databases (table 3.3). These included a combination of 52 known and 101 predicted interactions. 
Several interactions presenting a potential link to apoptosis were also found; in total, 12 different 
interacting proteins were identified in addition to four domain signatures. Based on the results 
obtained from the databases, it would seem that AHNAK might have an impact on apoptosis by 
playing a role in control of cellular growth and survival, since several of the protein interactants 
function in these processes. For instance, AHNAK was shown to interact with both the human and 
mouse homologs of cyclin dependent kinase 1 (CDK1) as well as cyclin dependent kinase 2 
(CDK2). These proteins are crucial to the control of the cell cycle and are known to phosphorylate 
proteins such as p53, the Myc proto-oncogene protein (MYC) and the baculoviral IAP repeat 
containing 5 (BIRC5) protein, which is a member of the inhibitor of apoptosis (IAP) family. CDK1 
has the ability to trigger apoptosis upon DNA damage by phosphorylating Bcl-XL, while 
phosphorylation of caspase 8 by CDK1 inhibits its activation and subsequent apoptosis. An 
interaction with a related protein, cyclin dependent kinase inhibitor 2A (CDKN2A), was also 
revealed. Referred to as a tumour suppressor, this protein promotes apoptosis by sequestering 
and inhibiting Mdm2 p53 E3 ubiquitin protein ligase homolog (MDM2), the protein responsible for 
p53 degradation. Other interactants that function in cellular growth and survival include epidermal 
growth factor receptor (EGFR), MYC, cell division cycle 5-like protein (CDC5L), v-akt murine 
thymona viral oncogene homolog 1 (AKT1), S100 calcium binding protein B (S100B) and tyrosine-
protein kinase Yes (YES1). The EGFR activates numerous signalling cascades, including the Ras, 
AKT and protein kinase C (PKC) pathways, which regulate cell growth and survival. The MYC 
protein functions in the regulation of gene transcription and may promote the transcription of 
growth-related genes. CDC5L is a DNA binding protein participating in the control of the cell cycle 
and may also potentially be a transcription factor. AKT1 has been shown to regulate numerous 
processes, including metabolism, growth, proliferation, angiogenesis and cell survival. The protein 
is also capable of preventing apoptotic induction through inhibiting components of the apoptotic 
machinery by means of phosphorylation. S100B participates in the control of cell cycle progression 
and differentiation and has been associated with certain diseases including type I diabetes, 
Alzheimer’s disease, amyotrophic lateral sclerosis, melanomas and other neoplastic diseases. 
Lastly, the non-receptor protein tyrosine kinase YES1 plays a role in regulating cell-cell adhesion, 
cytoskeleton remodelling and apoptosis as well as cellular differentiation, growth and survival. It 
also participates in the FasL signalling pathway and mediates AKT-mediated cell migration. Among 
all of the interactions that suggested a potential role for AHNAK in the regulation of cell growth and 
survival, only two were predicted interactions, namely those with Cdk1 (the mouse homolog of  
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Table 3.3: Results obtained from the bioinformatic analysis investigating the protein interactions for AHNAK 
 All interactions Interactions with possible ties to apoptosis 
Database No. of inter-
actions 
Known/ 
experimental 
Predicted Interactant 
from human 
Interactant from 
other organism 
No. of inter-
actions 
Interactants 
IntAct 17 5 12¥ 7 10 4 Cdk1; EGFR; MYC; CDC5L 
STRING 5 5 - 5 - 4 CDKN2A; AKT1; S100B; XRCC4 
BioGRID 21 21 - 16 5 4 CDK2; CDK1; EGFR; S100B 
DOMINE 98 9 23 HCP; 
11 MCP; 
55 LCP 
N/A N/A 4 Protein kinase C-terminal; protein-tyrosine 
phosphatase, receptor/non-receptor type; 
leucine-rich repeat; pleckstrin homology 
domain 
I2D 12 12 - 12 - 6 EGFR; S100B; YES1; APC; XRCC4; 
CDKN2A 
HCP – high confidence predictions; MCP – medium confidence predictions; LCP – low confidence predictions; N/A – not applicable; ¥ - interactions expanded by 
spoke model; Cdk1 – Cyclin dependent kinase 1 (mouse); EGFR – epidermal growth factor receptor; MYC – Myc proto-oncogene protein; CDC5L – cell division 
cycle 5-like protein; CDKN2A – cyclin dependent kinase inhibitor 2A; AKT1 – v-akt murine thymona viral oncogene homolog 1; S100B – S100 calcium binding 
protein B; XRCC4 – X-ray repair complementing defective repair in Chinese hamster cells 4; CDK2 – cyclin dependent kinase 2; CDK1 – cyclin dependent kinase 1 
(human); YES1 – tyrosine-protein kinase Yes; APC – adenomatous polyposis coli protein. 
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human CDK1) and MYC, which were identified by the IntAct database following the spoke 
expansion model. This model uses an algorithm to expand the interactions in a protein complex, 
identified by experimental methods such as tandem affinity purification, into a set of artefactually 
created binary interactions. Since this model assumes that every prey molecule interacts with the 
bait molecule, these interactions needs to be verified. The remaining two interactions that link 
AHNAK to apoptosis is the X-ray repair complementing defective repair in Chinese hamster cells 4 
(XRCC4) protein and the adenomatous polyposis coli (APC) protein. XRCC4 is essential to non-
homologous end joining, a process that repairs double strand DNA breaks and is required for 
normal development and tumour suppression, while APC is described as a tumour suppressor due 
to its role in processes such as transcriptional regulation, cell adhesion and migration as well as 
apoptosis. Four domain interactions was revealed for the PDZ domain located in AHNAK, including 
an interaction of medium confidence for the pleckstrin homology domain and high confidence 
interactions for the remaining three domains. The results obtained from the DOMINE database 
supports those obtained from the other databases since the majority of these domains implicate 
the interacting proteins identified by the other databases. The protein kinase C-terminal domain is 
found in protein kinases, enzymes responsible for the phosphorylation of proteins, and is thus 
associated with cellular processes such as differentiation, division, proliferation and apoptosis. In 
addition, the protein-tyrosine phosphatase receptor/non-receptor type domain which catalyses the 
opposite reaction of that of the protein kinase C-terminal domain, is also associated with the same 
cellular processes. The pleckstrin homology domain supports a protein-protein interaction with 
AKT1, since this domain is found in this AKT1. Lastly, the leucine-rich repeat domain can be found 
in a variety of proteins, including those involved in DNA repair and apoptosis. Even though 
potential links to apoptosis was found for AHNAK with the protein interaction databases, the search 
for cellular pathways was unsuccessful. AHNAK was not found to be involved in any cellular 
pathways by all four databases, indicating that the individual binary interactions for AHNAK still 
needs to be expanded and incorporated into cellular pathway databases.  
As with the initial GeneCards® search, the database searches for SAAL1 revealed very little 
information. No cellular pathways was identified with the pathway databases and, compared to 
AHNAK, considerably less protein interactions was identified (table 3.4). Across the databases, the 
number of protein interactions identified ranged between one and seven, while the DOMINE 
database did not produce any results. Only three protein interactions proved to be of relevance to 
apoptosis, namely those with ubiquitin specific peptidase 19 (USP19), pleckstrin homology-like 
domain family A member 3 (PHLDA3) and neural precursor cell expressed developmentally down-
regulated 4 E3 ubiquitin protein ligase (NEDD4). Interactions with PHLDA3 and NEDD4 were both 
known, while the interaction with USP19 was identified by the spoke expansion model by the IntAct 
database. However, known interactions between SAAL1 and USP19 were identified by other 
databases, thus confirming this interaction. In total, USP19 was identified by four databases, while 
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Table 3.4: Results obtained from the bioinformatic analysis investigating the protein interactions for SAAL1 
 All interactions Interactions with possible ties to apoptosis 
Database No. of inter-
actions 
Known/ 
experimental 
Predicted Interactant 
from human 
Interactant from 
other organism 
No. of inter-
actions 
Interactants 
IntAct 5 3 2¥ 3 2 2 USP19; PHLDA3 
STRING 1 1 - 1 - 1 USP19 
BioGRID 7 7 - 6 1 2 NEDD4; USP19 
DOMINE - - - - - - - 
I2D 4 4 - 4 - 2 USP19; PHLDA3 
¥ - interactions expanded by spoke mode; USP19 – ubiquitin specific peptidase 19; PHLDA3 – pleckstrin homology-like domain family A member 3; NEDD4 – neural 
precursor cell expressed, developmentally down-regulated 4, E3 ubiquitin protein ligase.  
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PHLDA3 was identified twice and NEDD4 only once. The deubiquitinating enzyme USP19 
regulates the degradation of numerous proteins as well as the stability of two members of the IAP 
family, namely BIRC2 and BIRC3. It is also associated with the regulation of the cell cycle by 
promoting the degradation of cyclin-dependent kinase inhibitor 1 B (CDKN1B). The PHLDA3 
protein is suggested to be a tumour suppressor. The protein is directly regulated by p53 and 
functions by inhibiting AKT1 translocation and activation. PHLDA3 thus mediates p53-dependent 
apoptosis by means of AKT1 inhibition. Lastly, NEDD4 is an ubiquitin-protein ligase and regulates 
the degradation of proteins by means of ubiquitination. NEDD4 targets the degradation of insulin-
like growth factor 1 receptor (IGF1R) and fibroblast growth factor receptor 1 (FGFR1). The former 
is referred to as an anti-apoptotic agent since it enhances cell survival, while the latter is involved 
in cellular differentiation, proliferation and migration. NEDD4 also regulates the degradation of the 
EGFR. Based on these interactions, one can suggest that SAAL1 may also have an impact on 
apoptosis by regulating cell survival since this seems to represent a common theme among the 
protein interactions. 
Among the four databases used for the identification of cellular pathways, only Reactome yielded 
results for CYPA. A total of nine pathways were identified; however, none of these seem to 
implicate CYPA in apoptosis. The majority of the pathways support an immunological function for 
CYPA, especially with regards to HIV infection. CYPA was shown to take part in the early phase of 
the HIV life cycle (REACT_6266.5) while five other pathways identified by the database clustered 
beneath this pathway. In addition, CYPA was also shown to take part in apolipoprotein B mRNA-
editing, enzyme-catalytic, polypeptide-like 3G (APOBEC3G)-mediated resistance to HIV-1 infection 
(REACT_9406.2). The basigin interactions pathway was also identified; here, CYPA binds basigin 
to form the basigin precursor molecule (REACT_12560.3). Lastly, the platelet degranulation 
pathway was identified where CYPA is inferred to be one of the cytosolic components released 
from the platelet cell (REACT_318.7). Based on the descriptions of these pathways, there seems 
to be no link to apoptosis for CYPA. The database searches for protein interactions was however 
more successful (table 3.5). A total of 238 interactions were identified across all five databases, of 
which the majority were known interactions. The I2D database identified the largest amount of 
interactions, that is, 78 interactions of which only one was predicted. Among the interactions 
showing potential links to apoptosis were some that were identified more than once by different 
databases, and thus the investigation identified 26 different protein interactants with potential links 
to apoptosis. As with the other candidate genes, a common theme is also present among the 
identified protein interactants; many of these proteins are involved in cellular proliferation and 
survival as well as processes associated with DNA damage, including preventing, inducing or 
repairing damage. The protein interactant with the most pronounced association with apoptosis 
also conforms to this theme, namely apoptosis inducing factor 1 mitochondrial (AIFM1), or AIF. 
This interaction was identified with both the human and mouse homologs by the IntAct database. 
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Table 3.5: Results obtained from the bioinformatic analysis investigating the protein interactions for CYPA 
 All interactions Interactions with possible ties to apoptosis 
Database No. of inter-
actions 
Known/ 
experimental 
Predicted Interactant 
from human 
Interactant from 
other organism 
No. of inter-
actions 
Interactants 
IntAct 46 19 27¥ 32 14 8 GABARAP; APP; H2AFX; AIFM1; Cdk1; 
Aifm1; RAD52; PCNA 
STRING 15 14 1* 15 - 3 APP; RB1; PCNA 
BioGRID 47 47 - 38 9 7 CDK2; COPS5; Cdk1; H2AFX; PAF; 
MAD2L1BP; PCNA 
DOMINE 52 5 7 HCP; 
11 MCP; 
29 LCP 
N/A N/A 4 Histone core; leucine-rich repeat; cell 
division binding GTP binding; histone H4 
acetyltransferase, NuA4 complex, Eaf6 
I2D 78 77 1 78 - 17 PDPK1; FOXO3; GABARAP; APP; RB1; 
H2AFX; DDIT3; PRKAA2; TRAF2; STK4; 
PRKAA1; STK3; SQSTM1; STK11; 
RB1CC1; RASSF5; ATG5 
HCP – high confidence predictions; MCP – medium confidence predictions; LCP – low confidence predictions; N/A – not applicable; ¥ - interactions expanded by 
spoke mode; * - based on co-expression evidence type; GABARAP – gamma-aminobutyric acid receptor-associated protein; APP – amyloid beta A4 protein; H2AFX 
– histone H2A.x; AIFM1 – apoptosis-inducing factor 1, mitochondrial; Cdk1 – cyclin dependent kinase 1 (mouse); Aifm1 – apoptosis inducing factor 1, mitochondrial 
(mouse); RAD52 – DNA repair protein RAD52 homolog; PCNA – proliferating cell nuclear antigen; RB1 – retinoblastoma 1; CDK2 – cyclin dependent kinase 2; 
COPS5 – COP9 constitutive photomorphogenic homolog subunit 5; PAF – PCNA-associated factor; MAD2L1BP – mitotic arrest deficient 2-like protein 1 (MAD2L1)-
binding protein; PDPK1 – 3-phosphoinositide-dependent protein kinase 1; FOXO3 – forkhead box protein 3; DDIT3 – DNA-damage-inducible transcript 3; PRKAA2 – 
5’-AMP-activated protein kinase catalytic subunit alpha-2; TRAF2 – tumour necrosis factor (TNF)-receptor associated factor 2; STK4 – serine/threonine protein 
kinase 4; PRKAA1 – 5’AMP-activated protein kinase catalytic subunit alpha-1; STK3 – serine/threonine protein kinase 3; SQSTM1 – sequestosome-1; STK11 – 
serine/threonine protein kinase 11; RB1CC1 – retinoblastoma 1 (RB1)-inducible coiled coil protein 1; RASSF5 – ras association domain-containing protein 5; ATG5 
– autophagy protein 5. 
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AIF is a major facilitator of caspase-independent apoptosis by binding to and fragmenting 
chromosomal DNA in a sequence-independent matter. AIF is also capable of activating caspase 7, 
thus amplifying the apoptotic process. The kinases Cdk1 and CDK2 were also identified and as 
mentioned previously, these proteins are important regulators of the cell cycle as well as the 
activity of p53 and BIRC5 by means of phosphorylation. The variant histone H2A.x (H2AFX) is 
present in a subset of nucleosomes. In general, histones are important regulators of transcription 
and are also involved in DNA replication, DNA repair and the maintenance of chromosomal 
stability. The DNA repair protein RAD52 homolog (RAD52) functions in genetic recombination and 
DNA repair by participating in the repair of double-stranded breaks. Proliferating cell nuclear 
antigen (PCNA) is vital to the DNA damage response by positioning itself at the replication fork and 
coordinating DNA replication with DNA repair and DNA damage tolerance pathways. 
Retinoblastoma 1 (RB1) is a well-known tumour suppressor and functions by regulating entry into 
cell division. The RB1-inducible coiled-coil protein 1 (RB1CC1) was also identified by the 
databases. This protein is a DNA-binding transcription factor and an important regulator of the RB1 
pathway. Another protein interactant involved in cell division is mitotic arrest deficient-like 1 
(MAD2L1)-binding protein (MAD2L1BP). This protein may be involved in the silencing of the 
spindle checkpoint, thus allowing mitosis to proceed. Referred to as a master kinase, 3-
phosphoinositide-dependent protein kinase 1 (PDPK1) plays a vital role in the control of cell 
proliferation and survival by phosphorylating and subsequently activating AKT1. The DNA-
damage-inducible transcript 3 (DDIT3) is a transcription factor and member of the 
CCAAT/enhancer-binding protein (C/EBP) family. DDIT3 prevents the binding of C/EBP 
transcription factors to DNA and also promotes apoptosis. Both the 5’-AMP-activated protein 
kinase catalytic subunit alpha 1 (PRKAA1) and 2 (PRKAA2) were identified by the protein 
interaction databases. As their names suggests, these proteins form the catalytic subunit of the 
AMP-activated protein kinase (AMPK), an essential regulator of cell growth and proliferation upon 
energy-deficient circumstances. The kinase is known to phosphorylate numerous proteins, 
including p53. Tumour necrosis factor (TNF) receptor-associated factor 2 (TRAF2) plays a key role 
in regulating cellular survival and apoptosis by regulating the activation of nuclear factor kappa B 
(NFκB) and Jun N-terminal kinase (JNK). The protein also has the ability to prevent the 
degradation of BIRC2 and BIRC3. The I2D database identified interactions with three 
serine/threonine kinases (STK), namely STK3, STK4 and STK11, and all three are pro-apoptotic 
kinases. STK3 and STK4 are stress-activated kinases that, upon apoptotic stimuli, translocate to 
the nucleus to induce chromatin condensation and DNA fragmentation. They are also capable of 
inhibiting AKT1. STK11 is referred to as a tumour suppressor kinase and is known to play a role in 
DNA damage response and apoptosis. STK11 is also a mediator of p53-mediated apoptosis. 
Finally, sequestosome 1 (SQSTM1) is potentially involved in cellular differentiation and apoptosis 
by regulating the activation of NFκB. Other protein interactants that can be associated with 
apoptosis by means other than cellular proliferation and DNA damage processes include gamma-
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aminobutyric acid receptor-associated protein (GABARAP), amyloid beta A4 protein (APP), COP9 
constitutive photomorphogenic homolog subunit 5 (COPS5), PCNA-associated factor (PAF), 
forkhead box protein 3 (FOXO3), Ras association domain-containing protein 5 (RASSF5) and 
autophagy protein 5 (ATG5). GABARAP is involved in the transport of GABA receptors and plays a 
role in apoptosis. APP is associated with pathways known to induce apoptosis, such as the JNK-
interacting protein (JIP)-mediated pathway. The COPS5 protein is likely a subunit of the COP9 
signalosome complex (CSN) which is known to play a role in the phosphorylation of p53 and c-Jun, 
a proto-oncogene. PAF is likely to provide protection from cell death induced by UV-light. FOXO3 
is a transcription factor known to induce apoptosis in the absence of survival factors. As mentioned 
previously ATG5 may be involved in apoptosis through modifications of the cytoskeleton. Lastly, 
RASSF5 is described as a tumour suppressor. The DOMINE databases also identified domain 
interactions for the pro-isomerase domain located in CYPA that may provide links to apoptosis. 
Two of these domain interactions are associated with and the modification of histones. The histone 
core domain is found in numerous histone proteins while the histone H4 acetyltransferase Nu4 
complex Eaf6 family signature is associated with the acetylation of histones and is thus involved in 
regulation of transcription, DNA damage response and cell cycle control. Another family signature, 
cell division protein GTP binding, is involved in cell cycle control, while the leucine-rich repeat, as 
mentioned previously, can be associated with apoptosis.  
Compared to those of AHNAK and CYPA, fewer results were obtained from the bioinformatic 
analysis for LIAS. Investigating the cellular pathways for LIAS identified a single pathway 
representing lipoic acid metabolism, as revealed by KEGG (hsa00785), HumanCyc (HS04528) and 
UniPathway (UPA00538). This pathway entails the biosynthesis of lipoic acid and subsequent 
lipoylation of lipoate-dependent enzymes, in which LIAS plays a central role. However, as with 
CYPA, there seems to be no link to apoptosis. With regards to the protein interactions, 63 
interactions were identified of which the majority were predicted interactions (table 3.6). Both the 
IntAct and BioGRID databases failed to produce any results and only four proteins interactions 
were identified that revealed potential links to apoptosis. These interactions were predicted by the 
STRING and I2D databases. Cyclin-dependent kinase 5 (CDK5) regulatory associated protein 1 
(CDK5RAP1) is a specific inhibitor of CDK5 and plays an important role in cell cycle arrest in 
neurons and is also known to phosphorylate p53 and regulate Bcl-2. The DNA replicating licensing 
factor MDM2 (MDM2) is essential for the control of DNA replication initiation and elongation and is 
required for cell division. The protein interactant with the most pronounced association with 
apoptosis is likely to be that of guanine nucleotide-binding protein subunit beta-2-like 1 (GNB2L1). 
This protein is capable of inducing apoptosis by disrupting the interaction between Bcl-2L and Bax, 
thereby promoting Bax oligomerisation. Finally, protein arginine N-methyltransferase 1 (PRMT1) is 
an arginine methyltransferase capable of inhibiting signal transducer and activator of transcription 
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Table 3.6: Results obtained from the bioinformatic analysis investigating the protein interactions for LIAS 
 All interactions Interactions with possible ties to apoptosis 
Database No. of inter-
actions 
Known/ 
experimental 
Predicted Interactant 
from human 
Interactant from 
other organism 
No. of inter-
actions 
Interactants 
IntAct - - - - - - - 
STRING 31 3 28* 31 - 1 CDK5RAP1 
BioGRID - - - - - - - 
DOMINE 19 5 3 HCP; 
11 LCP 
N/A N/A - - 
I2D 13 - 13 13 - 3 MCM2; GNB2L1; PRMT1 
HCP – high confidence predictions; LCP – low confidence predictions; N/A – not applicable; * - based on neighbourhood, fusion, co-occurrence, homology and co-
expression evidence types; CDK5RAP1 – cyclin dependent kinase 5 regulatory associated protein 1; MCM2 – minichromosome maintenance complex 2; GNB2L1 – 
guanine nucleotide-binding protein subunit beta-2-like 1; PRMT1 – protein arginine N-methyltransferase 1. 
Stellenbosch University  http://scholar.sun.ac.za
 114 
 
1 (STAT1), a transcription factor involved in the regulation of cellular differentiation, growth and 
survival. 
3.4 Conclusions 
Since the start of the bioinformatics era, this continually expanding field of study has made 
significant contributions to the understanding of the genome, including the analysis of high-
throughput data, assigning gene/protein annotations, building and exploring protein structures and 
providing knowledgebases that conveniently collects and integrate biological data while making it 
available to the everyday researcher. In particular, databases have been created covering almost 
every area of research and have become valuable tools that aid and complement molecular 
techniques. As described in this chapter, a bioinformatic approach was used to identify candidate 
genes with a potential role in apoptosis. Nucleotide sequences, obtained from the promoter-trap 
mutagenesis experiments performed in the pilot study, were analysed by means of the BLASTn 
tool to identify gene-specific sequences within the nucleotide sequences. The identified candidate 
genes were investigated by means of the GeneCards® database, and two candidate genes, 
AHNAK and SAAL1, were selected for further analysis based on their novelty to the apoptotic 
process. In addition, two candidate genes, LIAS and CYPA, previously identified in the pilot study 
were also included. A total of nine databases were selected to investigate protein interactions and 
cellular pathways for the four selected candidate genes with the aim of identifying a potential role 
for these genes in apoptosis.  
The BLAST analysis were successful for only three alignments, however results obtained in a 
study performed by a fellow researcher supported the identification of SAAL1 and AHNAK as 
candidate genes (Molenaar, 2012). The fact that three of the candidate genes, namely, LIAS, 
SAAL1 and AHNAK, were identified more than once in the BLAST searches performed with 
nucleotide sequences, whether in this study, the study performed by the fellow researcher or in the 
pilot study, provides increasing support for a potential role for these genes in apoptosis.  
The bioinformatic analysis investigating protein interactions and cellular pathways were successful, 
albeit more for AHNAK and CYPA than for SAAL1 and LIAS. The use of a number of different 
databases provided a good representation of the available data and even though some interactions 
or pathways were identified more than once by different databases, the majority were identified by 
only a single database. This highlights the heterogeneity present in the construction of 
bioinformatic databases and the different results they produce; it would thus seem advantageous 
to use more than one database when investigating a particular area of interest. A combination of 
both known, or experimentally verified, and predicted interactions was obtained by the protein 
interaction databases. Known interactions are of course important when expanding and exploring 
the larger biological context of a particular protein, but predicted interactions might prove to be of 
more value when annotating a gene with little known information or when assigning a gene/protein 
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to a new pathway/process. Predicted protein interactions provide clues to the function of a protein 
and may also implicate the protein in a cellular pathway. In addition, predicted interactions provide 
a foundation for molecular techniques that aims to experimentally ascertain an annotation for a 
gene/protein. In this study, the majority of the protein interactions identified for LIAS were 
predicted, including those with potential links to apoptosis. Even though a known function for LIAS 
exists, as confirmed by the results obtained from the cellular pathway investigation, these predicted 
interactions may suggest additional functions for LIAS.  
Several potential links to apoptosis were identified for the candidate genes, although they remain 
to be verified experimentally especially since the majority of them were of an indirect nature. An 
indirect link refers to a protein interactant which is primarily involved in a different process or 
pathway but can also have an impact on the apoptotic process, whether this impact would be 
consequence of the protein’s primary role or not. In contrast, direct links would be to proteins which 
are primarily involved in the apoptotic process itself, either as an inducer or mediator. Examples of 
the indirect links are the commonly identified cyclin dependent kinases, PRMT1, RAD52, USP19, 
EGFR and many others. Examples of direct links would be AIFM1, FOXO3, STK3 and STK4. In 
general, a common theme was present among the majority of the protein interactants for the 
candidate genes. Most of these proteins were involved cell cycle control, cellular proliferation, 
growth and survival. A number of transcriptional regulators were also identified. This observation 
highlights the fact that even though a core set of apoptotic molecules exist, the process can be 
affected by a multitude of other proteins. In addition it also supports the reality the cell death and 
cell proliferation/survival is a tightly regulated and complex balance beam.  
Future applications of the results described in this chapter include perhaps additional bioinformatic 
analyses, investigating other areas of interest such as gene expression and transcriptional 
regulation. Indeed, exploring these results by means of molecular techniques would assist in 
verifying the candidate genes’ involvement in apoptosis as well as aiding in their annotation, 
especially with regards to SAAL1 and LIAS.  
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Chapter 4: Investigating the gene expression of the novel candidate genes in two 
cancer cell lines 
 
4.1 Introduction 
Quantitative PCR (qPCR), or real-time PCR, is a modification of the traditional end-point PCR 
technique that allows for the concurrent detection and quantification of a DNA template in real time 
(Pfaffl, 2001). Following its first report in 1993, qPCR has since become the method of choice for 
measuring gene expression; however, its usefulness is not restricted to gene expression studies 
(Derveaux et al., 2010; Higuchi et al., 1993). Other applications of qPCR includes the validation of 
gene expression microarrays, copy number determination for genomic or viral DNA, allelic 
discrimination assays and mutation detection (Arya et al., 2005; Valasek and Repa, 2005). The 
ability of qPCR to produce accurate results across a dynamic range of several log orders of 
magnitude, as well as its impressive sensitivity and precision, are three important advantages of 
qPCR (Arya et al., 2005; Wong and Medrano, 2005). In addition, relatively high-throughput can 
also be obtained with the proper instrumentation (Wong and Medrano, 2005).  
Central to the qPCR technique is the use of fluorescent chemistries that bind to the template in 
either a non-specific or specific manner. The most popular non-specific chemistry used today is 
SYBR® Green I. This intercalating dye emits its fluorescent signal upon binding to the minor groove 
of double-stranded DNA (dsDNA) in a sequence-independent manner (Arya et al., 2005; Morrison 
et al., 1998). The dye is relatively cheap and can be incorporated into established and optimised 
protocols (Bustin and Nolan, 2004). A major disadvantage of SYBR® Green I is however nested 
within its nature; since the dye binds non-specifically to dsDNA, fluorescent signals are also 
emitted upon binding to miss-primed amplification products and primer-dimers. This necessitates a 
melting curve analysis, plotting fluorescence as a function of temperature, in order to determine the 
presence of the target amplicon by means of its melting temperature (TM) (Arya et al., 2005; 
Kubista et al., 2006). Specific chemistries entail the design and synthesis of sequence-specific 
fluorescently-labelled probes, which can prove to be very costly (Bustin and Nolan, 2004). 
However, since the emission of a fluorescent signal is dependent on the annealing of the probe to 
the specific target, potential false signals are avoided (Arya et al., 2005; Bustin and Nolan, 2004). 
In addition, the specificity of the probes make them amendable to multiplex reactions where 
multiple probes labelled with different fluorescent dyes can be included in one reaction (Arya et al., 
2005). The majority of these chemistries are designed around fluorescence resonance energy 
transfer (FRET) between a quencher and donor dye as the basis of its detection method (Bustin 
and Nolan, 2004). Examples of specific chemistries include Taqman® probes, dual hybridisation 
probes, molecular beacons and scorpions (Arya et al., 2005; Wong and Medrano, 2005).  
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The amplification process in qPCR follows the same phases as traditional PCR, and it is in the 
exponential phase, when optimal doubling of the template takes place in the absence of any 
limiting conditions, that quantification of the template takes place (Arya et al., 2005; Ginzinger, 
2002). Early in the exponential phase, an arbitrary threshold is set by the instrument based on the 
baseline of the experiment, the initial cycles where the accumulating fluorescence remains beneath 
the instrument’s limit of detection. As amplification proceeds, a cycle is reached where the 
fluorescent signal exceeds the threshold; a point that is defined as the cycling threshold, or CT, 
value. The CT values can then be extrapolated back to determine the initial amount of the template; 
the lower the CT value, the higher the amount of template present at the start of amplification (Fig. 
4.1) (Arya et al., 2005; Ginzinger, 2002).  
Three quantification strategies are commonly used to interpret the data generated by qPCR. The 
first method is referred to as absolute quantification, or the standard curve method, and is 
generally performed when the actual amount of the template needs to be measured such as in the 
determination of viral load in a diseased sample (Arya et al., 2005). In this method, the 
concentration of a target in an unknown sample is calculated from a standard curve generated by a 
set of standards for the specific target (Arya et al., 2005; Wong and Medrano, 2005). The 
remaining two methods are based on relative quantification, that is, the amount of template present 
in a sample is determined relative to that of a reference, which is normally a constitutively 
expressed reference gene (Valasek and Repa, 2005). In the relative standard curve method, 
otherwise known as the Pfaffl method, standard curves are also constructed for each of the target 
and reference genes, however, the curves are only used to the determine the efficiency of the 
qPCR reaction. The efficiency value is then incorporated into the calculation for the expression of a 
target gene relative to that of the reference gene(s) (Pfaffl, 2001). Due to the requirement of 
standard curves, the first two methods can be quite laborious and time consuming, especially when 
a large number of target genes are being investigated (Schmittgen and Livak, 2008). Lastly, the 
comparative CT method, or delta-delta CT method, was used in this study. This method is simpler 
when compared to the other two methods since it does not require the construction of standard 
curves; instead, it assumes a PCR efficiency of 100% or a value of two (i.e. optimal doubling of the 
PCR template in each cycle), which is then used for the calculation of relative gene expression. In 
addition, this method also assumes that the efficiencies of the reference gene(s) are similar to 
those of the target genes (Arya et al., 2005; Schmittgen and Livak, 2008). Thus, in order for this 
method to give an accurate ratio of the expression of a target gene relative to that of a reference 
gene, these two assumptions must hold true (Schmittgen and Livak, 2008). This is possible, for 
example, when using established and optimized primers and qPCR protocols where efficiencies 
have been calculated previously and shown to be comparable.  
This part of the study aimed to determine the relative expression of the novel candidate genes, 
LIAS, CYPA, AHNAK and SAAL1, in two cancer cell lines compared to matching control cell lines. 
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Figure 4.1: Illustration of an amplification plot obtained in qPCR depicting the estimation of the CT value. 
Obtained from http://www.langfordvets.co.uk/lab_pcr_ct_values.htm.  
This was done to aid in the characterisation of these genes and to determine whether they are 
differentially regulated in cancer. Since resistance to apoptosis is a central characteristic of 
tumours, this could also assist in the characterisation of the candidate genes in apoptosis 
resistance.  
 
4.2 Materials and methods 
4.2.1 Total RNA extraction and cDNA synthesis 
The sample material used in this part of the study originated from four cell lines, cultured and 
maintained at the UWC. These samples consisted of two cancer cell lines, namely Caki-1 (kidney 
cancer sample) and A549 (lung cancer sample), and two control cell lines, namely HEK293T 
(normal kidney sample) and MRC-5 (normal lung sample). Total RNA, extracted as described in 
section 2.2.1.6, was provided the collaborator Dr M. Meyer at the UWC.  
For cDNA synthesis, the Transcriptor First Strand cDNA Synthesis kit from Roche Applied 
Sciences was used and performed as described in section 2.2.1.7. A NanoDrop 
Spectrophotometer was used to determine the concentration, as well as integrity, of the 
synthesised cDNA. A 250 ng/µl dilution was prepared for each of the samples which were kept at 
4°C during use.  
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4.2.2 Quantitative PCR 
Quantitative PCR was performed to measure the expression levels of seven target genes and two 
reference genes. Target genes consisted of the four candidate genes, namely LIAS, CYPA, 
AHNAK and SAAL1, and also included three genes known to be involved in the apoptotic process, 
namely Bcl2 and caspase 3 (casp3) and 9 (casp9). The selected reference genes were GAPDH 
and ubiquitin C (UBC). The qPCR reactions were performed on the Applied Biosystems 
StepOnePlus™ (Life Technologies™) instrument at the Central Analytical Facility, University of 
Stellenbosch. The reactions were prepared with the KAPA SYBR® FAST qPCR Kit Master Mix (2 
x) ABI Prism™ (KAPA Biosystems) at a 1 x final concentration, to which specific primers and 250 
ng template cDNA were added; a final volume of 20 µl was obtained by the addition of ultrapure 
water. All primers were used at a final concentration of 200 nM, with the exception of the CYPA 
primers where a final concentration of 100 nM was used. Primer sequences and TA’s are listed in 
table 4.1. All reactions were performed in triplicate and non-template controls were included to 
control for contamination. The cycling parameters used for all qPCR reactions consisted of an 
initial enzyme activation step of 3 min at 95°C followed by a two-step cycling protocol with 
denaturation and annealing/elongation steps of 3 s at 95°C and 30 s at the primer-specific TA, 
respectively, which was repeated 45 times. A melt curve, ranging from 58°C to 95°C, was also 
performed after completion of the cycling protocol. Gel electrophoresis (50 min at 120 V) was 
performed with the qPCR amplification product on a 1.5% agarose gel.  
Since the primers used for the qPCR reactions have been optimised and successfully used before, 
the comparative CT method was used for the analysis of the qPCR results. This was done by 
making use of the freely available REST-384© (v. 1) software package (Pfaffl et al., 2002). This 
software performs a group-wise comparison between data for a sample and control group and 
performs a randomisation test to test for significant expression ratios. For the analysis, an 
assumed PCR efficiency of two was selected and the data was tested for significance by 
performing the recommended 2000 randomisations.  
 
4.3 Results and discussion 
4.3.1 Quantitative PCR 
During this part of the study, the relative expression levels of seven target genes were determined 
with qPCR; these genes are LIAS, CYPA, AHNAK, SAAL1, Bcl-2, casp3 and casp9. In addition, 
the UBC and GAPDH genes were also included to serve as reference genes. Intact and pure 
cDNA, as determined by the NanoDrop spectrophotometer, was used as the template material for 
the qPCR reactions. The samples originated from two cancer cell lines and two matched control 
cell lines. The use of sample matched controls allows for a comparison to be drawn between the 
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Table 4.1: Details of primers used for qPCR experiments 
Gene Primer 
orientation 
Primer sequence (5’-3’) Primer 
length (bp) 
Primer 
TA (°C) 
Product 
size (bp) 
GAPDH F TGATGACATCAAGAAGGTGGTGAAG 25 60 240 
R TCCTTGGAGGCCATGTGGGCCAT 23  
UBC F CGGTGAACGCCGATGATTAT 20 60 124 
R ATCTGCATTGTCAAGTGACGA 21  
LIAS F GCAACAATGAAAGCACTTCGTT 22 60 176 
R ACCAAAGGGCCACTTGCAGTA 21  
CYPA F GTTCTTCGACATTGCCGTCG 20 62 212 
R ACTTGCCACCAGTGCCATTA 20  
SAAL1 F TTGACAGCCTCATTCGGGTC 20 60 206 
R CTTTACTCCCTGAGCCACCG 20  
AHNAK F CAGTGTGCCCTCTGCCAATA 20 60 210 
R CCAGGCCCCTGAACATCAAT 20  
Casp3 F GGCCTGCCGTGGTACAGAAC 20 60 187 
R CAGCATGGCACAAAGCGACTG 21  
Casp9 F AGGCCCCATATGATCGAGGA 20 60 193 
R TCGACAACTTTGCTGCTTGC 20  
Bcl2 F GTCATGTGTGTGGAGAGCGT 20 60 192 
R AGTCTTCAGAGACAGCCAGGA 20  
F – forward; R – reverse; bp – base pair; TA – annealing temperature; °C – degrees Celcius. 
normal and malignant state of a particular cell line. The quantification of each gene was performed 
in triplicate in order to control for variation between reactions. For the most part, near-identical 
results were obtained from the triplicate reactions for each of the genes investigated as revealed 
by the amplification plots (Fig. 4.2). A melt curve was also performed on completion of the 
amplification cycling protocol. By measuring the fluorescence during a gradual increase in 
temperature, a specific TM is obtained for each amplification product in a sample; thus, if more than 
one product is present, for example in the case of non-specific binding by the primers or the 
formation of primer-dimers, more than one peak will be obtained. This additional step is especially 
important when using non-specific DNA-binding dyes such as SYBR® Green since the dye emits a 
fluorescent signal upon binding to any dsDNA template (Arya et al., 2005; Kubista et al., 2006). All 
triplicate reactions for each of the genes investigated revealed a single peak upon the melt curve 
analysis (Fig. 4.2).  
The selection of an appropriate constitutively expressed reference gene for qPCR analysis is of 
utmost importance. Since even minor, but inevitable, inter-sample variances can easily affect the 
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Figure 4.2: Representative example of an amplification plot (A) and melt curve (B) obtained during the qPCR 
reactions. The triplicate reactions for LIAS quantification in the lung cancer sample are displayed. Rn – 
normalised fluorescence.  
reliability of qPCR results, it is necessary to compensate for these differences by submitting all 
samples to normalisation with a reference gene (Arya et al., 2005; VanGuilder et al., 2008). An 
appropriate reference gene would exhibit constant expression in all tissues and under all 
conditions and would thus allow for the comparison of samples (Kubista et al., 2006; VanGuilder et 
al., 2008). Quite a large selection of reference genes is available today; however, many have been 
shown to be regulated in some tissues or under certain conditions (Arya et al., 2005; Pfaffl et al., 
2004). In this study, two genes, namely UBC and GAPDH, were selected as reference genes and 
were quantified in triplicate in all four samples. However, upon inspection of the results, differential 
expression was noted by investigating the amplification plots of both genes; large deviations in CT 
values was seen between the kidney control and kidney cancer samples for UBC, while GAPDH 
displayed large CT value deviations between the lung cancer and lung control samples. These 
results suggested regulation of UBC and GAPDH in these specific cancer samples. Based on the 
results, it was decided to use UBC as a reference gene for the lung samples only and GAPDH only 
for the kidney samples.  
The results obtained from the qPCR reactions were analysed in the REST-384© software package 
by following the comparative CT method for relative gene expression quantification. This method 
could be used since the gene-specific primers used in the qPCR reactions have been optimised 
before, achieving comparable PCR efficiencies (table A3). The fold change and absolute regulation 
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ratio, as well as the log2 value of the absolute regulation ratio, was calculated for each of the target 
genes. The software also tested for significant results by means of randomisation tests; target 
genes with a p-value less than 0.05 were deemed as showing significantly different gene 
expression in the cancer samples when compared to the matched control samples. In the lung 
cancer versus lung control samples, AHNAK (~ 600 fold) and Bcl-2 (~ 4 fold) showed significant 
up-regulation while LIAS (~ 24 fold) and Casp9 (~ 37 fold) showed significant down-regulation 
(table 4.2 and figure 4.3). CYPA (~ 1.5 fold) and SAAL1 (~ 1.2 fold) also showed slight up-
regulation with Casp3 (~ 1 fold) showing levels very similar to those in the control sample; 
however, these results were not statistically significant as determined by the randomisation tests. 
In contrast, all seven target genes (ranging between ~ 5 fold and ~ 96 fold) showed significant up-
regulation in the kidney cancer sample when compared to the kidney control sample (table 4.3 and 
figure 4.4).  
 
4.4 Conclusions 
The relative gene expression of seven target genes was successfully measured by means of 
qPCR and analysed by the comparative CT method with REST-384
©. The majority of the results 
revealed significant differential gene regulation in the two cancer cell lines as compared to the two 
control cell lines.  
Analysis of the relative expression of Bcl-2 revealed significant up-regulation in both the lung and 
kidney cancer samples (tables 4.2-4.3 and figures 4.3-4.4). This result is expected, since the gene 
has been shown to be overexpressed in numerous tumours, including cancers of the kidneys, 
breast, central nervous system, prostate and larynx (Placzek et al., 2010; Trask et al., 2002; 
Yoshino et al., 2006). Overexpression of Bcl-2 has also been associated with resistance to 
apoptosis, especially in cases of cytotoxic drug-resistant tumours (Azmi et al., 2011; Igney and 
Krammer, 2002). However, it is important to remember that Bcl-2 is not the only anti-apoptotic Bcl-
2 family member. Recently, a gene expression profile survey was conducted with all six anti-
apoptotic Bcl-2 family members across 68 cancer cell lines covering eight different tissue types; 
when compared to the other family members, particularly Mcl-1 and Bcl-XL, relatively low levels of 
Bcl-2 expression was observed and severe overexpression seemed to be limited to leukaemia cell 
lines (Placzek et al., 2010). These results suggest that when investigating the mechanism of 
apoptotic resistance in a particular cancer cell line or tissue, it is important to not limit the search to 
Bcl-2 but to also consider other members of the family such as Mcl-1 and Bcl-XL.  
Contrasting results were obtained for both casp3 and casp9. Significant down-regulation was 
observed for casp9 in the lung cancer sample with casp3 showing levels very similar to the control 
sample (table 4.2 and fig. 4.3). In contrast, significant up-regulation was observed for both genes in 
the kidney cancer sample (table 4.3 and fig. 4.4). It would be expected for both of these 
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Table 4.2: Descriptive results for the analysis of the relative gene expression of the seven target 
genes in the lung cancer sample as compared to the lung control sample 
Gene Sample Mean CT Std. error Fold change p-value Log2 
value 
Log2 std. 
error 
LIAS Control 20.21 0.12 -23.945 0.001 -4.582 7.749 
Cancer 24.38 0.08 
CYPA Control 27.74 0.01 1.493 0.514 0.578 3.098 
Cancer 26.75 0.09 
AHNAK Control 33.90 0.01 595.665 0.046 9.218 4.731 
Cancer 24.27 0.01 
SAAL1 Control 32.42 0.32 1.184 0.595 0.243 1.802 
Cancer 31.76 0.11 
Casp3 Control 27.12 0.12 -1.053 0.882 -0.075 3.329 
Cancer 26.78 0.08 
Casp9 Control 22.04 0.06 -36.716 0.024 -5.198 9.172 
Cancer 26.82 0.03 
Bcl2 Control 25.14 0.04 3.815 0.046 1.932 1.937 
Cancer 22.80 0.07 
CT – threshold cycle; Std. – standard.  
 
 
Figure 4.3: Relative expression ratio plot produced by the REST-384
©
 software showing the absolute 
regulation of the target genes in a log2 scale in lung cancer as compared to lung control. Values are the 
averages ± standard error of triplicate experiments. Target gene expression was normalised with the UBC 
reference gene. * indicates significant results for p < 0.05. 
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Table 4.3: Descriptive results for the analysis of the relative gene expression of the seven target 
genes in the kidney cancer sample as compared to the kidney control sample 
Gene Sample Mean CT Std. 
error 
Fold change p-value Log2 
value 
Log2 std. 
error 
LIAS Control 30.70 0.08 14.496 0.027 3.858 1.693 
Cancer 27.77 0.31 
CYPA Control 26.31 0.07 70.189 0.001 6.133 2.745 
Cancer 21.14 0.11 
AHNAK Control 29.42 0.06 95.538 0.001 6.578 2.411 
Cancer 23.77 0.01 
SAAL1 Control 31.13 0.21 4.702 0.001 2.233 0.501 
Cancer 29.83 0.04 
Casp3 Control 29.08 0.07 9.460 0.001 3.242 0.395 
Cancer 26.77 0.08 
Casp9 Control 30.74 0.23 45.615 0.001 5.511 2.926 
Cancer 26.16 0.05 
Bcl2 Control 26.39 0.02 73.534 0.001 6.200 2.527 
Cancer 21.12 0.10 
CT – threshold cycle; Std. – Standard. 
 
 
Figure 4.4: Relative expression ratio plot produced by the REST-384
©
 software showing the absolute 
regulation of the target genes in a log2 scale in kidney cancer as compared to kidney control. Values are the 
averages ± standard error of triplicate experiments. Target gene expression was normalised with the GAPDH 
reference gene. * indicates significant results for p < 0.05. 
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genes to display decreased expression in the cancer samples since this observation has been 
noted before in hepatocellular carcinoma, prostate and breast cancer for casp3 and prostate and 
colon cancer for casp9 (Huang et al., 2010; Nassar et al., 2008; Rodríguez-Berriguete et al., 2012; 
Sträter et al., 2010). However, variable levels of caspase expression in cancers are possible; 
casp9 was shown to be up-regulated in the lymphocytes of breast cancer patients while no 
significant changes was seen for casp1, casp3 and casp9 expression in prostate cancer tissues 
when compared to normal tissues (Khanna et al., 2004; Winter et al., 2001). In addition, apoptosis 
mediated by caspases can also be prevented by mechanisms downstream of transcriptional 
regulation. Members of the IAP family function to bind and inhibit caspases, including casp3 and 
casp9, and have been reported to be overexpressed in several cancers (Mita et al., 2008; 
Nachmias et al., 2004; Tamm et al., 2000). It would thus seem advantageous to investigate the 
expression of these proteins in cases where caspase gene expression in cancer cell lines or 
tissues revealed up-regulation or no significant changes in order to determine if post-transcriptional 
apoptotic resistance mechanisms are in place. Interestingly, alternative splicing of casp9 have 
been shown to produce both an anti-apoptotic and pro-apoptotic variant (Goehe et al., 2010). In 
non-small cell lung carcinoma cells, increased expression of the casp9b variant maintained the 
tumourigenic capacity of the cells and also resulted in decreased casp9 apoptotic activity. The 
altered mRNA processing resulted from the up-regulation of the heterogeneous nuclear 
ribonucleoprotein L (hnRNP L) which interacted with the exonic splicing silencer (Goehe et al., 
2010).  
In terms of the novel candidate genes, some contrasting results between the lung and kidney 
cancer samples were also obtained. Analysis of the relative gene expression for LIAS showed 
significant down-regulation in the lung cancer sample but significant up-regulation in the kidney 
cancer sample (tables 4.2-4.3 and figures 4.3-4.4). As mentioned in chapter 2, a definitive role for 
LIAS in cancer is yet to be established, although possible ties are discussed. Reports of LIAS gene 
expression in cancers in literature are scarce; however two studies have identified LIAS as a 
potential tumour antigen by means of serological studies (Hishizawa et al., 2005; Ito et al., 2004). 
By screening a cDNA expression library, originating from a leukaemic cell line, with autologous 
plasma obtained from a patient with adult T cell leukaemia (ATL), LIAS was identified as tumour 
antigen and relative expression of the gene was determined (Hishizawa et al., 2005). LIAS showed 
variable gene expression in human T-cell leukaemia cell lines and decreased expression in chronic 
and acute ATL (Hishizawa et al., 2005). By using a similar strategy, LIAS was also identified a 
potential tumour antigen in bladder cancer (Ito et al., 2004). The isolated clones in the cDNA 
expression library was a close partial match to human LIAS while a protein BLAST search (NCBI) 
revealed 87% identity to mouse LIAS. Again, LIAS gene expression was evaluated by means of 
qPCR and was shown to be up-regulated in various bladder cancer cell lines and tissues as well as 
gastric and renal cell cancer tissues compared to various normal tissues. Northen blot analysis 
Stellenbosch University  http://scholar.sun.ac.za
 128 
 
revealed similar results (Ito et al., 2004). Finally, LIAS was also shown to be up-regulated in a 
peripheral blood B-lymphocyte cell line in response to ionising radiation (Lin et al., 2007).  
CYPA showed significant up-regulation in kidney cancer but only slight up-regulation in lung cancer 
(tables 4.2-4.3 and figures 4.3-4.4). Nevertheless, an up-regulation is to be expected. Numerous 
other studies have shown CYPA to be up-regulated in a variety of cancers and, as discussed in 
chapter 2, CYPA might have a proliferative function in tumour cells. A similar observation was seen 
in the relative expression of SAAL1. Significant up-regulation was measured in the kidney cancer 
sample while only a slight up-regulation was detected in the lung cancer sample (tables 4.2-4.3 
and figures 4.3-4.4). However, in the case of SAAL1, there are no expected results and its 
molecular function is unknown. A gene expression profile in type 2 diabetes mellitus patients 
revealed decreased SAAL1 gene expression when compared to control subjects (Manoel-Caetano 
et al., 2012). Recently, a large-scale RNAi screen identified SAAL1 as a downstream target in p53-
p21 and p16-pRB pathways (Rovillain et al., 2011). The results obtained for SAAL1 in these two 
studies were however not discussed by the authors, who, due to the size of the studies, only 
discussed the main and most noteworthy results. Even though SAAL1 was identified as a 
downstream target of the abovementioned pathways, its functional role within the pathways needs 
to be established in order to determine how this could potentially be associated with apoptosis or 
cancer. A more tangible association for SAAL1 with a disease state was however recently 
identified. Sato and colleagues reported the overexpression of SAAL1 in the inflamed foot joints of 
a collagen-induced arthritic mice model and in human rheumatoid- and osteoarthritis patients (Sato 
et al., 2011). More specifically, the up-regulation was exhibited by synovial fibroblasts in the inner 
layer of the synovial membrane. In addition, the thickness of the synovial lining was shown to 
correlate with SAAL1 overexpression and the gene was suggested to be involved in the 
progression of synovitis (Sato et al., 2011).  
The final target gene AHNAK revealed similar results in the analysis its relative expression; a 
significant up-regulation in both the lung and kidney cancer samples (tables 4.2-4.3 and figures 
4.3-4.4). Even though its molecular function is still unknown, the gene is potentially involved in cell 
migration based on expression studies. A transcriptome and proteome analysis of six human 
metastatic tumour cell lines identified AHNAK to be essential for actin cytoskeleton dynamics, 
pseudopod protrusion and tumour cell migration and invasion (Shankar et al., 2010). AHNAK was 
also identified in a gene expression profile of gastric cancer tissues as one of the few genes shown 
to be up-regulated in tumours with perineural invasion compared to tumours without (Jhawer et al., 
2009). Furthermore, AHNAK was suggested to be of considerable relevance to angiotropism and 
extravascular migratory metastasis when a gene expression profile of metastatic melanoma 
tissues was constructed (Lugassy et al., 2011). In addition, an up-regulation in AHNAK gene 
expression was also observed in the cell membrane of migratory mesenchymal cells during 
embryonic development (Kingsley et al., 2001).  
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The qPCR technique used in this part of the study offered a specific and sensitive method for the 
measurement of the relative gene expression of the four novel candidate genes as well as three 
additional genes known to be involved in apoptosis. Significant differential expression in the cancer 
samples were obtained for the majority of the genes and the expression levels of several genes 
were supported by studies in literature. Promising avenues to explore in future work would be to 
repeat this work in tumour tissues and to include more genes known to be involved in apoptosis to 
potentially construct a gene expression profile of a particular cancer. This, for example, could 
assist in the generation of custom arrays which could potentially be used for diagnostic purposes. 
Investigating and comparing the gene expression of a novel candidate gene in these profiles could 
assist in their characterisation and potentially identify pathways of apoptotic resistance and/or 
tumour progression. In addition, the use of these candidate genes as potential biomarkers in 
cancer could also be investigated. For example, a gene like SAAL1 only showed up-regulation in 
kidney cancer, but not in lung cancer, whereas LIAS showed down-regulation in lung cancers, but 
up-regulation in kidney cancers. This data is completely novel and could be a valuable source as 
potential markers for cancer. 
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Chapter 5: Conclusions 
 
5.1 Final remarks and conclusions 
Apoptosis represents a finely orchestrated and highly conserved natural form of cell death (Fadeel 
and Orrenius, 2005; Kam and Ferch, 2000). It is executed in one of three pathways and can be 
induced by a variety of stimuli (Elmore, 2007). In spite of its opposing role, the importance of 
apoptosis has been equalled to that of mitosis and the process, which is mediated by numerous 
genes and proteins, is thus highly regulated (Elmore, 2007; Fadeel and Orrenius, 2005). Apoptosis 
is vital for the preservation of cell and tissue homeostasis but also performs several defensive and 
protective functions (Elmore, 2007). However, altered or deregulated apoptosis can have severe 
pathological consequences and apoptosis has been shown to play a central role in several 
diseases, including neurological and autoimmune diseases as well as many cancers (Adams and 
Cory, 2007; Kam and Ferch, 2000). Consequently, the search for apoptotic-based therapies has 
received much attention and of vital importance to this quest is the elucidation and characterisation 
of the specific mediators of apoptosis and their regulation. Even though much progress has been 
made since apoptosis’s initial description in 1972, more research is needed to fully understand the 
complete cascade of molecular events that make up apoptosis (Elmore, 2007; Kerr et al., 1972; 
Ola et al., 2011). Thus, this study aimed to assist in this characterisation, as well as to identify 
novel candidate genes potentially involved in resistance to apoptosis. These genes could also 
serve as potential targets for apoptosis-based therapeutic strategies.  
The first objective of this study was to verify the involvement of three novel candidate genes in 
resistance to apoptosis induced by C2-cermaide and camptothecin. These candidate genes were 
identified in a previously performed pilot study where apoptosis-resistant phenotypes were 
observed in CHO cells following promoter-trap mutagenesis by means of retroviral integration in 
the promoter sequences for each of the respective candidate genes. Since the pilot study made 
use of a haploid model, the results obtained needed to be verified in a diploid model. This was 
performed in the current study, in addition to using a more specific technique of gene knockdown in 
case the observed phenotype resulted from some other consequence from the technique used in 
the pilot study. The current study successfully verified the results obtained from the pilot study for 
two of the candidate genes, namely LIAS and CYPA. Following gene knockdown by means of 
RNAi, cells displayed significant levels of apoptosis resistance as measured by the apoptosis 
assays (Fig. 2.14-2.17 and 2.20-2.23). However, the results obtained for the third candidate gene, 
RPL9, contrasted the results obtained in the pilot study. Knockdown cell lines for this gene 
displayed sensitivity to apoptosis induction comparable to that shown by the wild type cells (Fig. 
2.18-2.19 and 2.24-2.25). These results excluded RPL9 as a candidate gene. RPL9 was most 
likely identified in the pilot study due to the fact that the gene’s chromosomal location is adjacent to 
LIAS; hence, the apoptotic resistance phenotype observed in the pilot was in fact attributed to 
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knockdown of LIAS. Since these two genes share a bi-directional promoter, the inverse PCR 
technique could have amplified sequences from the RPL9 gene adjacent to the promoter and to 
LIAS. Comparable results were obtained for both apoptosis assays performed, confirming 
apoptosis as the mode of cell death. Comparable results were also obtained for both of the 
apoptotic inducers, indicating that the observed apoptotic resistance phenotype was not restricted 
to a specific inducer. This is important to consider since the molecular events of apoptosis that 
ensues following induction can differ between different stimuli (Fulda, 2010; Kam and Ferch, 2000; 
Kolesnick and Krönke, 1998); hence the resistance phenotype is not restricted to certain set of 
molecular events. Furthermore, comparable results were also obtained for both knockdown cell 
lines generated for each of the candidate genes, confirming the specificity of the RNAi technique. 
Possible links to the apoptotic process for LIAS and CYPA are discussed in section 2.4. Even 
though no direct links to apoptosis were identified for LIAS, possible sequences of events that may 
potentially lead to apoptosis resistance are described. These involve the deregulation of metabolic 
processes and of ROS. In both cases, restoring the normal levels of LIAS, and thus LA, might 
restore sensitivity to apoptosis. As mentioned, the exogenous application of LA was shown to be 
capable of inducing apoptosis in tumour cells (Dozio et al., 2010; Shi et al., 2008; Simbula et al., 
2007; Wenzel et al., 2005). Interestingly, LA was however unable to induce apoptosis in normal 
cells (Van de Mark et al., 2003; Wenzel et al., 2005). This observation alludes to a potential 
anticancer therapeutic capacity for LIAS/LA; tumour cells are targeted and sensitised to apoptosis, 
while the surrounding normal cells are unaffected. This is in contrast to many traditional anticancer 
therapies, where normal tissues are often destroyed along with the tumour which can result in 
serious complications and side-effects (Nussbaumer et al., 2011). Additionally, this also suggests 
the expression of a cancer-specific epitope which is not recognised by LA treatment in normal 
cells. A more direct link to apoptosis was however identified for CYPA. Previous studies have 
shown a functional association with AIF, and it is through this association that CYPA contribute to 
DNA fragmentation during apoptosis (Candé et al., 2004; Tanaka et al., 2011; Wissing et al., 2004; 
Zhu et al., 2007). Specifically, Candé et al. (2004) reported resistance to apoptosis in cells deficient 
of CYPA, thus supporting the results obtained in this study. In addition, several other studies have 
reported overexpression of CYPA in tumour cells and that knockdown of CYPA expression results 
in apoptosis (Choi et al., 2007; Li et al., 2006; Sun et al., 2011; Yang et al., 2007). This observation 
also alludes to a potential anticancer therapeutic capacity for CYPA, similar to LIAS; while 
knockdown of CYPA results in apoptosis in tumour cells, normal cells become resistant to 
apoptosis. However, the ‘side-effects’ of CYPA knockdown in normal cells would have to be 
investigated in vivo.  
During the course of this study, a bioinformatic approach was used to identify and characterise 
novel candidate genes possibly involved in resistance to apoptosis. Candidate genes were 
identified by performing BLAST searches with nucleotide sequences obtained from the pilot study. 
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This resulted in the identification of two additional novel candidate genes, namely AHNAK and 
SAAL1. As mentioned in section 3.4, these candidate genes, as well as LIAS, were identified more 
than once by the BLAST searches. Future work would be to generate stable knockdown cell lines 
for AHNAK and SAAL1 using a diploid model to verify their involvement in apoptotic resistance. A 
total of four candidate genes, namely LIAS, CYPA, AHNAK and SAAL1 were subjected to further 
bioinformatic analysis in order to aid in their characterisation and to ascertain possible links to 
apoptosis by investigating the protein interactions and cellular pathway involvement for each of the 
candidate genes. Results obtained from the bioinformatic analysis for LIAS and CYPA supported 
the findings discussed in section 2.4. Interacting proteins for LIAS, as revealed by the STRING 
database, included the PDH, KGDH, BCKDH and GCS complexes (data not shown). In addition, 
the search for cellular pathways produced the metabolic pathway for LIAS. For CYPA, both the 
human and mouse AIF protein homologs were identified as interacting proteins (table 3.5). In terms 
of AHNAK and SAAL1, the bioinformatic analyses confirmed the novelty of these genes to the 
apoptotic process and no definitive function for these genes in apoptosis could be established. For 
all four candidate genes, possible links to apoptosis were however noted upon investigating the 
interacting proteins for each of the genes. These interactions provide promising avenues which can 
be explored in future studies by additional bioinformatic analyses or experimental methods.  
The final objective of this study was to investigate the gene expression levels of the candidate 
genes in normal and cancer cell lines. This was achieved by performing qPCR, a sensitive and 
reliable technique capable of quantifying the expression of a target gene in real time (Pfaffl, 2001). 
The comparative CT method was used for the analysis of the qPCR results which was normalised 
against one of two reference genes. The relative gene expression of three additional genes, 
namely Bcl-2, casp3 and casp9, was also investigated. Even though these genes are known to be 
involved in apoptosis and have been extensively investigated in cancer, it remains important to 
characterise these genes and their protein products since they represent promising targets for the 
development of apoptotic-based therapies. In particular, investigating the gene and protein 
expression of Bcl-2, and its anti-apoptotic family members, in different cancer cell lines and tissues 
can assist in the optimisation of therapeutic strategies targeting the anti-apoptotic Bcl-2 family 
members, such as the SMI’s described in chapter 1 (section 1.2.6). The up-regulation of LIAS 
observed in the kidney cancer sample (Fig. 4.4) was supported by studies in literature also 
reporting increased gene expression. However, the down-regulation of LIAS observed in the lung 
cancer sample (Fig. 4.3) supported the results obtained in chapter 2 where decreased expression 
levels maintained cell survival (Fig. 2.14-2.15 and 2.20-2.21). These observations warrant further 
investigation especially since a definitive role for LIAS in apoptosis and/or cancer progression is 
yet to be established. In addition, it should be noted that this paradox could have been influenced 
by the heterogeneity seen in different types of cancer, possible differences between cultured 
cancer cell lines and tumour tissues and between different stages of tumour development as well 
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as the possibility of a dual role for these genes that depends on the disease state and cellular 
environments. 
SAAL1 was shown to be up-regulated in both cancers (Fig. 4.3 and 4.4) and this was supported by 
a recent study which suggested that increased SAAL1 gene expression is needed for synoviocyte 
proliferation (Sato et al., 2011). As discovered during the bioinformatic analysis in chapter 3, very 
little information about SAAL1 is available and this was also observed in a literature search for the 
gene. To our knowledge, this is the first report of SAAL1 gene expression in cancer. The increased 
CYPA gene expression observed in the cancer cell lines (Fig. 4.3 and 4.4) is also supported by 
numerous other studies in literature. Possible reasons for this up-regulation in cancer are 
discussed in section 2.4.2, as well as how knockdown of CYPA could still potentially result in 
resistance to apoptosis. These reasons are intertwined with a protein interaction with AIF and 
based on this, it would be interesting to investigate the gene and protein expression, as well as 
protein localisation, of CYPA and AIF in various cancer and control tissues. Lastly, AHNAK was 
found to be overexpressed in both the lung and kidney cancer samples. Again, this was also 
supported by studies in literature which also suggested a role for AHNAK in cell migration and 
metastasis of tumours. This suggestion is in turn supported by a protein interaction identified by the 
bioinformatic analysis performed in chapter 3; a known interaction between AHNAK and YES1 was 
revealed by the I2D database (table 3.3). YES1 is known to play a role in cell-cell adhesion and 
cytoskeleton remodelling and is also mediator of AKT-mediated cell migration. It would thus seem 
that AHNAK and YES1 could function together in promoting cell migration and tumour metastasis. 
However, this would also contrast the results obtained in chapter 2; thus, further investigation is 
warranted.  
In conclusion, this study identified two novel candidate genes, namely AHNAK and SAAL1, 
potentially involved in the resistance to apoptosis. In addition, results obtained for two candidate 
genes identified in a previously performed pilot study, LIAS and CYPA, were also verified. 
Differential expression of these genes in cancer is also reported. Results obtained during this study 
can aid in the complete characterisation and functional annotation of these genes. Potential ties to 
apoptosis and associations with cancer are discussed for all four candidate genes and the 
possibilities of therapeutic strategies for anticancer treatments involving these candidate genes are 
noted.  
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Addendum A 
 
Table A1: Descriptive statistics for APOPercentage™ assay as calculated with Microsoft® Excell®  
Apoptotic 
inducer 
Inducer 
concentration 
Averages¥ Standard 
deviation§ 
F-test* T-test¤ 
LIAS KD1 
Camptothecin 0 100.00 0.00 N/A N/A 
 2 100.00 0.00 0.00 0.02 
 4 100.00 0.00 0.00 0.02 
 6 87.33 2.08 0.32 4.21E-04 
 8 79.00 4.36 0.27 7.68E-04 
 10 74.33 4.16 0.23 4.30E-04 
C2-ceramide 0 100.00 0.00 N/A N/A 
 20 94.00 1.73 0.23 0.02 
 40 92.67 2.08 0.20 1.15E-04 
 60 86.33 1.53 0.27 9.35E-06 
 80 76.33 3.51 0.22 2.25E-04 
 100 73.33 4.04 0.36 2.28E-05 
LIAS KD2 
Camptothecin 0 100.00 0.00 N/A N/A 
 2 100.00 0.00 0.00 0.02 
 4 100.00 0.00 0.00 0.02 
 6 92.00 2.65 0.43 2.90E-04 
 8 80.67 3.21 0.17 5.15E-04 
 10 76.00 2.00 0.07 2.59E-04 
C2-ceramide 0 100.00 0.00 N/A N/A 
 20 95.33 1.53 0.18 9.28E-03 
 40 92.00 1.00 0.06 8.82E-05 
 60 84.00 4.58 0.23 1.11E-04 
 80 76.00 5.00 0.36 3.41E-04 
 100 71.33 5.51 0.24 6.12E-05 
NIH-3T3 (for comparison with LIAS KD cell lines) 
Camptothecin 0 100.00 0.00   
 2 84.33 3.51   
 4 81.00 5.00   
 6 64.33 3.06   
 8 34.67 7.09   
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Apoptotic 
inducer 
Inducer 
concentration 
Averages¥ Standard 
deviation§ 
F-test* T-test¤ 
 10 21.00 7.55   
C2-ceramide 0 100.00 0.00   
 20 85.67 3.21   
 40 52.33 4.16   
 60 38.33 2.52   
 80 21.33 6.66   
 100 7.33 3.06   
RPL9 KD1 
Camptothecin 0 100.00 0.00 N/A N/A 
 2 90.67 1.53 0.30 0.03 
 4 79.00 2.00 0.37 0.83 
 6 67.00 1.00 0.20 0.02 
 8 41.33 4.51 0.49 0.22 
 10 18.667 2.08 0.38 0.07 
C2-ceramide 0 100.00 0.00 N/A N/A 
 20 90.00 2.65 0.43 0.08 
 40 81.00 2.00 0.48 6.52E-03 
 60 63.67 4.73 0.29 9.90E-03 
 80 37.00 4.00 0.30 3.57E-03 
 100 15.00 3.00 0.31 0.22 
RPL9 KD2 
Camptothecin 0 100.00 0.00 N/A N/A 
 2 90.67 2.52 0.46 0.05 
 4 80.33 2.08 0.35 0.54 
 6 68.00 2.65 0.36 0.04 
 8 44.33 7.23 0.29 0.17 
 10 21.33 2.52 0.48 0.03 
C2-ceramide 0 100.00 0.00 N/A N/A 
 20 91.00 1.00 0.16 0.02 
 40 78.67 3.06 0.32 0.04 
 60 61.67 1.53 0.20 2.74E-03 
 80 38.33 7.51 0.11 0.02 
 100 16.00 3.00 0.31 0.13 
NIH-3T3 (for comparison with RPL9 KD cell lines) 
Camptothecin 0 100.00 0.00   
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Apoptotic 
inducer 
Inducer 
concentration 
Averages¥ Standard 
deviation§ 
F-test* T-test¤ 
 2 85.33 2.31   
 4 79.33 1.53   
 6 62.00 2.00   
 8 36.00 4.58   
 10 14.00 2.65   
C2-ceramide 0 100.00 0.00   
 20 85.33 2.31   
 40 72.33 2.08   
 60 48.67 3.06   
 80 20.00 2.65   
 100 12.00 2.00   
CYPA KD1 
Camptothecin 0 100.00 0.00 N/A N/A 
 2 100.00 0.00 0.00 8.16E-03 
 4 92.67 2.08 0.35 8.64E-04 
 6 82.33 1.55 0.25 1.08E-04 
 8 73.33 0.58 0.02 5.06E-03 
 10 69.00 2.00 0.36 8.74E-06 
C2-ceramide 0 100.00 0.00 N/A N/A 
 20 94.67 2.52 0.46 9.09E-03 
 40 92.67 2.08 0.50 2.80E-04 
 60 86.33 1.53 0.20 4.43E-05 
 80 76.33 3.51 0.36 2.44E-05 
 100 73.33 4.04 0.20 1.92E-05 
CYPA KD2 
Camptothecin 0 100.00 0.00 N/A N/A 
 2 100.00 0.00 0.00 8.16E-03 
 4 91.33 1.53 0.50 6.52E-04 
 6 86.67 1.53 0.37 7.06E-05 
 8 73.67 2.31 0.20 2.20E-04 
 10 69.00 2.00 0.36 8.74E-06 
C2-ceramide 0 100.00 0.00 N/A N/A 
 20 97.33 1.15 0.20 1.29E-03 
 40 92.00 1.00 0.19 1.23E-04 
 60 84.00 4.58 0.31 3.73E-04 
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Apoptotic 
inducer 
Inducer 
concentration 
Averages¥ Standard 
deviation§ 
F-test* T-test¤ 
 80 76.00 5.00 0.22 6.79E-05 
 100 71.33 5.51 0.12 6.21E-05 
NIH-3T3 (for comparison with CYPA KD cell lines) 
Camptothecin 0 100.00 0.00   
 2 85.33 2.31   
 4 79.33 1.53   
 6 62.00 2.00   
 8 36.00 4.58   
 10 14.00 2.65   
C2-ceramide 0 100.00 0.00   
 20 85.33 2.31   
 40 72.33 2.08   
 60 48.67 3.06   
 80 20.00 2.65   
 100 12.00 2.00   
[Camptothecin] – µg/ml; [C2-ceramide] – µM; ¥ - Average values from triplicate experiments; § - Sample 
based estimate of standard deviation; * - Two sample F-test for variances. Based on the p-value generated 
by this test, the appropriate t-test was selected. ¤ - Two sample t-test assuming equal variances for F-test p-
value ≥ 0.05 and two sample t-test assuming unequal variances for F-test p-value <0.05. Data was seen as 
statistically significant (compared with wild type NIH-3T3 data) for t-test p-value < 0.05. 
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Table A2: Descriptive statistics for the Caspase-3/CPP32 assay as calculated with Microsoft® 
Excell®  
Apoptotic 
inducer 
Inducer 
concentration 
Averages¥ Standard 
deviation§ 
F-test* T-test¤ 
LIAS KD1 
Camptothecin 0 100.00 0.00 N/A N/A 
 2 100.00 0.00 0.00 0.02 
 4 100.00 0.00 0.00 9.49E-03 
 6 84.33 2.52 0.34 2.42E-03 
 8 79.00 1.73 0.06 4.09E-04 
 10 69.33 2.08 0.11 1.20E-04 
C2-ceramide 0 100.00 0.00 N/A N/A 
 20 93.00 2.65 0.43 0.02 
 40 88.00 2.00 0.03 8.66E-03 
 60 82.67 2.08 0.09 2.41E-04 
 80 75.00 4.58 0.32 6.67E-05 
 100 72.67 2.89 0.32 2.75E-05 
LIAS KD2 
Camptothecin 0 100.00 0.00 N/A N/A 
 2 100.00 0.00 0.00 0.02 
 4 100.00 0.00 0.00 9.49E-03 
 6 88.67 1.53 0.16 6.45E-04 
 8 76.00 2.00 0.08 5.53E-04 
 10 70.33 0.58 0.01 3.92E-03 
C2-ceramide 0 100.00 0.00 N/A N/A 
 20 93.00 2.00 0.43 0.01 
 40 87.33 0.58 0.01 8.81E-03 
 60 82.00 3.00 0.18 3.07E-04 
 80 75.00 2.65 0.40 2.06E-05 
 100 71.00 3.61 0.43 4.26E-05 
NIH-3T3 (for comparison with LIAS KD cell lines) 
Camptothecin 0 100.00 0.00   
 2 89.33 2.52   
 4 79.33 3.51   
 6 67.33 3.51   
 8 33.67 7.02   
 10 14.67 6.03   
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Apoptotic 
inducer 
Inducer 
concentration 
Averages¥ Standard 
deviation§ 
F-test* T-test¤ 
C2-ceramide 0 100.00 0.00   
 20 85.33 2.31   
 40 50.33 6.03   
 60 33.67 6.51   
 80 19.33 3.21   
 100 9.67 4.16   
RPL9 KD1 
Camptothecin 0 100.00 0.00 N/A N/A 
 2 93.67 1.15 0.13 0.42 
 4 81.00 2.00 0.31 1.00 
 6 62.00 4.00 0.49 0.85 
 8 34.00 6.08 0.36 0.53 
 10 15.00 4.58 0.31 0.70 
C2-ceramide 0 100.00 0.00 N/A N/A 
 20 94.33 1.53 0.50 3.55E-03 
 40 81.67 2.08 0.32 0.02 
 60 71.00 2.00 0.20 3.54E-04 
 80 30.00 8.19 0.20 0.27 
 100 15.00 5.29 0.08 0.17 
RPL9 KD2 
Camptothecin 0 100.00 0.00 N/A N/A 
 2 95.33 2.08 0.33 0.19 
 4 81.67 2.52 0.41 0.78 
 6 63.00 4.36 0.46 0.93 
 8 37.33 6.11 0.36 0.94 
 10 17.00 5.29 0.25 0.40 
C2-ceramide 0 100.00 0.00 N/A N/A 
 20 94.00 2.65 0.25 0.01 
 40 83.33 3.21 0.47 0.02 
 60 70.33 3.06 0.36 6.08E-04 
 80 28.33 5.51 0.35 0.27 
 100 13.67 2.08 0.35 0.06 
NIH-3T3 (for comparison with RPL9 KD cell lines) 
Camptothecin 0 100.00 0.00   
 2 92.00 3.00   
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Apoptotic 
inducer 
Inducer 
concentration 
Averages¥ Standard 
deviation§ 
F-test* T-test¤ 
 4 81.00 3.00   
 6 62.67 4.04   
 8 39.00 4.58   
 10 13.67 3.06   
C2-ceramide 0 100.00 0.00   
 20 86.67 1.53   
 40 73.67 3.06   
 60 41.67 4.04   
 80 23.33 4.04   
 100 9.67 1.53   
CYPA KD1 
Camptothecin 0 100.00 0.00 N/A N/A 
 2 100.00 0.00 0.00 0.04 
 4 97.67 0.58 0.04 0.01 
 6 85.00 2.00 0.20 1.01E-03 
 8 77.33 3.51 0.37 2.68E-04 
 10 71.33 1.53 0.20 8.14E-06 
C2-ceramide 0 100.00 0.00 N/A N/A 
 20 97.33 0.58 0.13 3.48E-04 
 40 91.33 2.08 0.32 1.16E-03 
 60 84.33 2.08 0.21 8.38E-05 
 80 74.33 4.16 0.49 1.09E-04 
 100 71.00 2.00 0.37 1.88E-06 
CYPA KD2 
Camptothecin 0 100.00 0.00 N/A N/A 
 2 100.00 0.00 0.00 0.04 
 4 96.67 0.58 0.04 0.01 
 6 96.67 2.08 0.21 7.94E-04 
 8 76.67 2.08 0.17 1.67E-04 
 10 72.00 3.61 0.42 2.83E-05 
C2-ceramide 0 100.00 0.00 N/A N/A 
 20 96.33 1.15 0.36 9.43E-04 
 40 91.67 2.08 0.32 1.08E-03 
 60 83.67 3.06 0.36 1.37E-04 
 80 75.00 3.61 0.44 7.86E-05 
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Apoptotic 
inducer 
Inducer 
concentration 
Averages¥ Standard 
deviation§ 
F-test* T-test¤ 
 100 71.00 3.61 0.15 1.1E-05 
NIH-3T3 (for comparison with CYPA KD cell lines) 
Camptothecin 0 100.00 0.00   
 2 92.00 3.00   
 4 81.00 3.00   
 6 62.67 4.04   
 8 37.00 4.58   
 10 13.67 3.06   
C2-ceramide 0 100.00 0.00   
 20 86.67 1.53   
 40 73.67 3.06   
 60 41.67 4.04   
 80 23.33 4.04   
 100 9.67 1.53   
[Camptothecin] – µg/ml; [C2-ceramide] – µM; ¥ - Average values from triplicate experiments; § - Sample 
based estimate of standard deviation; * - Two sample F-test for variances. Based on the p-value generated 
by this test, the appropriate t-test was selected. ¤ - Two sample t-test assuming equal variances for F-test p-
value ≥ 0.05 and two sample t-test assuming unequal variances for F-test p-value <0.05. Data was seen as 
statistically significant (compared with wild type NIH-3T3 data) for t-test p-value < 0.05. 
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Table A3: Previously calculated qPCR efficiencies of primers for target genes and reference genes 
Gene Lung control Lung cancer Kidney control Kidney cancer 
GAPDH 1.97 1.95 1.96 1.95 
UBC 1.94 1.97 1.95 1.94 
LIAS 1.95 1.93 1.92 1.95 
CYPA 1.95 1.94 1.94 1.97 
AHNAK 1.92 1.94 1.94 1.95 
SAAL1 1.92 1.93 1.94 1.92 
Casp3 1.96 1.95 1.93 1.94 
Casp9 1.93 1.95 1.95 1.93 
Bcl-2 1.95 1.98 1.94 1.98 
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